The 13th annual Peter Como HD Symposium has been made possible through the commitment and generosity of our dedicated sponsors and membership, enabling us to provide a full range of programming and educational activities to meet the needs of the worldwide HD community. The Symposium was renamed this year in honor and in memory of Dr. Peter Como, who was a founding member of the Huntington Study Group, and who passed away earlier this year.

Beginning in 1984, Dr. Como worked as a neuropsychologist at the University of Rochester caring for a generation of individuals and families affected by Huntington disease and other disorders such as Parkinson, Alzheimer and Wilson diseases. No matter what their need, Dr. Como was a tireless and dedicated clinician to hundreds, if not thousands, of individuals affected by Huntington disease. Dr. Como was devoted to caring for his patients, and his patients were devoted to him.

In addition to his clinical work, Dr. Como was a founding member of the Huntington Study Group (HSG). Among his earliest contributions to the HSG was leading the development of the cognitive and behavioral components of the Unified Huntington's Disease Rating Scale (UHDRS), the most widely used outcome measure in Huntington disease. Dr. Como also led investigations of therapies for Huntington disease and was involved in almost every major HSG study since its inception, including CARE-HD, 2CARE, Pre-2CARE, PREQUEL, MINO, PHAROS, PREDICT-HD, and RESPOND.

In 2009, Dr. Como joined the U.S. Food and Drug Administration where he remained committed to those affected by Huntington disease and served as their advocate within the agency and beyond. While at the FDA, he continued his service to HSG, leading and participating in educational sessions for researchers, clinicians, and families, and to the Huntington’s Disease Society of America (HDSA).
Abstracts from HSG 2019

1 Quality of Care for Huntington’s Disease in the United States: Findings from a National Survey of Patients and Caregivers

Karen E. Anderson1, Jack Griffin2, Al Kinel1, Abdul R. Shaikh1, Temitope Olofinuyi1, Stevan Ramirez2, Joni Steiman3,5, George J. Yohrling4, Shari Kinel1
1Georgetown University, Department of Psychiatry & Department of Neurology, Washington DC, USA; 2Griffin Foundation, Naples, FL, USA; 3Strategic Interests, LLC, Rochester, NY, USA; 4Guidehouse LLP, Washington DC, USA; 5Huntington Study Group, Rochester, NY, USA; 6Huntington’s Disease Society of America, New York, NY, USA

Background: Little is known about the quality of care for people living with Huntington’s disease (HD) in the United States.

Objective: To enhance our understanding of the HD care experience for patients and families, and identify gaps in care provision in the United States. This study focused specifically on care needs outside of routine clinic visits.

Methods: Web-based survey for persons self-identifying as being affected by HD (PAHD, which included individuals with, or at risk for HD) or as caregivers/family members were disseminated via social media and patient advocacy partners from April–May 2017. Survey completion required 5–10 min.

Results: Total responses were 797, (n = 585 caregiver/family respondents; n = 212 PAHD) from 45 states. Overall 459 (57.6%) answered questions about current level of care provision. Of these, 41.0% reported receiving medical care, 5.7% community care, 31.4% both medical and community care, and 22.0% reported having no current medical or community care. Top reasons cited for receiving ‘No other care support for HD’ (n = 101) were ‘high cost of care’ (27.7%) and ‘live too far away’ (26.7%). Caregiver/family respondents reported helping the affected individual with budget/finances (60.5%), housekeeping (57.1%), daily help (53.2%), finding community resources (42.3%), safety (38.1%), medical care (33.9%), home physical therapy (16.0%), and meals on wheels (5.9%). Questioning about healthcare visits revealed that patients were only given information/discussed next steps half (53.1%) of the time, but questions about depression and other mental health issues were more routinely explored (89.9%).

Conclusions: A significant proportion of HD care is currently provided by caregivers at home, greatly magnifying the burden of disease. Enhancing resources for both formal and informal care for patients and families should be a central goal for HD organizations. Development of patient/caregiver outcome measures to track impact of any interventions is crucial.

Lay Summary: This project identifies gaps in care that are experienced by people with Huntington’s Disease and their families. Areas where there are not enough support or resources include care given outside of the clinic, such as in home care, and training non-specialists in how to care for people with Huntington’s Disease. The next phase of this project will seek solutions to reduce the burden of care for all people affected by Huntington’s Disease.

2 Behavioral Distinctions Between Physical and Cognitive Apathy Observed in Premanifest Huntington’s Disease (HD)

Kelly Atkins, Sophie Andrews, Julie Stout, Trevor T-J Chong
Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia (all authors)

Patient reported outcomes clearly document apathy as a pervasive problem in HD. We sought to examine motivational deficits with an economic decision-making task, thus providing a performance based outcome measure of apathy. Motivation may be defined as a willingness to exert effort for rewards. Not all effort is the same; physical demands may be valued differently to cognitive ones. Little is known about how these effort domains are affected in premanifest HD.

We administered an economic effort-based decision-making task to 20 people confirmed to have the HD gene and 20 matched controls. Participants were first trained extensively on two tasks requiring effort that was either primarily cognitive or physical. They then had to select between a baseline low level of effort for a low reward option, and a high effort for a higher reward option. Separate choices were made for the cognitive and physical tasks, which facilitated computational models of motivation in each effort domain.

Our premanifest HD participants (DBS(150–435)) demonstrated similar levels of physical motivation to controls in that both groups were equally likely to invest physical effort for reward. In contrast, our pre-symptomatic HD group consistently preferred the less cognitively effortful option, F(1,45) = 7.56, p < .05, suggesting that they were less motivated than controls to invest cognitive effort for reward.

These data suggest that physical and cognitive motivation are dissociable in pre-symptomatic HD and that cognitive apathy may occur earlier in the disease course than physical apathy. These findings contribute to our current understanding of the dissociations between physical and cognitive costs, which are central to current conceptualisations of apathy in HD. Moreover, our results support the clinical utility in defining distinct subtypes of apathy, and the relevance of these subtypes when designing interventions or clinical trials targeting apathetic states.

Lay Summary: Our study describes a novel and objective way of measuring apathy, a pervasive psychiatric symptom of HD, that may be useful for trials or interventions targeting apathy. Moreover, our results suggest people with the HD gene may experience a type of cognitive apathy, prior to the development of physical symptoms with which a diagnosis of HD is made.

3 Multidimensional Apathy in Huntington’s Disease: The Utility of the Dimensional Apathy Scale

Published online: 08 October 2019
Kelly Atkins, Sophie Andrews, Trevor T-J Chong, Julie Stout
Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia (all authors)

Recent conceptualisations of apathy describe distinct subtypes (executive, initiation, and emotional) that differentially affect goal-directed behaviour, however, the presence of these subtypes over the disease course has not been described in HD. The aim of this study was to evaluate the use of a self-report measure of these subtypes, the Dimensional Apathy Scale (DAS), in people with pre-manifest and manifest HD and their care partners. 72 people with the HD gene (38 pre-symptomatic and 34 manifest) along-side 72 matched controls completed the DAS and the Total Functioning Capacity (TFC). A subset of 38 partners completed the informant versions of all measures.

Higher TFC scores were associated with higher scores on the executive, \( r = -0.47^* \), initiation, \( r = -0.53^* \) and emotional, \( r = -0.51^* \) apathy subtypes. Relative to healthy controls and the pre-symptomatic group, the manifest HD group endorsed higher levels of apathy on executive, \( F = 16.96, p < .001 \), and initiation subscales \( F = 14.61, p < .001 \), with large effect sizes, and on the emotional subscale \( F = 7.84, p = .001 \), with a moderate effect size. Across the HD group, internal consistency reliability was found to be good for executive (\( x=0.82 \)) and initiation (\( x=0.86 \)) subcales, but very poor for the emotional subscale (\( x=0.27 \)). Likewise, interrater reliability between the HD group and their respective informant was adequate for executive and initiation subscales (\( ICC > .7 \), but poor for the emotional subscale (\( ICC = .45 \)).

Manifest HD participants endorsed higher apathy levels than pre-manifest or control participants on all three subtypes of apathy on the DAS, suggesting that the apathy observed in HD has pervasive impacts across various forms of goal-directed behaviour. The association between DAS subscale scores and TFC suggests that the DAS is sensitive to disease progression, at least after the onset of functional decline. Low internal and interrater reliabilities on the emotional subscale, however, indicate that this subscale should be interpreted with caution.

**Lay Summary:** Our review of a commonly used patient reported apathy measure will assist clinicians to better recognize and assess apathy, a pervasive psychiatric symptom, in Huntington’s disease.

4

Presymptomatic Testing and Confidentiality in the Age of the Electronic Medical Record

Stacey K. Barton, Kevin J. Black, Joel S. Perlmutter
Washington University School of Medicine, St. Louis, MO, USA (all authors)

**Background:** For over 20 years, presymptomatic testing for Huntington disease (HD) has been conducted using accepted guidelines meant to support and educate patients seeking testing while maximizing confidentiality and minimizing the risk of genetic discrimination. Advances in electronic medical records (EMRs) have created challenges in meeting these guidelines that include in-person disclosure of test results vs. patient portal access and risk of unintended disclosure via the EMR to those outside of the testing team.

**Methods:** We reached out to 13 HDSA Centers of Excellence with questions relevant to our concerns.

**Results:** Ten institutions responded; several requested not to be identified, often regarding concern about their own practices. All documented presymptomatic testing encounters in the EMR, although two used a pseudonym and one system was not linked to the primary EMR. Just over half allowed the use of a pseudonym, however, at least one institution did not sanction the practice. Many institutions intentionally documented little information in the EMR note to obscure the visit diagnoses. Over half had different processes for self-pay patients such as using an outside lab rather than the hospital lab. Most could avoid documenting the test report in the EMR, and one site did not document the visit that revealed test results. All could prevent test results provided through the patient portal before in-person disclosure. Several institutions had agreements with their laboratory directors to order the HD test results using a generic name such as “genetic analysis” and/or to provide results only on paper.

**Discussion:** There is no consensus among nationally respected institutions as to how to resolve the conflicts between the advantages of a shared medical record and the ability to maintain control of highly confidential medical information. More importantly, current practices potentially compromise patient confidentiality.

**Lay Summary:** It is important for patients to understand institutional practices of documenting HD testing in the electronic medical record (EMR). There is no consensus among peer institutions and many practices leave patients open to potential genetic discrimination and unable to control access to their results in their EMR.

5

Influence of Age of Onset on Huntington’s Disease Phenotype

Lauren Kwa, Danielle Larson, Chen Yeh, Danny Bega
Northwestern University Feinberg School of Medicine, Chicago, IL, USA (all authors)

**Background:** Huntington’s Disease (HD) is an inherited neurodegenerative disorder that is characterized by progressive motor, cognitive, and behavioral deficits [1]. Average age of onset is 40 years old [2,3]. It has been suggested that older onset patients may have a milder disease course with decreased odds of behavioral symptoms at onset [4]. However, phenotypic differences based on age of onset have not been well characterized in a large HD population.

**Objectives:** To use a large database to determine the difference in symptom profiles and disease progression between patients with early onset, typical onset, and late onset adult HD.

**Methods:** Data were obtained from Enroll-HD. Adults with manifest/motor-manifest HD were included. Age groups were defined as follows: young onset (20–29 years), typical onset (30–50 years), and late onset (51+ years). Subjects in each group were categorized by TFC total score bins, from Stage I (least severe) to Stage V (most severe). Motor, cognitive, and behavioral symptoms were analyzed annually. Descriptive statistics were calculated. Chi-square test and Kruskal-Wallis test, as appropriate, were used to determine \( p \) values and Bonferroni \( p \) value correction was used to do pairwise comparison.

**Results:** 7311 manifest HD subjects were analyzed of which 612 were young onset, 4189 typical onset, and 2510 late onset. The rate of decline in TFC score from baseline to visit 1 was significantly faster in the young onset participants (\( 1.79 \) points) compared to the typical (\( 1.21 \) points, \( p < 0.05 \)) or late onset (\( 1.15 \) points, \( p < 0.05 \)) participants. Additional analyses of differences between age-of-onset groups while controlling for TFC score are presented for motor, cognitive, and behavioral variables.

**Conclusions:** Young age of onset is predictive of a faster functional decline for adults with HD when compared to those with typical and late age of onset. Motor and behavioral symptom profiles differ based on age of onset.

**References:**


The objective of this study was to evaluate memory impairment in premanifest gene carriers for Huntington's disease (pre-HD) by comparing performance on the California Verbal Learning Test-II (CVLT-II) in pre-HD with that of healthy adult (HA) and manifest HD subjects.

**Background:** Verbal memory impairment is well documented in HD; however, less is known about the nature and extent of memory deficits in pre-HD. The CVLT-II is a standardized well-validated test of verbal learning and memory that assesses immediate free recall, free and cued recall over short and long delays, and yes/no recognition memory.

**Methods:** Participants included 77 HD, 46 pre-HD, and 54 HA subjects followed at the UCSD Huntington’s Disease Center of Excellence. Recall, recognition, learning characteristics, errors, and retention were analyzed using the CVLT-II, which was administered using standard procedures (Delis et al., 2000) and scored using CVLT-II software (Delis & Fridlund, 2000).

**Results:** Pre-HD participants performed significantly worse than HA (ps < .05), but significantly better than HD (ps < .001) participants on Total Immediate Recall, Short and Long Delay Recall (Free and Cued), and Recognition Discriminability. Pre-HD individuals did not differ from the HA group, but performed significantly better than the HD group, on Learning Slope Trials 1–5, Semantic Clustering, and Intrusions (ps < .001). Finally, there were no group differences in Repetitions or Retention.

**Conclusions:** We conclude that subtle declines in immediate and delayed recall may be evident prior to clinical diagnosis of HD, while more frontally-mediated processes, such as strategic aspects of encoding (i.e. semantic clustering), some error types (e.g. intrusions), and retrieval problems (demonstrated by better recognition versus recall) may be less impacted in the earliest stages of disease progression.

**Lay Summary:** The objective of this study was to evaluate memory function in premanifest gene carriers for HD. We found that subtle declines in immediate and delayed recall may be evident even prior to clinical diagnosis of HD.
Neurology Clinic D, CING; 3 Department of Primary Care and Population Health, University of Nicosia Medical School; 4 Department of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King’s College London, UK; 5 Clinical Imaging Research Centre, National University of Singapore, Singapore; 6 Neuroscience, Ophthalmology, and Rare Diseases (NORD), Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffman-La Roche Ltd., Basel, Switzerland; 7 UK Dementia Research Institute at UCL, London, UK; 8 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; 9 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

Background: There is a pressing need for sensitive biomarkers in Huntington’s disease (HD). Mutant huntingtin (mHTT) and neurofilament light (NFL) have been proposed as potential biofluid biomarkers for application in clinical trials. However, little is known about their longitudinal dynamics during the natural history of HD.

Aims: We aimed to characterize the longitudinal trajectories of mHTT in CSF and NFL in CSF and blood plasma.

Methods: We used 24-month longitudinal data from the HD-CSF study. CSF mHTT, CSF NFL, and plasma NFL were measured using immunosays. Participants underwent standardized clinical assessments, CSF and blood collections, and optional brain MRI. Data were modeled using mixed effects models, and associations with clinical and imaging outcomes were studied with Pearson’s partial correlations. Receiver operating characteristics curves were used to test discriminative ability, and samples size calculations to assess feasibility for clinical trials.

Results: 93% of the participants completed the 24-month follow-up. CSF mHTT, CSF NFL, and plasma NFL increased over time in HD mutation carriers and had trajectories distinct from healthy controls. A single measurement at baseline of each analyte significantly predicted subsequent change in analyte. Baseline measurements for each analyte had better accuracy than rate of change in analyte for distinguishing between controls and HD mutation carriers, and between premanifest and manifest HD. Sample size calculations provide participant numbers needed to incorporate these biomarkers into clinical trials.

Conclusion: This longitudinal study provides the first characterization of how mHTT and NFL fluctuate with time in HD mutation carriers. These data will facilitate the interpretation of drug-related alterations in mHTT and NFL in current and future clinical trials.

Lay Summary: Having sensitive biomarkers that respond when a drug is working could help make clinical trials run faster and with smaller numbers of people. In order to understand drug related changes in biomarkers we need to know how they alter in HD mutation carriers without a drug. This study will help us do this.

Enroll-HD Study Status

The Enroll-HD Platform Team

Background: Enroll-HD is a clinical research platform that includes an observational, prospective study of HD. The objectives of Enroll-HD are: 1) enhance the design and expedite the conduct of clinical trials; 2) improve the understanding of the phenotypic spectrum and disease mechanisms; 3) foster good clinical care. Over 21,500 participants (18,734 currently active) have been recruited from 19 countries and 163 study sites. The data collected from these participants is monitored using a rigorous risk-based process.

Enroll-HD also serves as a registry that can be used to facilitate recruitment, by identifying potentially eligible participants who can be invited by investigators to participate in clinical trials. Selection criteria (e.g. local CAG, UHDRS TMS) can be queried to generate listings of participants potentially eligible for a given clinical trial. To improve support for future clinical trials and observational studies, the study has been focusing on the recruitment of at risk, premanifest and early-stage participants. The implementation of the new recruitment strategy is positively impacting the participant population, with an increase of the desired cohorts.

Platform studies are clinical studies that utilize at least one or more Enroll-HD platform services. These services include site feasibility, study guidance documents and templates, potentially eligible participant listings, study set-up support, monitoring and data management. The Enroll-HD Clinical Training Portal is an online resource launched in January 2017 where HD research personnel can complete and maintain study-relevant training, presently UHDRS Motor Certification, GCP (all users), and Enroll-HD Plasma Collection (Enroll-HD study users only). There are currently more than 1600 active users, and it enables faster, more cost-effective set-up of clinical trials and studies, standardizes the quality of training, and reduces workload at sites.

Results: 93% of the participants completed the 24-month follow-up. CSF mHTT, CSF NFL, and plasma NFL increased over time in HD mutation carriers and had trajectories distinct from healthy controls. A single measurement at baseline of each analyte significantly predicted subsequent change in analyte. Baseline measurements for each analyte had better accuracy than rate of change in analyte for distinguishing between controls and HD mutation carriers, and between premanifest and manifest HD. Sample size calculations provide participant numbers needed to incorporate these biomarkers into clinical trials.

Conclusion: This longitudinal study provides the first characterization of how mHTT and NFL fluctuate with time in HD mutation carriers. These data will facilitate the interpretation of drug-related alterations in mHTT and NFL in current and future clinical trials.

Lay Summary: Having sensitive biomarkers that respond when a drug is working could help make clinical trials run faster and with smaller numbers of people. In order to understand drug related changes in biomarkers we need to know how they alter in HD mutation carriers without a drug. This study will help us do this.

Enroll-HD Study Status

The Enroll-HD Platform Team

Background: Enroll-HD is a clinical research platform that includes at its core an observational, prospective study of HD. The objectives of Enroll-HD are: 1) enhance the design and expedite the conduct of clinical trials; 2) improve the understanding of the phenotypic spectrum and disease mechanisms; 3) foster good clinical care. Over 21,500 participants (18,734 currently active) have been recruited from 19 countries and 163 study sites. The data collected from these participants is monitored using a rigorous risk-based process. Recoded data and biosamples are made available to researchers.

Enroll-HD also serves as a registry that can be used to facilitate recruitment, by identifying potentially eligible participants who can be invited by investigators to participate in clinical trials. Selection criteria (e.g. local CAG, UHDRS TMS) can be queried to generate listings of participants potentially eligible for a given clinical trial. To improve support for future clinical trials and observational studies, the study has been focusing on the recruitment of at risk, premanifest and early-stage participants. The implementation of the new recruitment strategy is positively impacting the participant population, with an increase of the desired cohorts.

Platform studies are clinical studies that utilize at least one or more Enroll-HD platform services. These services include site feasibility, study guidance documents and templates, potentially eligible participant listings, study set-up support, monitoring and data management. The Enroll-HD Clinical Training Portal is an online resource launched in January 2017 where HD research personnel can complete and maintain study-relevant training, presently UHDRS Motor Certification, GCP (all users), and Enroll-HD Plasma Collection (Enroll-HD study users only). There are currently more than 1600 active users, and it enables faster, more cost-effective set-up of clinical trials and studies, standardizes the quality of training, and reduces workload at sites.

Lay Summary: Having sensitive biomarkers that respond when a drug is working could help make clinical trials run faster and with smaller numbers of people. In order to understand drug related changes in biomarkers we need to know how they alter in HD mutation carriers without a drug. This study will help us do this.
Materials and methods: This is a case-control study consisting of pre-symptomatic (n = 20), early symptomatic (n = 20) and advanced stage (n = 16) HD patients as well as age matched controls (n = 56). Data regarding demographics, clinical characteristics and lifestyle were collected, including information on dietary intakes using a detailed Food Frequency Questionnaire (FFQ). Untargeted metabolomics analysis will be performed using Liquid chromatography-Mass spectrometry (LC-MS) approaches on serum samples obtained from Cypriot HD patients and healthy controls. Interpretation of metabolomics data will be performed using different bioinformatics tools and databases to identify metabolites and their associated mechanisms influenced by olive oil consumption and the MD.

Results: Expected to demonstrate an overlap between the pathways/metabolites perturbed in HD and those influenced by olive oil intake and MD adherence, thus providing biological plausibility to the available epidemiological evidence, further supporting the neuroprotective effects of olive oil and the MD. Therefore, highlighting the potential use of the MD and olive oil in non-pharmacological interventions aiming to delay HD onset and progression.


References:


Lay Summary: Identify pathways/metabolites in HD and those influenced by olive oil intake and MD adherence in Cypriot HD patients using untargeted metabolomics analysis and bioinformatics analysis, tool and databases. I believe this is important to the HD community as it provides biological plausibility to the available epidemiological evidence, further supporting the neuroprotective effects of olive oil and the MD and also the potential use of MD and olive oil in non-pharmacological interventions aiming to delay HD onset and progression. The use of metabolomics may provide early biomarkers for HD detection.

12 Understanding the Effects of Stress in Families Impacted by Huntington’s Disease: Associations of Coping and Psychiatric Symptoms

Abagail E. Ciriegio1, Lisa Halc2, Anna C. Pfälzer2, Katherine McDonell2, Heather Riordan2, Sarah Moroz2, Daniel O. Claassen2, Bruce E. Compas1

Vanderbilt University, Nashville, TN, USA; 2The Huntington Disease Society of America Level 1 Center of Excellence at Vanderbilt University Medical Center, Nashville, TN, USA

Huntington’s disease (HD) can be conceptualized as a disorder that affects both patients and families. The stressors for patients resulting from the progression of the disease are well documented. However, sources of stress and their impact on offspring of HD patients are less understood. These offspring are faced with stressors that are chronic, unpredictable, and uncontrollable. Further, it is essential to examine the ways adolescent and young adult offspring cope with the stress of being from a family impacted by HD. Previous research has shown that the use of coping strategies that include acceptance and cognitive reappraisal (i.e., secondary control coping) is most adaptive for unpredictable and uncontrollable stress. We obtained reports of coping with HD related stress and psychiatric symptoms from a sample of adolescent (10–19 years; n = 16) and young adult (20–29 years; n = 8) offspring of HD patients. First, levels of a wide range of psychiatric symptoms including depression, anxiety, and

Figure 1. Flowchart of the study design.
obcessive-compulsive problems were elevated in these offspring. The use of secondary control coping in response to HD related stress was significantly and negatively correlated with symptoms of depression ($r = -0.45$, $p = 0.036$), anxiety ($r = -0.57$, $p = 0.005$), and obsessive-compulsive behaviors ($r = -0.56$, $p = 0.006$). To our knowledge, this is the first study to empirically document the association of coping and psychiatric symptoms in adolescent and young adult offspring of HD patients. Important, these findings suggest that teaching secondary control coping skills (e.g., acceptance, cognitive reappraisal) may be important in building resilience in these offspring of HD patients.

**Lay Summary:** Families impacted by Huntington's disease are faced with stressors that are chronic, unpredictable, and uncontrollable. To our knowledge, we are the first study to empirically document the association of coping with these stressors and psychiatric symptoms in adolescent and young adult offspring of HD patients.

13 Gene Expression Profiling of Depression in Huntington’s Disease

Gabriela D. Colpo, Natalie P. Rocha, Erin Furr Stimming, Antonio L. Teixeira
McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA (all authors)

**Background:** Besides motor symptoms, Huntington’s disease (HD) is marked by behavioral changes. Among psychiatric symptoms, depression is of great relevance as it is considered a significant burden. In addition, the presence of depression is a predictor of suicide. This preliminary study investigates the gene expression profile by RNA-seq in HD patients with and without depression, and between subjects with HD and healthy controls.

**Methods:** We performed a RNA-seq analysis of blood of HD patients with depression ($n = 8$), HD patients with no depression or history of depression ($n = 8$) and healthy control subjects ($n = 8$), all matched for age. Preprocessing of data and between-group comparisons were calculated using DESeq2. The Wald test was used to generate $p$ values and log2 fold changes. Genes with a $p$ value $<0.05$ and absolute log2 fold change $>1$ were called as differentially expressed genes. In addition, we clustered differentially expressed genes by their gene ontology (GO) using GeneSCF and the enrichment of GO terms was tested by Fisher exact test.

**Results:** In this exploratory analysis, we found 19 genes differently expressed between HD patients with depression and HD without depression. Among these genes, 6 were upregulated and 13 downregulated. According to the GO analysis, these genes are involved in pathways such as apoptotic process and immune response. In the analysis between all HD patients ($n = 16$) and healthy controls we found 60 genes differently expressed, of which 21 were upregulated and 39 downregulated. According to the GO analysis, these genes are involved in neuron migration, neuron-cell-cell adhesion, brain development, among others.

**Conclusion:** Based on our preliminary results, we suggest that different genetic pathways are involved in depressive phenotype in patients with HD. This information may lead to a better understanding of depression in HD, a more accurate diagnosis, and more effective treatments.

**Lay Summary:** This study investigates the gene expression profile in HD patients with and without depression, and between subjects with HD and healthy controls. This information may help us better understand depression in HD and have a more accurate diagnosis, and more effective treatments.

14 Successful Living Kidney Donation in a Patient with Huntington’s Disease

Christa S. Cooper1, Sarah M. Chen1, Bryan Bernard1, Jennifer G. Goldman2

1Rush University Medical Center; 2Shirley Ryan AbilityLab and Northwestern University

**Objective:** To report a case of a Huntington’s Disease (HD) patient who underwent living kidney donation and examine the decision-making process and ethical considerations of this.

**Background:** HD is an autosomal dominant, incurable, neurodegenerative disease with motor, cognitive, and psychiatric symptoms. According to UNOS, approximately 95,000 people within the United States await kidney donor. There are currently no published ethical or medical guidelines regarding kidney donation in persons with HD.

**Methods:** A 46-year old Caucasian male with 6 years of clinically manifest and genetically confirmed HD wished to donate his kidney to an unnamed recipient. He first expressed interest in altruistic kidney donation with the thought that “he wanted to help others.” His clinical exam revealed moderate chorea, mildly impaired cognitive functions, and normal psychological functions. Discussions between the HD and transplant teams ensued as literature regarding this in HD is scant. Our patient underwent neuropsychological testing revealing mild deficits in executive functions, recent memory, and visual perception, consistent with mild cognitive impairment, and stable psychological function. After completing prerequisite testing (i.e., laboratory and urine tests, ECG, chest x-ray, and CTA abdomen and pelvis) by the HD and transplant teams, he was deemed eligible for kidney donation. He underwent laparoscopic nephrectomy 16 months after first inquiry.

**Results:** He tolerated the procedure well and had an excellent post-operative course. Follow up office visit one week post-op revealed discontinuation of pain medications and resumption of biking for transportation. His HD symptoms remained stable throughout hospitalization and post-operative course.

**Conclusion:** After undergoing the appropriate neurological, neuropsychological, and medical screening and pre-operative work-up, we believe a diagnosis of HD is not an absolute contraindication for kidney donation. A team approach and communication between the HD and transplant teams are essential. Decision-making capabilities, cognitive status, comorbid conditions, and support system must be taken into account.

**Lay Summary:** This is a case report of a Huntington’s Disease patient who underwent living kidney donation and it examines the decision-making process. This case is important to the HD community because it will help to guide future decision making for HD patients that may be considering kidney donation as there are currently no published guidelines.

15 A New Screening Tool, the Huntington’s Disease-Behavioral Questionnaire (HD-BQ), for Assessing Behavioral Disturbances in HD

Jody Corey-Bloom1, Sannee Aboufadel1, Ilex Beltran-Njera2, Haileigh Smith1, McKenna E. Williams2, Paul E. Gilbert2,3
1Department of Neurosciences, University of California San Diego, La Jolla, CA, USA; 2Department of Psychology, San Diego State University, San Diego, CA, USA; 3San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego/La Jolla, CA, USA

**Objective:** To examine the usefulness of a new behavioral questionnaire for patients with, and at risk for, Huntington’s disease (HD).

**Background:** Behavioral changes, including apathy, depression, irritability, anxiety, disinhibition, and difficulty prioritizing and initiating activities, are characteristic features of HD. For families and caregivers, they are often the most distressing aspect of the disease and their assessment is therefore important.

**Methods:** The HD-BQ, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Unified Huntington’s Disease 

---

*Abstract*
Results: The HD-BQ discriminated between HD (mean 31.4, range 0–79), PM (mean 22.7, range 0–73) and NC (mean 15.3, range 0–65) subjects (p < .001). Importantly, the HD-BQ identified significant differences between PM and NCs (p = .048) that traditional cognitive (SDM p = .033; MoCA p = .043; MMSE p = .277), functional (TFC p = .83), and motoric (TMS p = .009) measures did not. Effect sizes, measured by Cohen’s D, were also 60% greater for the HD-BQ (d = 0.93) as compared to the HADS (d = 0.58) and PBA-s (d = 0.38) for NC vs HD subjects. Questionnaires completed independently by 55 HD subject/caregiver pairs revealed a discrepancy in the perception of impairment between patients and their caregivers, with caregivers identifying significantly more behavioral changes (mean difference = 14.9 points; p < .001).

Conclusions: The HD-BQ is a quick, reliable instrument for screening behavioral changes in individuals with, and transitioning to, HD. Behavioral changes are a possible early marker for HD onset. When possible, information regarding behavior should be corroborated by an informant since HD patients tend to underestimate their impairment.

Lay Summary: The objective of this study was to examine the usefulness of a new behavioral questionnaire for HD. We found that the HD-BQ revealed significant differences between HD subjects, premanifest HD subjects, and normal controls. We also found that HD subjects tend to underestimate their impairment.

16 A Novel Huntington’s Disease Mouse Model to Assess the Role of Neuroinflammation on Disease Progression

Heather Dalenberg1, Angelica Bachman1, Haley Nelson1, Kari Pollock1, Peter Deng1,2,3, David Cameron1,2, Joseph Anderson1, Ian Nolta1, Kyle Fink1,4
1Stem Cell Program and Institute for Regenerative Cures, University of California Davis Health Systems, Sacramento, CA, USA; 2Department of Neurology, University of California Davis Health Systems, Sacramento, CA, USA; 3Genome Center, MIND Institute, and Biochemistry and Molecular Medicine, University of California, Davis, CA, USA

Huntington’s disease (HD) is a fatal autosomal-dominant neurodegenerative disease that affects 1 in every 10,000 individuals in the United States. HD is caused by a trinucleotide CAG repeat expansion of the huntingtin gene (HTT), which results in the mutated huntingtin protein (HTT). Although the exact cellular function of HTT is still not fully understood, researchers have found it to be essential in embryonic development and that it controls levels of brain-derived neurotrophic factor (BDNF). Our lab developed novel immune deficient HD mouse models for two commonly used lines, the YAC128 and R6/2 mice, to enable transplantation studies using engineered human cells in addition to studying the impact of the immune system on disease progression. The primary goal of this project was to evaluate these novel immune deficient HD mice (YAC-NSG and R6/2-NSG) using behavioral and histology studies to the immune competent parental mouse strains and to immune deficient mice that had engraftment of a human immune system. We used flow cytometry to confirm the novel HD strains lacked functional immune cells and in vivo imaging to access human MSC retention compared to a commonly used immune deficient line, the NSG mouse. We found that YAC-NSG and R6/2-NSG were able to retain human MSCs for the same length of time as the NSG mice. We performed behavioral assessments starting at 3 months of age until a year old with monthly testing on the accelerated and in the open field. At 12 months, brains were isolated and evaluated using immunohistochemistry for striatal volume and HTT aggregate. These results suggest that the novel immune deficient mice could be good models for human stem-cell based therapies and that the immune system may play an important role in the pathology of HD.

Lay Summary: Our group has created two novel Huntington’s disease mouse models that lack a functional immune system. These mice enable studies of the role of the immune system, allow for the evaluation of transplanted human cells without immune suppressive drugs, and can be engrafted with a functional human immune system to study the interaction of a human immune system to the human mutant protein in a mouse.

17 A Study on Huntington Disease in Cyprus Reveals a Probable Founder Effect and Limited Uptake of Predictive Testing Among Affected Families

Christiana A. Demetriou1,2, Alexandros Heraclides1, Chrysanthi Salafiori3, George A. Tanteles4, Kyprola Christodoulou3, Yiolanda Christou2, Eleni Zamba-Papanicolaou3,2,1
1Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus; 2Neurology Clinic D, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; 3The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus; 4Clinical Genetics Clinic, The Cynt institute of Neurology and Genetics, Nicosia, Cyprus; 5Neurogenetics Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

The aim of this study was to examine Huntington Disease (HD) epidemiology, clinical characteristics and genetic testing trends in Cyprus, an island in southern Europe with extensive western European colonization in the past. All registered HD patients in the Cyprus Republic, since 1994, were included. Detailed pedigrees and clinical information were recorded and maps, showing the geographic distribution of HD, were constructed. Requests for genetic testing were also examined.

The project identified 58 clinically manifested cases, 55 of which belonged to 16 families of Cypriot origin concentrated in a confined geographical cluster in southeast Cyprus. In 2015 prevalence of symptomatic HD was 4.64/100,000 population, while incidence was 0.12/100,000 person-years. Prevalence displayed a marked increase during the past 20 years. Disease characteristics of HD patients were similar to those reported in western European populations. Since 1994, a total of 229 tests were performed of which 50.2% were diagnostic, 47.6% were predictive and 2.2% were prenatal. Using prevalent cases and Conneally’s 1:5 ratio, there are roughly 210 individuals in the Cypriot population who are potential carriers of the HTT mutation and only 54.2% of these potential carriers have sought predictive testing. Also, the heterozygotes in the Cypriot population are estimated to 120 and only 68.3% (n = 82) of them have been identified through genetic testing. Lastly, ~35.20% of all subjects carrying the mutation are currently symptomatic.

The similarity of HD characteristics, incidence and prevalence in Cyprus with those in western European populations, together with the geographical clustering observed, support the possibility for a relatively recent founder effect of HD in Cyprus, potentially of western European origin. Genetic testing trends demonstrate limited uptake of predictive testing among affected families, which becomes particularly important in light of the recent availability of prenatal genetic testing and discovery of huntingtin lowering therapies.

Lay Summary: This abstract describes the only study of the epidemiology of Huntington Disease in Cyprus, a genetically interesting population. In addition, it includes a detailed investigation of genetic testing uptake among affected families, demonstrating limited uptake of predictive testing. Local stakeholders need to address this issue since it becomes of extreme importance as prenatal genetic diagnosis becomes more popular and as huntingtin lowering therapies are being discovered and approved.
Novel Cell-Based Delivery Platform for DNA-Binding Domains Designed to Repress Mutant Huntingtin

Peter Deng1,2,3, Julian Halmai1,2, Nicole Coggins1, Jennifer Walda1,2, Jasmine Carter1,2, David Cameron1,2, Jan Nolta1, David Segal3, Jasmine Carter 1,2, Casiana Gonzales 1,2,4, Krista Thongphanh1,2, Samantha Del Campo1,2, David Cameron2,1, Jan Nolta1, David Segal3, Kyle Fink1,2
1Stern Cell Program and Institute for Regenerative Cures, University of California Davis Health Systems, Sacramento, CA, USA; 2Department of Neurology, University of California Davis Health Systems, Sacramento, CA, USA; 3Genome Center, MIND Institute, and Biochemistry and Molecular Medicine, University of California, Davis, CA, USA; 4Department of Biological Sciences, California State University, Humboldt, CA, USA

The advent of nuclease-deficient DNA binding domains (DBDs) such as zinc fingers and CRISPR/dCas9 for tunable gene expression have revolutionized approaches towards treating genetically-linked neurologic disorders such as Huntington’s Disease. An effective delivery system that can traffic these proteins to target tissue remains a key barrier for translating gene modifying DBDs into the clinic. Cell-based delivery methods, such as mesenchymal stem cells (MSC), are an attractive delivery vehicle for DBDs since such cells can be readily reprogrammed to secrete large proteins and are not limited in their transgene packaging size unlike adenovirus. To evaluate this system, we have engineered bone-marrow derived MSCs to act as in-vivo biofactories that secrete DBDs into the extracellular space whereby the DBDs are uptaken by neighboring cells, and shuttled into the nucleus to alter gene expression. Previously, MSC-dBD proof-of-concept studies were evaluated with lentiviral-engineered bone marrow-derived MSCs that secrete a zinc finger protein to reverse a neuronal imprinting event in a neuronal reporter mouse model. We observed significant reversal of the imprinting event via IHC and western blotting for a fluorescent reporter (YFP) in the hippocampus, cerebellum, and cortex as compared to control treatment groups 3- and 6-weeks post-intracranial transplantation of MSC-DBDs. Presently, we have adapted our MSC-dBD system for the secretion of larger DBDs such as transcription activator-like effectors and dCas9 protein fused with a repressive domains as silencing approaches towards Huntington’s Disease. In the current study, we evaluate the secretion, distribution, and uptake of secreted DBDs in both in-vitro and in-vivo models for HD. We report the first-of-its-kind use of MSCs as a delivery platform for gene modifiers in neurologic disease – expanding the range of gene delivery vehicles in the field.

Lay Summary: A major barrier in advancing promising gene therapies in the clinic are effective delivery systems for large gene modifying proteins. The utilization of a mesenchymal stem cell based system may prove advantageous in this regard since they are able to package very large proteins and can further act as a biofactory for protein production once transplanted into the body. These secreted proteins can then be uptaken by neighboring cells such as neurons where a gene modifying event can occur in a therapeutically relevant manner.

Cognitive Interference of Gait Initiation in Huntington’s Disease

Radhika Desai, Lori Quinn
Teachers College, Columbia University, New York, NY, USA (all authors)

Background: Gait initiation encompasses the preparation and execution of the first step of a gait sequence, and requires appropriate motor planning integration and scaling. Cognitive loads have the ability to interfere with both the scaling and timing of gait initiation. However, deficits in duration and magnitudes of gait initiation, along with related cognitive interference patterns, have not yet been identified in individuals with HD.

Methods: 48 participants, including 33 individuals with manifest HD (20 males, 13 females, mean age 54.67 ± 12.57, mean total motor score (TMS): 11(2)), and 15 healthy controls (8 males, 7 females, mean age 53.2 ± 13.18) wore 3 APDM inertial sensors during a 14 m walk for a single task condition, and again during a cognitive load condition. During the cognitive load condition, participants walked and performed a verbal DKEFS task, altering categorical fruits and vegetables. A repeated measures 2-way ANOVA assessed magnitudes and durations of anticipatory postural adjustments (APAs) across groups and conditions.

Results: A significant main effect, (F(1, 46) = 46.65, p < .00), was found between groups, among measures of APA acceleration amplitudes. Pairwise comparisons revealed significant differences (p = .04) of acceleration amplitudes between No-Load and Cognitive-Load within the HD group. No significant differences were present among acceleration amplitudes for the control group between conditions. Furthermore, differences in durations between conditions were not present in both HD and controls.

Conclusions: Substantially large acceleration values characterize an impairment of APAs in individuals with HD. Impaired scaling of accelerations are worsened when in the presence of a cognitive load in HD. In contrast, durations of APAs are preserved across groups and conditions, revealing a discrepancy in movement scaling in HD. Additional research is needed to identify the neural correlates behind motor planning and scaling in HD. Lay Summary: Components of gait initiation are susceptible to cognitive load and reflect motor planning integrity. HD groups exhibited larger magnitudes of APA accelerations across conditions but maintained durations. This atypical time-scaling pattern provides a behavioral window into motor planning deficits in individuals with HD.
21 Genetic Modulators of 3-Nitropropionic Acid Neurotoxicity: Implications for Huntington’s Disease
Paula Dietrich, Shanta Alli, Megan Mulligan, Robert Williams, Ioannis Dragatis
The University of Tennesse, Health Science Center, Memphis, TN (all authors)

Although several genetic animal models of Huntington’s Disease (HD) have been generated and analyzed over the past decades, none of them recapitulate the striatal neurodegeneration typical of adult-onset HD. On the other hand, systemic administration of the mitochondrial toxin 3-nitropropionic acid (3NP), an irreversible inhibitor of complex II succinate dehydrogenase (SDH), induce striatal-specific degeneration in pri-mates and rodents. 3NP models have been validated by several research groups as reliable models for HD, since they recapitulate not only the striatal neurodegeneration but also several other phenotypic and biochemical features characteristic of the disease. Notably, while the mechanisms underlying preferential striatal vulnerability and degeneration in HD are still unknown, biochemical studies in HD brain tissue and in HD cellular models indicate that mitochondrial dysfunction, and in particular complex II inhibition, plays an important role in HD pathogenesis.

We have found that systemic administration of 3NP induces extensive striatal lesions in the C57BL/6 J mouse strain, while the DBA/2 J mouse strain is completely resistant and shows no signs of striatal damage. Using recombinant inbred BXD (C57BL/6 J X DBA/2 J) strains, we identified a 2 MB resistance locus in chromosome 7. This region contains 15 genes, and among them, Ccnd1, the gene encoding Cyclin D1, a major effector of cell cycle re-entry. Our preliminary results indicate that Cyclin D1 is differentially activated in the striatum of C57BL/6 J and DBA/2 J parental mouse strains in response to 3NP, suggesting a direct link between cell cycle re-entry and cell death. Consistent with this hypothesis, evidence of aberrant cell cycle reactivation has been observed in several models of neurodegenerative diseases, as well as in HD post-mortem brain. Further analyses of the role of Cyclin D1 and cell cycle re-entry in 3NP-induced neurodegeneration may therefore pave the way for the development of novel therapeutic strategies for HD and other neurodegenerative disorders.

Lay Summary: Our study aims to identify genetic factors that confer resistance to striatal neuronal cell death in a non-genetic mouse model of HD. Our findings may lead to the identification of genetic modula-tors of HD and pave the way to the development of new and more effective therapeutic treatments for HD and other neurodegenerative disorders.

22 Prevalence of Huntington’s Disease in a Small City in the State of Alagoas, Brazil
Valmir dos Santos Júnior1,2, Maria Aparecida Santos de Souza Alencar3
1Information Technology Course Federal Institute of Alagoas - IFAL Arapiraca AL – Brazil; 2Huntington Youth Association of Brazil (ABH Joven); 3Huntington Association of Brazil (ABH)

Huntington’s Disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expansion in the CAG trinucleotide in HTT gene responsible for coding a protein called huntingtin. In Feira Grande, a small town in northeastern of Brazil, HD was described for the first time in 2010.

Objectives: The goal of this study was to investigate the HD prevalence in Feira Grande town. It was the only study done after 8 years since the first HD case was reported in this region.

Methodology: This research was exploratory and with quantitative approach. A semi-structured questionnaire (with quantitative approach) was applied during meetings to get some epidemiological data from health professionals and government managers of this town.

Results: Until May 2018, 23 individuals were reported as HD affected in Feira Grande. And 10 HD affected individuals immigrated to other regions looking for caregivers or other reasons. There are more than 200 individuals at HD risk. Therefore, the prevalence of Huntington’s disease in this town is 10.4 cases per 10,000, higher than in European countries with 1/10,000.

Conclusions: Feira Grande town, in the state of Alagoas, currently has the highest prevalence of Huntington’s disease in Brazil, already reported, when compared to the other two known clusters: in Ervâlia-MG and in Sobral-CE. The HD families have scarce support of government. They do not have multidisciplinary assistance and HD information. Therefore, this study is important to collaborate with researchers about the HD epidemiology in Brazil.

Lay Summary: This study is important to collaborate with researchers about the HD epidemiology in Brazil.

23 Genetic Testing for Huntington’s Disease: One Center’s Experience and Lessons Learned
Erin Furr Stimming, Raja Mehanna, Maria Rossetti, Amber McCarthy
UT Health McGovern Medical School, Houston, TX, USA (all authors)

There is increasing demand and interest from at-risk and symptomatic individuals for molecular testing for Huntington’s disease (HD). This has been spurred by recent advances in HD clinical research including the investigation of potential disease-modifying agents. The Huntington’s Disease Society of America (HDSA) provides a genetic testing protocol for Huntington’s disease which is utilized by clinics nationwide. Implementation of this protocol relies on a clinical team of specialists including genetic counselors, neurologists, mental health professionals and social workers. Here we report on the first three years of a rapidly growing Huntington’s disease genetic testing program. We outline current practices in a clinic that has more than quadrupled in size since inception. We discuss challenges to successful adherence to the HDSDA guidelines and strategies for overcoming these barriers. We evaluate the evolving landscape of HD treatment and its implications for genetic counseling and genetic testing. We call for applying lessons learned in the genetic testing of people with Huntington’s disease to similar diseases.

Lay Summary: We report on experience of genetic testing over the past few years for Huntington’s Disease. We identify a trend in an increase in the uptake of and interest in diagnostic and/or predictive genetic testing.

24 Percutaneous Endoscopic Gastronomy Tubes in Huntington’s Disease
Allison Dyke1, Samuel Frank2
1University of New Hampshire at Manchester, Manchester, NH, USA; 2Beth Israel Deaconess Medical Center, Boston, MA, USA

Background: Huntington’s disease (HD) is a fatal hereditary neurodegenerative disorder characterized by progressive motor and cognitive symptoms. When swallowing is impacted, percutaneous endoscopic gastrostomies (PEG) tubes are often recommended. However, the impact of PEG tubes in HD is unknown.

Methods: A retrospective chart review of living and deceased HD pa-tients was conducted to examine whether PEG tubes impact pneumonia risk, length of life, weight, serological nutritional measures or skin issues. The groups with and without PEG placement were compared. For between-groups analyses independent samples t-tests and chi-square test for independence were performed. For within-group analyses paired-samples t-tests were performed.
Results: Records of 39 patients who had a PEG inserted and 109 who did not were examined. The mean age of patients living with HD was 58.3 ± 12.7 years and deceased 57.7 ± 10.3 years. At the time of analysis, the mean duration of HD was 14.2 ± 7 years. Groups were similar in gender, age, and weight at admission. In those deceased (n = 62), insertion of a PEG tube increased length of life with HD (16.8 ± 6.7 vs. 13.2 ± 4.9 years, p = 0.02). Other measures impacted by PEG placement were reduced cholesterol levels (172.2 ± 34.1 vs. 150.5 ± 23.4, p = 0.05), increased prevalence of skin ulcers (44% vs. 12%, p < 0.001) and increased rate of pneumonia (77% vs. 35%, p< 0.001). Insertion of a PEG tube did not significantly change weight or albumin levels.

Conclusions: PEG tube placement in advanced HD provided benefit in length of life, but weight, nutritional measures and the rate of pneumonia were either not impacted or made worse with the insertion of a PEG tube. The impact on quality of the extended life needs further study, but providers, patients and families should consider all options when discussing preferences for interventions.

Lay Summary: To date there is no study that evaluates the risk of developing pneumonia after the insertion of a PEG feeding tube specifically in HD patients. This study examined whether PEG feeding altered the risk of developing aspiration pneumonia, prolonged life, impacted weight or serological nutritional measures and changed the rate of skin issues in HD patients. Results of this study are important to the HD community, as they illustrate the effectiveness of PEG feeding tubes in the HD population, which can allow families and patients to make informed decisions regarding their treatment plans.

25 Composite UHDRS Shows Extensive Spatial Correlation with Gray Matter and White Matter Volume in Huntington's Disease Gene Carriers

C Estevez-Fraga1, EB Johnson1, FB Rodrigues1, P Zenun1, A Durr2, B Leavitt3, RAC Roos1, DR Langbehn2, S Gregory1, G Rees1, RI Scali1, SJ Tabrizi1, and the TrackHD investigators

1UCL Institute of Neurology, London, UK; 2Pitié Salpêtrière Hôpital, Paris, France; 3UBC, Vancouver, Canada; 4Leiden University Medical Centre, Leiden, The Netherlands; 5Carver College of Medicine, Iowa City, IA, USA

Objective: This work sought to determine the structural correlates of variability in UHDRS in HD gene expansion carriers (HDGC).

Background: Symbol digit modalities test (SDMT), Stroop word-reading test and Total Motor Score (TMS) are the most reliable clinical measures in Huntington’s disease (HD). Recently a composite measure of motor, cognitive and functional outcome (cUHDRS) has been proposed as a sensitive clinical tool in early HD(1).

Methods: Participants were recruited from the TRACK-HD study which included 120 premanifest (preHD) and 123 early HD patients. Clinical assessments were performed at four sites. 3 T MRI data were acquired according to a standardized protocol. Nine participants were excluded from the analysis due to poor quality scan or incomplete clinical assessments leaving to a standardized protocol. A total of 234 HDGCs (118 preHD and 116 early HD). Correlation analysis due to poor quality scan or incomplete clinical assessments leaving to a standardized protocol. Correlation analysis was performed using voxel-based morphometry (VBM) in SPM12. We studied the correlation between SDMT, TMS, and cUHDRS scores with gray matter (GM) and white matter (WM) volumes at baseline. Results were considered significant at cluster-level p < 0.05 (FWE-corrected).

Results: Clinical impairment in HDGC was correlated with GM volume in caudate and putamen as well as with surrounding WM volume. This correlation between cUHDRS and both GM and WM volumes was spatially extensive and statistically significant.

Conclusion: In HDGCs, cUHDRS shows a significant correlation with GM and WM volumes in a fashion that extends throughout the basal ganglia and surrounding WM, suggesting this composite clinical measure links closely with underlying HD pathology.

Lay Summary: Composite UHDRS is the principal outcome in the EU of the phase 3 trial with antisense oligonucleotides. This research shows which areas of the brain are correlated with this scale. It shows an extensive association between the scale and both white and gray matter when compared to other established scales.

26 Correlation Between Structural Neuroimaging and Clinical Outcomes in a Small Sample of Patients with Early Huntington’s Disease

Carlos Estevez-Fraga1, Eileanoir B Johnson1, FIlipe B Rodrigues1, Paul Zeun1, Alexandra Durr1, Elin M Rees1, Nicola Z Hobbs1, Raymond AC Roos1, Bernhard Landeweermeyer2, Sarah Gregory1, Rachael I Scali1, Geraint Rees1, Sarah J Tabrizi1

1UCL Institute of Neurology, London, UK; 2Pitié Salpêtrière Hôpital, Paris, France; 3Ixico, London, UK; 4Leiden University Medical Centre, Leiden, The Netherlands; 5University of Ulm, Ulm, Germany

Objective: Here we sought to correlate the best clinical measures in HD with atrophy rates and brain volumes in a small sample of early manifest patients.

Background: Scores on the symbol digit modalities test (SDMT), Stroop word-reading, Total Motor Score (TMS) and composite UHDRS scores are correlated with disease progression and brain changes in large samples of patients with Huntington’s disease (HD).

Methods: Participants were recruited from the PADDINGTON study and comprised 49 early HD patients from 4 sites. Statistical analysis was performed using Stata version 12.0. The boundary-shift integral (BSI) was used to calculate change over 15 months in whole brain, caudate and ventricular volumes. Baseline gray matter (GM), white matter (WM), whole-brain (WB) volumes and voxel-based morphometry (VBM) analysis were performed using SPM12. VBM results were considered significant at p < 0.001.

Results: Ventricular BSI correlated with SDMT (p = 0.038), Stroop (p = 0.005), TMS (p = 0.026) and cUHDRS (p = 0.006). GM volume showed statistically significant correlations with SDMT (p = 0.001), Stroop (p = 0.03), TMS (p = 0.001) and cUHDRS (p = 0.045). WB volume correlated with SDMT (p < 0.001), Stroop (p = 0.045), TMS (p = 0.02). Brain BSI showed correlations with Stroop (p = 0.03) and cUHDRS (p = 0.03), all results shown at an uncorrected level.

VBM showed correlations between baseline GM volumes of several different subcortical nuclei with all clinical measures.

Conclusion: There were statistically significant associations between clinical measures and change over time in brain volumes, suggesting that clinical decline is closely linked to ongoing pathology in HD.

Lay Summary: This is important to the HD community because it shows that even in a small sample of patients with early HD we can see a significant association between different brain areas and clinical scales. This might mean that if one drug has an impact in the scale it may be associated with reduced brain loss.

27 Dual-Task Performance During Standing Balance and Walking in Persons with Huntington’s Disease

Lori Quinn1, Greg Youdan1, Lisa Muratoro2, Xuayao Li1, Nora Fritz3

1Teachers College, Columbia University, New York, NY, USA; 2Stony Brook University, Stony Brook, NY, USA; 3Wayne State University, Detroit, MI, USA

Background: Individuals with Huntington disease (HD) experience declines in both motor and cognitive function, and these impairments result...
Abstract

in difficulty performing motor and cognitive tasks simultaneously which may contribute to fall risk. Little is known about performance of individuals with HD on motor-cognitive dual-tasks or the relationship of clinical dual-task measures with disease-specific measures of disability, cognitive function, and reports of falls.

Methods: Forty-three individuals with HD (mean age: 53.6 years; mean TMS: 40.6) and 15 healthy controls (mean age: 52.2 years) completed 7 m walk test, standing balance, seated cognitive performance (Stroop, Symbol Digit Modalities Test (SDMT), Delis-Kaplan Executive Function System (DKEFS)) and dual-task performance while standing (+ Stroop) and walking (+ DKEFS). Mann-Whitney tests were used to assess between-group differences, correlations to clinical measures were assessed using Spearman correlations, and Fisher r-to-z transformations were used to compare correlations.

Results: Individuals with HD performed worse than healthy controls on both cognitive and motor dual-tasks in both standing (greater sway in Standing+Stroop (p < 0.001)) and while walking (slower walking (p = 0.003)), and had poorer executive function (lower DKEFS (p < 0.001)). Within the HD group, cognitive dual-task performance during standing was more strongly associated with disease-specific measures than dual-task during walking (TMS: p = 0.0042, TFC: p = 0.022). Motor dual-task performance during both standing and walking was also correlated with TMS (Walking+DKEFS: r = -0.42; Standing+Stroop: r = 0.64). Better motor dual-task performance was significantly correlated with better performance on the Stroop (Walking+DKEFS: r = 0.38; Standing+Stroop: r = -0.39) and SDMT (Standing+Stroop: r = -0.58) and was correlated with fewer reports of falls (Standing+Stroop: r = 0.51) in the prior 6 months.

Conclusions: Standing dual-task performance may be a more sensitive measure of motor impairment than walking dual-task performance. Standing dual-task performance may be a contributing factor to falls and overall motor function, and a target of clinical intervention to address these impairments directly.

Lay Summary: Individuals with HD experience declines in motor and cognitive function, yet little is known about the ability of individuals with HD to perform motor and cognitive task simultaneously, and how this might relate to overall function and fall risk. This study shows that performing multiple tasks at once (dual-tasks) is related to both motor and cognitive function, and may be a contributing factor to falls. These results are important because they provide a critical target for clinical intervention to improve motor function and reduce fall risk.

28 Novel PET Data and Analysis of Early HD from Pride-HD

Ralf Reilmann1, Warren C. Olanow2, Mika Leinsonen2, Andrew McGarry2, Michal Geva3, Ferdinando Squitieri3, Frederic Saudou4, Lynn Raymond5, Igor Grachev5, Philipp M. Meyer5, Michael Hayden3,6, Osama Sabri7, Karl Kieburtz2
1George-Huntington-Institute, Technology-Park, Muenster, Germany; 2Clintrex LLC, Sarasota, Florida, USA; 3John Hopkins University, USA; 4CMMC-UBC, Canada; 5John’s Hopkins Institute, USA; 6UT Southwestern Medical Center at Dallas, USA

Pridopidine is a selective Sigma-1 receptor (S1R) agonist. The S1R is an intracellular protein located mainly at the Mitochondria Associated Membranes (MAM), modulating diverse cellular processes including calcium signaling, mitochondrial function and BDNF levels.

Importantly, loss of function mutations in the S1R are associated with neurodegenerative diseases, while S1R activation exerts neuroprotective effects.

Pridopidine demonstrates neuroprotective effects which are mediated via the S1R in different preclinical models of neurodegeneration, including HD and AD. Pridopidine rescues the loss of dendritic spines in HD YAC128 striatal neurons, and the loss of mushroom spines in AD PS1-KI and APP-KI hippocampal neurons. Pridopidine also normalizes calcium-signaling abnormalities observed in HD (YAC128) and AD (PS1-KI and APP-KI) neuronal cultures. SIR knock-out (KO) or inhibition, using known SIR antagonists abolishes pridopidine effects.

Pridopidine exhibits a robust and dose dependent neuroprotective effect against mHTT-induced cell death in human HD iPSCs, and in mouse HD neurons. In HD cortico-striatal cultures, pridopidine rescues BDNF axonal transport, synaptic activity and increases phosphorylation of the pro-survival ERK protein. Pridopidine restores mitochondrial function in YAC128 neurons and in human HD neuronal stem cells as measured by increased ATP production, respiration and mitochondrial membrane potential. Furthermore, pridopidine enhances homeostatic plasticity, a key mechanism for maintaining synaptic stability and strength shown to be impaired in HD neurons.
HD. This is thought to be important for maintaining cognitive functions that are impaired early in HD.

Clinical data supports S1R as the primary target of pridopidine. Pridopidine 45 mg bid dose is shown to have full (>90%) and selective occupancy of the S1R in healthy volunteers and HD patients (PET imaging, unpublished data). In the PRIDE-HD trial, 45 mg bid pridopidine demonstrated a significant effect in maintaining Total Functional Capacity (TFC, an accepted endpoint measuring disease stage) after 1-year treatment, indicating functional benefit.

Lay Summary: Pridopidine represents a drug in clinical development with novel moxa for the treatment of HD. We present here compelling preclinical data demonstrating neuroprotective effects of pridopidine in models of HD and other neurodegenerative disorders. Pridopidine is in clinical development, and a phase 3 trial in HD is planned to be initiated in the near future.

30 Pridopidine Rescues Multiple Mitochondrial Functions Impaired in Human and Mouse HD Models by Activation of the Sigma-1 Receptor

Michal Geva1, Luana Naia2, Philip Ly3, Carla Lopes2, Sandra I. Mota2, Carina Maranga2, Michael Hayden1, A. Cristina Rego1,2

Pridopidine demonstrates neuroprotective functions in several preclinical models of neurodegenerative disorders, including enhancement of neuronal plasticity, axonal transport, and upregulation of neurotrophic factors, via activation of the Sigma-1 receptor (S1R). The S1R is a chaperone protein localized in the mitochondria-associated endoplasmic reticulum (ER) membranes (MAM), where it regulates ER-mitochondrial Ca2+ signaling, generation of reactive oxygen species (ROS) and mitochondrial fission which features are disturbed in Huntington disease (HD). Here, we investigated the protective effect of pridopidine on various mitochondrial functions in human and mouse HD models. Using primary neurons from YAC128 HD mice, expressing the mutant human HTT gene, we observed that pridopidine enhances mitochondria-ER tethering while serving that pridopidine enhances mitochondria-ER tethering while improving mitochondrial activity, elongation and motility. A similar increase on mitochondrial respiration was observed in human HD neural stem cells (NSCs) treated with pridopidine. Increased susceptibility to oxidative challenge was observed in HD mouse neurons, human HD NSCs and in human HD lymphoblasts, resulting in increased levels of ROS and deficient antioxidant response. Pridopidine treatment rescues the antioxidant response and reduces ROS levels in all three HD models. These protective effects of pridopidine were abolished after knock down of the S1R. The protective effect of pridopidine was further confirmed in-vivo, in YAC128 HD mice treated with pridopidine before the appearance of the first symptoms. In-vivo, pridopidine reduced mitochondrial ROS levels through regularized mitochondrial complexes activity, accompanied by a significant recovery of motor coordination. These data indicate pridopidine exerts neuroprotective activities, by enhancing the impaired mitochondrial function in HD, via activation of the S1R. Restoration of mitochondrial function represents a mechanism by which pridopidine exerts its neuroprotective effects.

Lay Summary: This abstract provides data to support mechanistic and protective effects in HD human and mouse models, for a drug in clinical development for HD. This is unpublished data, presenting profound preclinical data suggesting a therapeutic effect for HD patients.

31 Discovering Dominant Features Associated with Disease Progression in Huntington’s Disease: A Data-Driven Approach Using the Enroll-HD Database

Naghmeh Ghazaleh1, Richard Houghton1, Giuseppe Palermo1, Scott Schoebel3, Peter A. Wijeratne2, Jeffery D. Long2,4

1Prilenia Therapeutics, Herzliya, Israel; 2CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; 3Centre for Molecular Medicine and Therapeutics, BC Children’s Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada; 4FMUC-Faculty of Medicine, University of Coimbra, Coimbra, Portugal

This study systematically tested and ranked the statistical importance of potential prognostic factors on different aspects of disease progression in manifest Huntington’s Disease (HD, Stages I–V). Enroll-HD registry data from participants with adult-onset HD, aged 25–65 years, Independence Scale ≥70 at baseline and ≥2 annual visits were used in the analysis (N = 1608; CAG repeats: 36–64). We considered 103 features for each participant, including demographics, clinical characteristics, comorbidities, symptoms, pharmacological and non-pharmacological treatments and Independence Scale at baseline. A random forest-based algorithm was used to rank the features in terms of their ability to predict outcomes (using an importance measure called the permutation importance accuracy). The outcome measures for each patient were their estimated 2-year change from baseline in the composite Unified Huntington’s Disease Rating Scale (uHDRS), and 2-year change in the component scores: Total Motor Score (TMS), Single Digit Modality Test (SDMT), Stroop Word Reading Test (SWRT) and Total Functional Capacity (TFC). CAP (CAG-age product) ranked as the first most predictive feature of progression for all outcomes and CAG14 as the second for all except SWRT, where Independence Scale ranked as second and CAG as third. Independence Scale ranked third for SDMT, TMS and uHDRS and eighth for TFC. Other features associated with faster progression that ranked in the top 10 for at least three of the five outcomes were: being accompanied to visits (for all outcomes), history of cognitive impairment (all but SWRT), ever used tetrabenazine (all but TFC), ever used antipsychotics (all but TMS) and age of onset (all but TFC and uHDRS).

Though causality of the associations and collinearity between features should be further explored, the results suggest the important predictors that are candidates for statistical control in further analyses of observational data in HD.

This study was funded by F. Hoffmann-La Roche Ltd.

Lay Summary: Using data from Enroll-HD, we showed that beyond clinical measures, the product of an individual’s CAG repeat length and age, CAG repeat length itself and Independence Scale score are the best predictors of Huntington’s disease (HD) disease progression. Other factors such as attending visits accompanied, history of cognitive impairment and use of tetrabenazine or antipsychotics were also related to progression. These features should be taken into consideration when analyzing data in other HD studies.

32 Development of a Novel Patient-Reported Outcome Measure for Huntington Disease: The Huntington Disease Health Index (HD-HI) Study

Alistair M. Glidden1, Elizabeth A. Luebbe1, Molly J. Elson2, Steven B. Goldenthal3, Christopher W. Snyder4, Christine E. Zizzi1, Olivia S. Brumfield1, Ray Dorsey1, Chad R. Heatwole1

1University of Rochester, Rochester, NY, USA; 2Emory University, Atlanta, GA, USA; 3University of Michigan, Ann Arbor, MI, USA; 4Rochester Institute of Technology, Rochester, NY, USA
Background: Properly validated patient-reported outcome measures for use in Huntington disease (HD) clinical trials are needed for upcoming trials. 

Objective: To develop a multifaceted disease-specific patient-reported outcome measure for individuals with HD that can measure relevant changes in disease burden over time.

Methods: We performed 40 qualitative interviews and analyzed 2082 quotes regarding the symptomatic burden of HD. We subsequently performed a cross-sectional study with 389 participants to assess the prevalence and relative importance of 216 symptoms in HD. We selected questions for the Huntington Disease Health Index (HD-HI) to maximize its usability, responsiveness, and overall relevance to individuals with HD. Similar symptomatic questions were statistically grouped to form 13 individual HD-HI subscales. We performed cognitive interviews, test-retest reliability testing, and known groups validity testing on the HD-HI to optimize and further validate the instrument.

Results: Beta testing was conducted with 15 participants, as was test-retest reliability testing. The wording of one question was modified based on participant input. Test-retest reliability demonstrated the reliability of the instrument while known groups testing demonstrated the capability of the instrument and its subscales to differentiate between groups of individuals with different levels of disease severity.

Conclusions: Initial evaluation of the HD-HI provides evidence that it is a valid and reliable outcome measure for serially assessing the multifaceted disease burden experienced by individuals with HD.

Sponsorship: Research support provided by NJ Cure and the Huntington Study Group.

Lay Summary: The Huntington Disease Health Index (HD-HI) is a valid, multifaceted, disease-specific patient-reported outcome measure designed to measure therapeutic gain during clinical trials. Here we describe its development and validation process in individuals with HD while outlining its key performance metrics.

Assessment of Mental Health Difficulties in Huntington’s Disease: Does Informant Presence Make a Difference?

Sarah Gunn1, John Malby1, Maria Dale2

1Neuroscience, Psychology and Behaviour, College of Life Sciences, University of Leicester, Leicester, LE1 9HN, United Kingdom; 2Leicestershire Partnership NHS Trust, Adult Mental Health Psychology, OSL House, East Link, Meridian Business Park, Leicester LE19 1XU, United Kingdom

Background: People with neurodegenerative conditions often have communication difficulties and cognitive impairments, making mental health assessment difficult. Informants close to the patient are often included in assessment, but effects of informant presence are unexamined. This study investigated effects of informant presence during assessment of people with Huntington’s disease (HD).

Methods: 4109 people split into four subsamples (manifest HD, premanifest carriers, genotype-negative and relatives not at genetic risk) were compared on the short-form Problem Behaviors Assessment affect, apathy, and irritability subscales, comparing participant-only versus informant-present report. Differences in affect, apathy and irritability scores between participant-only and informer-present conditions were examined via multiple regression, controlling for demographic, disease-related and individual confounds.

Results: Significant differences in apathy and irritability were found between participant-only and informant-present conditions for the premanifest, manifest and genotype-negative subsamples. When controlling for confounds, informant presence still significantly increased reported irritability for the manifest, premanifest and genotype-negative groups, and significantly increased apathy for the manifest group.

Discussion: Apathy may be systemically underreported in participant-only interviews, supporting prior findings of people with HD underreporting mental health symptoms. Affect was uninfluenced by informant presence, potentially due to lower symptom observability. Irritability ratings were higher with informant present for both HD and non-HD individuals, suggesting that underreporting via self-report may be attributable to non-HD factors.

Implications: Informant contributions to apathy assessments may be particularly important for people with HD. Clinicians should also note potential underreporting of irritability and affect, which is not remediated by incorporating informants.

Lay Summary: Mental health difficulties in people with HD are common, but often not recognized/expressed by the individual. Clinicians therefore rely on relative/carer input to identify such difficulties. We found this input is crucial for accurately assessing irritability/apathy, but low mood may still be underreported; this has important implications for assessment and support.

Development of Assessments for Later Stage Huntington’s Disease: UHDRS Structured Interview of Function and HD Clinical Status Questionnaire

O.J. Handley1, S. Capodarca2, S. Frank3, R.L.M. Fuller4, M. Orth5, J.L. Levey6, E. Neacey7, C. Sampaio8

1Cardiff University, UK; 2European Huntington’s Disease Network; 3European Huntington’s Disease Network; 4Beth Israel Deaconess Medical Center, USA; 5CHDI Management, Inc.; 6Ulm University, Germany; European Huntington’s Disease Network

Background: The purpose of this study is to develop two assessments that can be used to measure critical milestones and events during the later stages of Huntington’s disease (HD). An important aspect of the evaluation will be to assess whether the assessments can be administered to a companion either in-person or remotely (i.e. by phone contact with the companion). Therefore, these assessments will be evaluated for their internal consistency, reliability and validity.

Objective: To evaluate these assessments for their internal consistency, reliability and validity.

Methods: Up to 170 dyads of Manifest HD Gene Expansion Carrier Participants and their Companion Participants are planned to be enrolled in this study from approximately 15–20 English-speaking study sites. The study includes two sequential parts, Part 1 and Part 2. Part 1 of this study will evaluate the clinical, functional, and validity of the Unified Huntington’s Disease Rating Scale (UHDRS) and the UHDRS SIF using a cross-over design of the original UHDRS Total Functional Capacity, Functional Assessment Scale and Independence Scale (UHDRS TFC, FAS and IS) and the UHDRS SIF. The UHDRS SIF is a structured interview based on the UHDRS function scales (TFC, FAS and IS) and is administered to a Companion Participant only, either remotely or in-person. Part 2 will assess the clinimetric properties of the HD Clinical Status Questionnaire (HDCSQ), a questionnaire designed specifically to capture information on disease milestones that occur during the later stages of HD, and the UHDRS SIF using a cross-sectional design.

Current status and outlook: This study is in start-up. The First Participant In (FPI) is expected during 1Q2020. Study recruitment is scheduled to end during 2021. Preliminary results from Part 1 will be available during 2020 and full report will be available by the end of 2020. Upon establishing the internal consistency, validity, and reliability these assessments may be incorporated into a large scale, global observational study of HD and/or other HD clinical studies as well as use them for planning clinical trials.

Lay Summary: The purpose of this study is to develop two assessments that can be used to measure critical milestones and events during the later stages of Huntington’s disease. An important aspect of the evaluation will be to assess whether the assessments can be administered to a companion either in-person or remotely (i.e. by phone contact with the companion).
Main Features of Mortality in Huntington’s Disease: Analysis from Enroll-HD Dataset

Ilka Hatakeyama1,2, Paddy Byrne2, Jennifer Hoblyn1,2, Cristin Ryan2
1Bloomfield Hospital, Dublin, Ireland; 2Trinity College Dublin, Dublin, Ireland

Background: Huntington’s Disease (HD) is an autosomal dominant inherited disorder of a progressive nature. It involves a combination of motor, psychiatric and cognitive symptoms that ultimately leads to demise within 15–20 years from initial presentation. The advanced stages of HD require specialized multidisciplinary care in order to maximize the quality of life for these individuals and their family members. However, data describing the later stages of HD is scarce and published studies are limited.

Aims and Objectives: The aim of this study is to depict the main features of mortality in HD and to identify any risk factors that may be influencing death rates. This will be achieved by analyzing data collected by Enroll-HD, a fully integrated clinical research platform.

Methods: Data was obtained from Enroll-HD in a total of 15,301 participants. From this, the deaths of those individuals with manifest HD will be analyzed (N=477). Statistical analysis will be performed with SPSS software (version 25). Descriptive statistic results for continuous variables will be presented as mean (± standard deviation) whereas proportions will be applied for categorical variables. Some of the variables such as age, onset of symptoms, other comorbidities and habits will also be tested as covariates.

Results: As a primary outcome, it is intended to have a clear description of the elements involved in the mortality of HD patients. We will identify and describe any correlations between variables and mortality, in order to determine potential risk factors for death in HD.

Lay Summary: In order to develop specialized multidisciplinary care and maximize the quality of life for HD patients, up-to-date data and in-depth research about the late stages of the disease and description of main aspects of death are essential. The aim is to depict mortality and to identify risk factors that may be influencing death rates.

Experiences of Unauthorized Genetic Testing Disclosure Among Young People

Bonnie L. Hennig-Trestman, Catherine Martin
Huntington’s Disease Youth Organization, Boca Raton, FL, USA

Background: Although predictive testing (PT) is accessible, the percentage of people at-risk who request PT is estimated to range between 3 and 25%. Factors such as psychological and social challenges are suggested to contribute to such low utilization of PT. This study seeks to examine the personal experiences of at-risk individuals that in fact contribute to such low PT utilization.

Methods: Through social media platforms such as Facebook and Instagram the HD Youth Organization (HDYO) initially asked young people (<35yo) affiliated with HDYO to share their testing experiences. Due to the frequency of respondents reporting experiences of unauthorized disclosure to test or disclosure of results for themselves or family members. HDYO then created a one-question online survey asking, “Have you ever experienced a time where a family member’s HD information (or even your own information) was disclosed without their consent?”

Results: Fifty-one young people responded to this inquiry. Twenty people (40%) affirmed that a family member’s or their own information was disclosed without their consent. Seven of the 20 respondents added comments. Each comment described incidences where healthcare practitioners disclosed one or more elements of HD testing information: healthcare practitioners included parent’s HD status in the respondent’s medical record; calls to family members answering questions about testing when the young person specifically indicated not to contact family members; a healthcare professional asked about CAG repeats for another family member even though the young person didn’t know the family member was tested; and a situation where the healthcare provider commented that the respondent was the “last of the family to get tested” even though the person was unaware of others family members’ testing status.

Conclusion: Although best practices have been developed to protect people at-risk, it remains important to educate healthcare providers on how to assure unintentional disclosure is avoided.

Lay Summary: Forty percent of young people who responded to a social media inquiry about unauthorized discloser during genetic testing affirmed that a family member’s or their own information was disclosed without their consent. Although best practices have been developed to protect people at-risk, it remains important to educate healthcare providers on how to assure unintentional disclosure is avoided.

Analyzing Sex Differences in Huntington’s Disease Using Enroll HD

Samantha Hentosh1, Weldon Furr2, Liang Zhu1, Natalia P. Rocha1, Erin Furr2
1UTHealth McGovern Medical School, Houston, TX, USA; 2LSU Health Shreveport, Shreveport, LA, USA

Rationale: Neurodegenerative diseases are influenced by a multitude of factors from genetics to environmental exposures. While much is known about the genetics of Huntington’s disease (HD), sex-dependent differences in outcomes for this particular disease have not been fully uncovered. Other neurodegenerative diseases have been shown to have clear sex-dependent differences in disease prevalence and onset. Interpretation of these differences has an important role in optimizing treatment and better understanding disease mechanism in HD.

Objective: This study was designed to analyze sex-dependent differences in manifest HD patients from the Enroll HD database.

Methods: Longitudinal study including data from baseline and follow-up visits of manifest HD patients (N=8045) from the Enroll-HD database (PDS4). Linear mixed models (GLIMMIX procedure) were used to assess sex-dependent differences regarding the motor, behavioral, and cognitive functioning over a series of 4 annual visits.

Results: Manifest HD patients showed significant sex-dependent differences in motor and depressive symptoms. Both sexes showed worsening motor and depressive symptoms over the course of 4 annual visits, female patients consistently presented with more severe motor and depressive symptoms than males (p < 0.0001). We did not find any difference between sexes regarding age at clinical HD diagnosis or the number of CAG repeats. There were no sex-dependent differences when we evaluated cognitive performance and severity of apathy, irritability/aggressive, psychosis and executive function scores as measured by the Problem Behaviors Assessment – Short (PBA-s) over the four visits.

Conclusions: Our analyses suggest that females overall have worse motor and depressive symptoms than males in the course of HD progression. The importance of continuing to identify sex differences in disease phenotype, progression, and neuropathology is critical for further advancing our understanding and treatment of HD.

Lay Summary: This study analyzes sex-dependent differences in Huntington’s disease using a database that collects information of those affected (Enroll HD). It is important to the HD community because knowledge of sex-dependent differences may inform advancement in treatment and better understanding of disease mechanism.

First FDA-approved Human AAV Gene Therapy Clinical Trial in Adults with Early Manifest Huntington’s Disease
Objective: Design a Phase I/II clinical trial to explore the safety, tolerability, and efficacy of striatally-administered recombinant adeno-associated virus serotype 5, microRNA huntingtin (AAV5-miHTT; AMT-130) gene therapy to lower huntingtin protein (HTT) in the brains of adult, early-manifest Huntington’s disease (HD) patients.

Background: AMT-130 uses a therapeutic approach that efficiently lowers HTT mRNA and HTT protein by an RNA interference mechanism that targets the toxic mutant HTT (mHTT) exon 1 and avoids off-target effects. It is produced in large-scale commercial-grade quantities using a baculovirus expression system and insect cell line. Neuropathology, motor function, and survival improve when mHTT is lowered by 25% to 75% in the brains of transgenic HD animal models. Studies in small and large animals performed under GLP regulations show that high doses of AMT-130 are safe and well-tolerated after intra-striatal administration of AMT-130 by convection enhanced delivery.

Design/Methods: The human equivalent dose (HED) to lower mHTT was extrapolated using a regression plot based on the brain biodistribution in small and large HD transgenic models. A clinical trial was designed using preclinical data and historical patient data from the TRACK-HD study. Results: Bioanalytical modeling indicated that the AMT-130 HED to achieve a 75% lowering of mHTT in the striatum and 50% in the frontal cortex was 6 x 1013 AMT-130 genome copies/brain administered in a single dose. An analysis of historical HD patient data suggested that an 18-month, double-blind, mutation-surgery (sham)-controlled clinical trial enriched for early manifest subjects with 44 HTT CAG repeats, was optimal to evaluate active clinical outcomes will be explored.

Conclusions: We designed a clinical trial to assess safety and explore changes in clinical parameters and biomarkers related to HD progression. This clinical trial was approved by the FDA to enroll HD subjects in 2019.

Lay Summary: We report the design of the first FDA-approved AA gene therapy trial in adult patients with early manifest HD (≥44 HTT CAG repeats) that will enroll patients in 2019. AMT-130 is a one time therapy, delivered intrastrially, and uses a novel RNA interference approach that targets both full length HTT protein aggregates and importantly, also the highly toxic HTT exon 1 protein fragments.

39 Clinical Studies of Deep Brain Stimulation for Huntington Disease with Chorea

AnChao Yang1, Kaili Liang Wang1, Yue Huang2,8, Jean Marc Burgunder3,4, HongQu Gu1, Kai Zhang1, HuanGuan Liu4, Zhong Pei5, HuiFang Shang6*, FanChao Meng1, JianGuo Zhang1*

1Functional Neurosurgery Department, Beijing TianTian Hospital, Capital Medical University, China; 2China National Clinical Research Centre for Neurological Diseases, Neurology Department, Beijing TianTian Hospital, Capital Medical University, Beijing, China; 3Neurology Department, University of Bern, Bern, Switzerland; 4SoMS, Faculty of Medicine, UNSW Sydney, Sydney, Australia; 5Neurology Department, Huaxi Hospital, Sichuan University, Chengdu, China; 6Neurology Department, the 1st Hospital, Zhongshan University, Guangzhou, China; *corresponding authors, email: zjguo73@126.com; hfsfang2002@163.com; presenting author email: yue.huang@unsw.edu.au

Chorea in HD is difficult to manage clinically. Case reports and small series have suggested that deep brain stimulation targeting bilateral global pallidus internus (Gpi-BDS) may improve HD chorea. In our Functional Neurosurgery Department, Beijing TianTian Hospital, we have performed Gpi-BDS on thirteen HD patients with medically refractory chorea from 2012 January to 2018 January. We followed them up for 6 months (n = 13), 12 months (n = 11), 24 months (n = 9), and 36 months (n = 4) and assessed them using motor section of the UHDRS. Chorea and dystonia subscores were significantly improved and maintained for up to 36 months. Total motor scores and hypokinesia sub-score were significantly improved up to 24 and 12 months respectively. Other subscores remained unchanged at any follow-up time-point. At 6 months follow-up, independence scale (IS), functional assessment (FA) and total functional capacity (TFC) were significantly improved. The data from our 13 HD patients provide further evidence for a positive effect of Gpi-BDS in HD patients with Chorea. Therefore, we have set up to conduct a multi-centred, blinded, prospective study in China to consolidate the findings. Patients will be recruited and followed-up at three centres (Beijing, Chengdu and Guangzhou). DBS will be conducted by the same neurosurgery team (Beijing TianTian Hospital) to ensure the consistent quality. Patients will be randomly selected to stimulation ON or OFF right after operation. The primary aim of this study is to evaluate efficacy and safety of Gpi-BDS in the treatment of chorea in patients with HD. Secondary aims include impact of Gpi-DBS on quality of life, on cognitive, behavioural and functional performances of HD. Furthermore, relevant indicators of Gpi-DBS during intraoperative monitoring for predicting postoperative clinical outcomes will be explored.

Lay Summary: Chorea in HD is difficult to manage clinically. From 2012.01 to 2018.01, we have performed deep brain stimulation targeting bilateral global pallidus internus (Gpi-BDS) on 13 HD patients with significant improvement of HD chorea up to 36 months. Therein, we are about to conduct a multi-centred study to further consolidate the findings.

40 Anosognosia Related to Memory but not Executive Functioning, Motor Dysfunction, or Genetic Susceptibility in Huntington’s Disease

Shelby B. Hughes, Ciaran M. Considine, Daniel O. Claassen

Vanderbilt University Medical Center, Nashville, TN, USA (all authors)

Objective: Individuals with Huntington’s disease (HD) frequently exhibit a lack of awareness for obvious disease manifestations, termed anosognosia. Existent research is limited and tends to focus on motor impairment (rather than neurobehavioral and functional manifestations). Neurobiological origins have been proposed (e.g., nondominant frontostriatal dysfunction), with cognitive models proposing mediation via memory and executive functioning impairment. This study measured anosognosia across multiple domains of symptoms in HD patients, then related severity of anosognosia to clinical indicators.

Method: 32 HD patients were administered Deckel & Morrison’s Anosognosia Scale (AS; 1996) as a component of routine assessments.
Corresponding author: Lay Summary: This study looked at potential contributory factors associated with anosognosia in the HD population, specifically cognitive functions and disease severity. Our study shows that anosognosia may be mediated by memory dysfunction, but not by executive dysfunction or disease severity.

41 Comorbidities and Medications in Huntington’s Disease, Parkinson’s Disease and the General Population in a US Claims Database

Lianna Ishihara1, Edward Wild2, David Oliveri3
1Roche Products Ltd., Welwyn Garden City, UK; 2Huntington’s Disease Research Centre, UCL Institute of Neurology, London, UK; 3Genesis Research, Hoboken NJ, USA

Truven MarketScan has been previously used to explore healthcare utilization and direct medical costs among Huntington’s disease (HD) patients by stages of disease progression. This study characterizes the comorbidities, symptoms and treatment patterns of patients with HD compared with patients with Parkinson’s disease (PD) and the general population (GP) excluding neurodegenerative diseases. US claims data can offer valuable insights on the natural history of HD and provide information on standard practices used in a real-world setting.

Patients were matched by age, gender, database type (Commercial/Medicaid) and enrollment prior to the index date (1 January 2017). Diseases and medications selected for this study were related to HD and its symptoms, as well as psychiatric comorbidities, common diseases and commonly used medications. All comorbidities were reported by International Classification of Diseases Version 10 (ICD-10) subheadings, and specific comorbidities and symptoms defined using ICD-10 codes. Medications were reported by therapeutic class and defined using national drug codes.

A total of 587 patients with HD were matched to patients diagnosed with PD and GP controls, of which 453 (77%) had at least one HD ICD-10 code recorded in 2017. Major depressive disorders and other anxiety disorders were the most frequently reported disease subheadings in patients with HD; incidences were also higher in patients with PD than in GP. Patients with HD used antidepressants and antipsychotic therapies most and at a higher frequency than in patients with PD and GP.

These results indicate that major depressive and anxiety disorders are common to both HD and PD relative to the GP. Antidepressants and antipsychotics are commonly used in HD. Further studies exploring specific comorbidities and their relationship to medication use in these patient populations are ongoing.

42 A Fully Automatic Pipeline for Estimation of Putamen and Caudate Volume

Richard Joules1, Richard Parker1, Robin Wolsa2,3
1IXICO Pte, London, UK; 2Imperial College London, London, UK

Introduction: The striatum is a prominent area in Huntington’s pathology where longitudinal atrophy has been employed to assess disease progression and potential treatment effects in clinical trials. Common methods for assessing atrophy require cross sectional segmentations for initialisation. Additionally, cross-sectional volumes of striatal structures are required to estimate dosage in clinical trial interventions where compounds are directly administered to the striatum.

Several methods exist to segment the caudate and putamen, the commonly accepted gold-standard being manual segmentation. This is resource intensive and susceptible to inter- and intra-rater variability. Here, we present a method for fully automated segmentation of the caudate and putamen, LEAP (Wolz;Neuroimage;2010), as applied to a HD cohort.

Method: We have optimized a multi-atlas pipeline to generate segmentations of the caudate and putamen from T1W images in a HD cohort. In brief, images are brain extracted (Pincram;Heckermann;PLOS ONE; 2015) and inhomogeneity corrected (Avants;Neuroinformatics;2011). Pre-processed inputs are compared to a reference database of >500 images with pre-existing caudate and putamen masks. A consensus atlas is generated from the 10 most similar images which is subsequently refined to generate a final regional segmentation.

Results: Test sets of 100 T1W images, with manual caudate and semi-automated putamen “ground-truth” segmentations were processed with the LEAP pipeline. Comparison of LEAP results to the ground truth reveal significant correlations in estimated volumes, r = 0.96 (p < 0.001), for both the caudate and putamen. A significant spatial overlap in segmentations, as measured with DICE was observed for both putamen and caudate with a mean dice DICE of 0.901 (sd=0.03) and 0.8 (sd=0.06) respectively.

Conclusion: We have presented a fully-automatic pipeline for caudate and putamen segmentation allowing for efficiency saving in clinical trial deployments and reduction of potential inter-segmenter variance when compared to manual segmentation.

Lay Summary: This work describes a fully automatic method for segmentation of the caudate and putamen, providing an efficient and robust method for cross-sectional volume estimates and defining regions of interest for estimating longitudinal atrophy in the striatum, a key biomarker in clinical trials of HD.

43 Early Motor Phenotype Influences Neuropsychiatric and Cognitive Disturbances in Huntington’s Disease

Parunyou Julayanont1, Kenneth M. Heilman1,2, Nikolaus R. McFarland1
1University of Florida College of Medicine, Gainesville, FL, USA; 2Malcom Randall Veterans Affairs Medical Center, Gainesville, FL, USA

Funding Information: This study was funded by F. Hoffmann-La Roche Ltd.

Lay Summary: This study looked at the most common medical conditions that affect people living with Huntington’s disease (HD). It also examined the type of drugs prescribed to patients to treat these conditions. The results were compared with patients living with Parkinson’s disease (PD) and the general population. Anxiety and depression were more common in HD and PD than in the general population. Patients with HD were prescribed antidepressants and antipsychotic drugs more often than patients with PD and the general population.
Objective: To determine the influence of motor phenotype on the characteristics of neuropsychiatric disturbances and cognitive impairments in the early motor-manifest Huntington’s disease (HD) individuals.

Methods: From the ENROLL-HD study, 307 HD patients who completed cognitive evaluations were included. Cognitive impairment was defined as at least two domains of cognitive impairment with functional impairment (FIS ≥85). Dementia (HD-Dem) was defined as at least two domains of cognitive impairment with functional impairment (FIS ≤80).

Results: At the onset of motor manifestation, MCI was present in 84% and dementia in 5% of patients. After 5 years of motor abnormalities, 24% of participants met the criteria for MCI and 69% for dementia. Executive dysfunction including slow processing speed were the most prevalent impaired domains found in 70%. Language impairment was reported in 55% and memory deficits were reported in 53%. To classify subtypes of MCI, isolated impairments of “Executive Functions” (including processing speed) and “Representational Functions” (language and memory) were found in 30% and 15%, respectively, while the combined impairments were reported in 55% of HD-MCI cases.

Conclusion: A high prevalence of MCI is present even in the early stage of motor manifestation in HD. Based on the pathophysiology and prevalence of cognitive impairments; we classified MCI among HD patients into “Executive” MCI, “Representational” MCI and Combined “Executive-Representational” MCI.

Abstract

Fall Risk and Functional Balance Are Related to Postural Sway in Huntington’s Disease

Deb Kegelmeyer1, Sandra Kostyk2, Doris Walterhouse1, Anne Kloos1
1School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, OH, USA; 2Department of Neurology, The Ohio State University, Columbus, OH, USA

Background: Postural instability is a common problem in Huntington’s disease (HD), yet little is known about trunk control and postural stability with respect to functional motor and falls. This study explored postural sway between individuals with HD and controls in relation to functional gait, balance, and falls measures.

Methods: Postural sway was measured under 4 conditions (standing on firm and foam surfaces; eyes open and closed) using the Boditrak2 pressure-sensing mat. Sway measures assessed: 1) maximal center of pressure distance reached (COPmax), 2) total COP distance traveled (COPtotal), 3) right and left weight distribution (percent). In addition, gait and balance function were measured using the 25 ft walk test, the Functional Gait Assessment (FGA), Timed Up and Go test (TUG), and six month fall history.

Results: Nineteen individuals with HD (mean age 53 y.o.; 7 males; mean years since onset 7.5); and 11 controls (mean age 43.5; 6 males) participated. Postural sway differed between those with HD (59.7%) and controls (43.4%) only in COPtotal on a firm surface with eyes open (p = .038). Six individuals with HD were unable to stand on foam with eyes closed for the full 30 s while all controls completed this condition (p = .038). In individuals with HD, fallers (n = 10) exhibited significantly unequal left and right weight shift and COPmax when standing on foam in both the eyes open and closed conditions (p < .05) than non-fallers. Lower TMT and FGA scores correlated with higher COPtotal on firm surfaces, eyes closed (r = −.496 and −.575; p < .05). Gait speed did not correlate with postural sway.

Conclusions: Postural sway measures while standing on dense foam may be a simple useful tool for fall risk screening in HD. Greater multidirectional sway standing on a firm surface with eyes closed may indicate balance deficits that affect gait and fall risk.
Although structured survey and prevalence to determine the incidence have not been done in Pakistan, it is postulated from certain indirect studies that our 15,000 family members may require support and information in the KPK region about this disease. In Pakistan people are reluctant to disclose their disease because of culture, so it is also worth mentioning that the number of affected people may be much higher. There is no “Specialized Treatment Center” for degenerative neurological disorders anywhere in Pakistan. These disorders are dealt with by general physicians or interns, but they only manage the medical side of the treatment, about 29% of a patient’s need, whereas the remaining 80% of the management of these disorders is missing. Therefore, in the care and treatment of such patients, the larger element has completely been neglected or has not been taken care of. This leaves these patients at mercy of the drugs only, which have a limited role in the treatment of such disorders as proven by many studies and reviews of randomized control trials conducted in the West. Therefore, there is a dire need for an institute where the medical treatment as well as general supportive care and rehabilitation of these patients can be carried out.

**Patient Services: Must Meet Urgent Needs Now.**

Accordingly, the Huntington Disease Care and Cure Society of Pakistan assists people affected by this devastating nerve disorder, both directly and indirectly, to boldly face the painful and miserable death it brings. This is possible through unconditional quality care, treatment, counseling, and support of the people. The society’s foremost objective is to establish a nursing home at Peshawar, and then a chain of network-clinics and nursing homes in the capital cities of the other three provinces in the long run, provided the resources permit.

**Education, Awareness, Understanding and Know-How.**

To ensure this noble cause is successful, the society is bent on educating the lay public by disseminating information by organizing awareness programs and campaigns on electronic and print media through bulletins, journals, and audio-video-conferences.

**Lay Summary:** Huntington Disease Care and Cure Society of Pakistan is a curtain raiser against HD, is committed to fight for humanity, under the patronage of the Netherlands, to be up to the task and presenting for their initial visit for HD-related health care concerns. The expert assessment of several HD specialists, to identify needs and an optimal plan of care, in the context of a complex illness such as HD, is crucial for individuals and families establishing a relationship for care in an HD Center.

**48 CAG Length Does Predict Duration of Huntington’s Disease Illness**

Douglas R Langbehn
University of Iowa, Iowa City, Iowa, USA

**Background:** There are published claims that, although CAG length is a strong predictor of HD onset-age, it surprisingly does not predict the duration of clinical illness until the time of death. However, we have noted a potential, subtle source of confounding not addressed in the underlying statistical models. We therefore reanalyzed one of the underlying datasets with an alternative model that addresses this potential confounding.

**Methods:** For the purpose of this reanalysis, we were granted access by EHDN to the final Registry database. We fit Cox proportional hazard survival models for the time from HD onset until death and included both CAG length and age of HD onset as predictor variables. In alternative models, we defined onset as the age of UHDRS diagnosis or the clinical rater’s estimate of symptom onset-age. We first fit simple linear models to test the null hypotheses of no age and no CAG effect. We followed this with nonlinear models that more accurately described the relationships between CAG length, onset-age, and time until death. However, we have noted a potential, subtle source of confounding not addressed in the univariate and multivariate models, we defined onset as the age of UHDRS diagnosis or the clinical rater’s estimate of symptom onset-age. We first fit simple linear models to test the null hypotheses of no age and no CAG effect. We followed this with nonlinear models that more accurately described the relationships between CAG length, onset-age, and time until death. We used age-stratified Kaplan-Meier survival plots to illustrate the possible CAG effects in the raw data.

**Results:** After controlling for onset-age (using either definition), CAG length has a highly significant influence on the remaining lifespan. For subjects experiencing onset at the same age, prognosis is clearly worse for those with longer CAG lengths. The phenomenon is easily observed in age-stratified plots of the raw data. The proportional hazard influences of onset-age and CAG are both nonlinear and can be illustrated using restricted cubic spline models.

**Conclusion:** Conditional on onset-age, CAG length does indeed influence length of HD illness until death. Previous analyses suggesting the contrary did not consider the influence of onset-age, which tends to be younger with longer CAG lengths. Perhaps age-dependent protective factors partially mask this CAG influence?

**Lay Summary:** It has recently been claimed that the length of the CAG expansion does not influence the remaining lifespan after the onset of HD illness. Reanalysis of one of the data sources used to
claim this suggests that this is not the case. For people with similar ages of onset, longer CAG lengths are associated with shorter remaining lifespans.

49 An Atlas of Age and CAG-Dependent HD Phenotypes

Douglas R Langbehn1, Cristina Sampaio2, Clement T Loy3, Amrita Mohan2, Elizabeth McCusker4

1University of Iowa, Iowa City, Iowa, USA; 2CHDI Foundation, Princeton, New Jersey, USA; 3Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia; 4Sydney University Medical School, University of Sydney, Sydney, NSW, Australia

Objective: To document the range of Huntington disease (HD) phenotypes in detail for various CAG repeat lengths, age-ranges, and declining functional levels.

Introduction: A fundamental feature of HD is the variable CAG repeat expansion in the Huntingtin gene. Much is known about the variation in onset of motor manifestations and its inverse relationship to expansion in the Huntingtin gene. Much is known about the variation in HD states and for judging the degree to which an individual

Methods: The December 2018 Enroll-HD data-cut contains 27,554 observations of 11,429 individuals with HD gene CAG expansions. This large sample allows detailed observational summaries by five-year age range for all common HD CAG lengths. Further, it allows descriptive plots relating specific ENROLL measurements to age and CAG.

Results: This descriptive atlas is an initial data-reduction that allows easier

Long-term safety, tolerability, biomarker and clinical effects of the HTT-lowering ASO RG6042 are currently being evaluated in a global clinical programme, including an ongoing 15-month OLE study (NCT03342053) in 46 individuals who previously participated in the Phase I/IIa study (NCT02519036). Patients in the OLE were randomized to receive 120 mg RG6042 every 4 weeks (Q4W) or every 8 weeks (Q8W).

At the time of abstract submission, over 400 doses of RG6042 have been administered in participants of this study, with all individuals having received at least 11 doses Q4W or six doses Q8W. The safety and tolerability data to date suggest that RG6042 is well tolerated over greater than one year of treatment. There were fewer overall adverse events (AEs), serious AEs and potentially drug-related complications in the Q8W regimen than the Q4W regimen.

Cerebrospinal fluid (CSF) mutant HTT (mHTT) data available at a 9-month analysis suggest that CSF mHTT levels can be lowered by a median of 47% in the Q8W regimen and 66% in the Q4W regimen with both magnitudes exceeding the minimum considered pharmacologically relevant. Transient increases in CSF neurofilament light chain and Tau are observed in both the Q4W and Q8W groups from data available to date which decreased on continued treatment. The plasma exposure (pharmacokinetics [PK]) and CSF mHTT reduction (pharmacodynamics [PD]) from this study informed a PK/PD model which has been used to simulate a less frequent dosing regimen (every 16 weeks) that would achieve pharmacologically relevant targets for potential efficacy — a hypothesis currently being tested in the Phase III GENERATION HD1 study.

Funding Information: The OLE study was funded by Ionis Pharmaceuticals Inc. and F. Hoffmann-La Roche Ltd.

Lay Summary: Lowering the huntingtin protein (HTT) is a promising therapeutic strategy in Huntington’s disease (HD) which has the potential to slow or stop clinical disease progression. Long-term information about lowering HTT in people with HD using RG6042, an antisense oligonucleotide injected into the spinal fluid, is currently being collected in a global clinical programme. Results from the 15-month extension of the Phase I/IIa study on the safety, tolerability and biological response of RG6042 in patients with HD are being presented.

51 Intrathecal Drug Delivery of Antisense Oligonucleotides in Huntington’s Disease: Experience of Ionis/Roche RG6042 Development Programme and Best Practice Considerations for Real-World Use

Blair R Leavitt1, Edward J Wild2, Jee Bang3, Anne Smith4, Valerie Schlegel1, Scott Schobel1, Alessia Nicotra1, G. Bernhard Landwehrmeyer5, Sarah J Tabrizi2, and Mark Guttmann8 on behalf of the OLE investigator network

1Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; 2UCL Huntington’s Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK; 3Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland; 4F. Hoffmann-La Roche Ltd., Basel, Switzerland; 5Roche Products Ltd., Welwyn Garden City, UK; 6Ionis Pharmaceuticals Inc., Carlsbad, CA, USA; 7Genentech Inc., South San Francisco, CA, USA
Intrathecal administration involves the introduction of a drug substance into the intrathecal (subarachnoid) space of the spinal column through a spinal needle inserted typically into the lower back via lumbar puncture (LP) or via a special device (e.g. a surgically implanted catheter connected to a drug reservoir). This procedure is used when drugs cannot cross the blood–brain barrier. Once injected, drugs administered via the intrathecal route are distributed within the cerebrospinal fluid from which they can access target tissues in spinal cord and brain. The method is commonly used in spinal anesthesia, pain management and chemotherapy; but with the advent of antisense oligonucleotides (ASO) for treatment of neurological conditions, the indications have expanded to include spinal muscular atrophy, and as potential new indications, amyotrophic lateral sclerosis, Alzheimer’s disease and Huntington’s disease (HD).

We use the intrathecal route to deliver RG6042 (previously HTRs), an investigational, huntingtin mRNA-targeting ASO to patients with HD. Considerable experience on intrathecal administration via LP has been gained in the RG6042 clinical development programme, including the double-blind, placebo-controlled, multiple ascending dose, Phase I/IIa study (NCT02519036) in 46 patients with early manifest HD and an ongoing Phase II open-label extension (NCT03342053) where patients receive 120 mg RG6042 monthly or every other month in a 62-week treatment period (total procedures ≥400 in the programme to date).

We will report on the experience with intrathecal drug delivery across these two studies and present information on suggested best practices in HD. Procedure-related videos will be shared, including use of spinal ultrasound. Finally, we will provide a forward-looking outlook on real-world considerations of implementing intrathecally delivered therapies in the clinical interface.

**Funding Information:** The studies were funded by Ionis Pharmaceuticals Inc. and F. Hoffmann-La Roche Ltd.

** Lay Summary:** Injection into the spine via lumbar puncture (known as intrathecal administration) can be used to deliver a drug to the brain when delivery by other methods (pills, intravenous administration, etc.) will not result in enough drug reaching the brain. Intrathecal administration is increasingly being used for drug delivery in neurological diseases. We have gained experience with intrathecal delivery during the clinical development programme of a new experimental drug, RG6042, for people with Huntington’s disease (HD). The presentation will share lessons learnt so far and present information about this important procedure that allows antisense oligonucleotide huntingtin-lowering drugs to be given to people with HD.

52  
Utilizing 24(S)-hydroxycholesterol to Identify Patient Populations and Clinical Endpoints: Negative Emotion Processing in Huntington’s Disease as Proof of Principle

Michael Lewis1, Jing Dai1, Joe Kennedy1, Beth Borowski2, Amrita Mohan2, Sarah Tabrizi3, Albert Robichaud4, James Doherty4, Michael Quirk1  
1Sage Therapeutics, Pharmacology and Translational Science, Cambridge, MA, USA; 2CHDI Foundation, New York, NY, USA; 3UCL Institute of Neurology, University College, London, UK

24(S)-hydroxycholesterol (24(S)-HC) is an endogenous, brain specific, cholesterol metabolite that acts as a positive allosteric modulator of the N-methyl-D-aspartate (NMDA) receptor. Alterations in plasma and/or brain levels of 24(S)-HC have been identified in several diseases, including Smith-Lemli-Opitz syndrome, Niemann Pick, Huntington’s disease (HD), and some forms of dementia. Although a broad range of pathology and core symptomology is observed across these different disorders, all manifest some degree of behavioral and psychiatric symptoms. One important question to be addressed is whether 24(S)-HC is associated with these symptoms and which features are most directly associated with decreased glutamatergic tone.

Cognitive deficits are a hallmark of HD and precede the onset of motor impairments by decades. One of the most consistent cognitive findings in HD are deficits in emotional face processing, which are present in both manifest and pre-manifest HD. Previous work has established that levels of 24(S)-HC are decreased in plasma and brain in HD patients, suggestive of decreased NMDA receptor function. Here, we investigated the relationship between 24(S)-HC and emotional face processing in samples from TRACK-HD, a longitudinal biomarker study of pre-manifest and early stage HD. Plasma samples from the TRACK-HD study (60 control; 60 Pre-HD; 60 HD) were analyzed for 24(S)-HC via liquid-liquid extraction and analyzed with LC-MS/MS. Regression analysis was then performed between oxysterol levels and performance on the Ekman and Friesen emotion recognition task.

We find that 24(S)-HC levels are positively correlated with performance on an emotional face processing task that is not due to overall neurodegenerative processes. Importantly, we found no relationship between emotional face processing and other oxysterols (25-, 27-HC) suggesting a specific role for central nervous system derived 24(S)-HC. These data support a critical role for NMDA receptor function in negative emotion processing in HD and identify emotion recognition as a potential clinical endpoint.

** Abstract **

We have identified a peripherally detectable, brain specific, cholesterol metabolite that may reflect altered NMDA signaling in HD. We found significant correlations between this metabolite and a number of cognitive endpoints in HD. Behavioral and cognitive issues often precede the motor symptoms of HD, sometimes by many years, and there are currently no treatments available for non-motor aspects of Huntington’s disease. We are currently investigating a novel NMDA therapeutic in HD.

53  
Reliability, Feasibility and Validity of a Novel Digital Monitoring Platform Assessing Cognitive and Motor Symptoms in People with Stage I and II Huntington’s Disease (HD)

Florian Lipsmeier1, Cedric Simillion1, Atieh Bamdadian1, Anne Smith2, Scott Schoebel1, Christian Gossens1, Patrick Weidt1, Edward Wild2, Michael Lindemann1

1Roche Pharma Research and Early Development, pRED Informatics, F. Hoffmann-La Roche Ltd., Basle, Switzerland; 2Ionis Pharmaceuticals Inc., Carlsbad, CA, USA; 3F. Hoffmann-La Roche Ltd., Basel, Switzerland; 4University of Ulm Medical Center, Ulm Germany; Current address: Dept. of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Bonn, Germany; 5Huntington’s Disease Research Centre, UCL Institute of Neurology, London, UK

Longitudinal monitoring of HD signs and symptoms through frequent, home-based testing promises to enhance standard clinical tests that are potentially limited by natural symptom fluctuations, inter-rater variability and subjectivity. A preliminary analysis of the ongoing RG6042 open-label extension study (OLE) (NCT03342053) demonstrated that frequent remote monitoring yields reliable and valid measures of cognition and motor symptoms in HD when compared with established clinical measures. The Roche HD digital monitoring platform includes a smartphone application with seven active tests (Symbol Digit Modalities Test [SDMT], Stroop Word Reading, Speeded tapping, Chorea, Balance, U-turn, and 2-min walk test) and continuous passive monitoring. This platform is used in an ongoing, natural history study in patients with Stage I/II HD (NCT03664808). A cross-sectional baseline analysis will be conducted. We will extract predefined sensor features (e.g. number of correct
responses on the SDMT and U-Turn turn speed) from active tests and passive monitoring, as carried out in a cross-sectional baseline analysis with a similar HD population (RG69042 OLE). Features will be averaged from all tests performed over a 2-week period and compared with standard clinical measures at baseline. Intra-class correlation coefficients and Spearman correlations will be used to quantify test-retest reliability, and convergent validity of novel digital measures compared with equivalent in-clinic tests.

We will report on preliminary adherence to demonstrate acceptance and feasibility of the approach and evaluate the test-retest reliabilities of active test features and compare with those collected in a separate study. Results will be reported for correlations of digital test features with related clinical scores. Further evidence of the feasibility, validity, and reliability and agreement between digital and established clinical measures will support continued use of frequent remote digital monitoring of cognitive and motor symptom severity in patients with HD.

**Funding Information:** This study is funded by Ionis Pharmaceuticals and F. Hoffmann-La Roche Ltd.

**Lay Summary:** These investigations aimed to find out if motor and cognitive symptoms in Huntington’s disease (HD) could be reliably measured using a series of at-home tests, developed for use on a smartphone application (app). The researchers will investigate whether the information taken from the in-app tests during two studies are as reliable as in-clinic assessments of HD. This app has the potential to improve how disease progression is monitored in HD. It could result in more efficient clinical trials and improved routine patient care.

**54 HD 101: Educating Occupational Therapy Practitioners about Huntington’s Disease**

Deb Lovecky1, Dèbbie Amin2, Sandra Kostyk3, Ashwini Rao4, K.M. “Shelley” Watkins5, Cindy Sargent6

1Huntington’s Disease Society of America (HDSA), New York, NY, USA; 2American Occupational Therapy Association, Bethesda, MD, USA; 3The Ohio State University, Columbus, OH, USA; 4Columbia University, New York, NY, USA; 5University of Virginia, Charlottesville, VA, USA; 6University of Alabama, Birmingham, AL, USA

HDSA currently has 47 HDSA Centers of Excellence (plus 6 partner sites) that provide exemplary medical and social services to HD families including physical, occupational and speech evaluations. However, ensuring access to ongoing community based rehabilitation services has been a challenge. The number of HD experienced therapists in the areas of physical, occupational and speech therapy are limited. Thus, HDSA sought to create strategic partnerships with the most relevant professional organizations to develop continuing education courses that would provide community based therapy specialists with the tools and knowledge needed to evaluate, assess and treat a person with HD.

HDSA formed an alliance with the American Occupational Therapy Association (AOTA) in 2015. Utilizing HD knowledgeable therapists from HDSA Centers of Excellence, a fully-accredited, multi-module course that provided up to four free continuing education credits (CEs) was created to provide essential information about HD. The course was hosted on the AOTA website for a period of three years. At the completion of the course, participants were tested on knowledge learned in key areas including disease symptomology/progression, evaluation/management of persons with HD throughout the course of the disease, as well as strategies to address special issues pertinent to HD. Over a three-year period, more than 2200 continuing education credits were issued to licensed occupational therapy practitioners by AOTA for the four modules comprising the course.

By educating community-based occupational therapy practitioners, in the specific areas of knowledge needed to assess, evaluate and provide ongoing services, HDSA has improved access to knowledgeable rehabilitation professionals in the community. Partnering with the AOTA, the premier professional organization for licensed occupational therapists, provided HDSA with access to the broadest number of trained OTs in the US. Offering free CE credits ensured that the maximum number of professionals were exposed to the course and the information provided.

**55 Improving Access to Care: Educating Community-based Medical Professionals about HD**

Deb Lovecky1, Jennifer Bomberger2, Gena Dolson2, Jess Dropkin2, Rupinder Hayer2, Catherine Murray2, Ronan O’Beirne2, Jenny Bang2, Danny Bega3, Daniel Claassen3, Samuel Frank3, Madaline Harrison3, Sandra Kostyk3, Erin Furr Stimming4, Victor Sung4, Vaslerie Suski5, Claudia Testa6

1Huntington’s Disease Society of America (HDSA), New York, NY, USA; 2Medscape, New York, NY, USA; 3University of Alabama, Birmingham, AL, USA; 4Johns Hopkins University, Baltimore, MD, USA; 5Northwestern University, Chicago, IL, USA; 6Vanderbilt University, Nashville, TN, USA; 7Beth Israel Deaconess Medical Center, Boston, MA, USA; 8University of Virginia, Charlottesville, VA, USA; 9The Ohio State University, Columbus, OH, USA; 10University of Texas Health Science Center, Houston, TX, USA; 11University of Pittsburgh, Pittsburgh, PA, USA; 12Virginia Commonwealth University, Richmond, VA, USA

**Overview:** Huntington’s disease is rare and thus there are a limited number of trained, qualified clinicians in the community. While HDSA has strategically placed 53 HDSA Centers of Excellence in major population hubs, many HD families are unable to or elect not to use one within their region. To that end, HDSA identified a need to educate community based healthcare providers about Huntington’s disease in order to address this segment of the HD community that does not currently utilize the services provided by an HDSA Center of Excellence.

**The Process:** In 2017, HDSA joined with Medscape to create a one year accredited multi-module Continuing Medical Education (CME) course for primary care providers, neurologists and psychiatrists not familiar with HD. The goal was to provide basic knowledge about the disease, its progression and current treatment options so providers who might currently be treating a person with HD in the community, or who might provide care in the future, would have the necessary tools and resources.

Experts from HDSA Centers of Excellence assisted in program development and served as presenters/panelists.

**Findings:** By the end of 2018, 12,294 learners had viewed the three modules with Medscape awarding 5040 continuing education credits. The most surprising outcome was the number of psychiatrists who participated and earned credits. Of the 12,294 learners, 4576 (37%) were community-based psychiatrists who earned 60% of the CE credits awarded (3041).

While HDSA continues to expand the number of HDSA Centers of Excellence, in order to provide expert care to more HD patients and families, partnering with experienced medical education providers, like Medscape, expands the network of HD knowledgeable community based providers. Offering the expert knowledge, tools and ongoing resources these medical professionals need remains key to ensuring quality care for all persons affected by HD.
Lay Summary: While HDSA continues to expand the number of HDSA Centers of Excellence, in order to provide expert care to more HD patients and families, partnering with experienced medical education providers, like Medscape, expands the network of HD knowledgeable community-based providers. Offering the expert knowledge, tools and ongoing resources these medical professionals need remains key to ensuring quality care for all persons affected by HD.

56
High Intensity Onabotulinum toxinA Therapy for the Management of Severe Dystonia in Juvenile-onset Huntington’s Disease

Leslie C. Markun, Lin Zhang, Alexandra O. Duffy, A. Joshua Dayanathan, Vicki L. Wheelock
University of California Davis, HDSA Center of Excellence, Sacramento, CA (all authors)

Background: Symptomatic management of dystonia in individuals with Juvenile-onset Huntington’s disease can often be difficult and refractory to medication treatment. Few case reports have described symptomatic management with botulinum toxin treatment.

Methods: A single movement disorders neurologist (LZ) performed intramuscular onabotulinum toxinA injections using electromyographic guidance. Standard dosing based on activity of muscle recruitment was selected. Treatment plan adjustments in dosing and frequency were made based on patient response.

Results: Patient 1 was a 20 year-old girl with Juvenile-onset Huntington’s disease starting at age 6 years with progressive bradykinesia, rigidity and painful severe dystonic spasms. She had severe arm involvement with forced elbow flexion causing her to have several extorions of her head. She additionally had retrocollis, lingual and jaw opening dystonia and blepharospasm. She had a partial response to treatment with clonazepam, baclofen and carbidopa/levodopa. She underwent botulinum toxin treatment at targeted muscle groups every 6–8 weeks totaling 600–800 units per treatment. Response with marked improved motor control was noted with six weeks of good effect. She had continued response to treatment for 3 years.

Patient 2 was a 22 year-old girl with Juvenile-onset Huntington’s disease starting at age 13 years with progressive rigidity and severe dystonia of her arms bilaterally and severe anterocollis. Her fingers were clutched and passive upper extremity motion was extremely limited. She was treated trisexyphenidyl and amantadine, but with inadequate symptomatic relief. She underwent botulinum toxin treatment every 6–8 weeks at targeted muscle groups totaling 300–400 units per treatment. Response with improved motor control was noted with eight weeks of good effect. She had continued response to treatment for 6 years.

Conclusions: We report two patients treated with high intensity botulinum toxin injections that resulted in substantial symptomatic relief for acquired dystonia in Juvenile-onset Huntington’s disease.

Lay Summary: Symptomatic management of dystonia in individuals with Juvenile-onset Huntington’s disease can often be difficult to treat. We describe a technique of high intensity botulinum toxin therapy as a management option.

57
Risky Behaviors in HD Patients: A First Look at a New Measure

Katherine McDonell1, Abagail E. Ciriegio2, Lisa Hale1, Anna C. Pfalzer1, Heather Riordan1, Sarah Moroz1, Bruce E. Compas2, Daniel O. Claassen1
1The Huntington Disease Society of America Level 1 Center of Excellence at Vanderbilt University Medical Center, Nashville, TN, USA; 2Vanderbilt University, Nashville, TN, USA

Cognitive and psychiatric changes associated with Huntington disease (HD) typically emerge early in the disease process and are often the most burdensome for patients and caregivers. One aspect of HD that is commonly observed but not well-studied is a tendency towards risky, impulsive behaviors. These behaviors, including hypersexuality, reckless driving, substance use, and physical aggression, can be extremely detrimental and can lead to adverse personal, social, and legal consequences. However, there is currently little literature regarding these symptoms, and no empirically validated measures are available to screen for them.

We present findings on a new measure: The Risky Behavior Questionnaire for HD Patients (41 items, internal consistency reliability = .91). In a pilot sample of 13 HD patients (mean age = 44), 64% of patients endorsed engaging in risky behaviors, further 46% of patients scored in the moderate to severe range for levels of depression. Levels of depression were significantly correlated with total number of risky behaviors (r = .65, p = .031) and specifically with inappropriate sexual behaviors (r = .75, p = .012) and physical abuse of others (r = .73, p = .011). These findings suggest the importance of screening for risky and impulsive behaviors as part of an overall mental health profile of HD patients.

Lay Summary: Risky, impulsive behaviors in HD patients are not well-studied. We present findings on a new measure: The Risky Behavior Questionnaire for HD Patients. These findings suggest the importance of screening for risky and impulsive behaviors as part of an overall mental health profile of HD patients.

58
D-Serine and Metabolic Pathways in Huntington’s Disease of Varying Severity: A Cross-Sectional Pilot Study

Andrew McGarry1, John Gaughan1, Ruin Moaddel2, Basant Pradhan1, Hamza Shaikh1, Cory Hackmyer3, Irving Wainer4
1Cooper University Healthcare at Rowan University, Camden, NJ, USA; 2National Institute on Aging, Bethesda, MD, USA; 3Touro College of Osteopathic Medicine, Middletown, NY, USA; 4Chief Science Officer, Mitchell Woods Pharmaceuticals

Introduction: In HD, no treatment exists for cognitive disability. D-serine (DSR), the most biologically active D-amino acid in the brain, plays a role in dendritic development, synaptic plasticity, and neuronal migration. It is a co-agonist of the N-methyl-D-aspartate receptor and predominantly active at synaptic NMDAR, where long-term potentiation and depression are mediated. DSR may be of importance for cognitive function, though little is known about DSR biology in HD. Here we report initial data in a cross-sectional study of HD patients of varying severities, and explore the relationship between other metabolites and disease severity as measured by the UHDRS.

Methods: 12 symptomatic participants with genetically confirmed HD of varying severity (TFC 3–13) underwent plasma draw and lumbar puncture. Metabolites were analyzed using the AbsoluteIDQ kit p180 (Biocrates Life Science AG, Austria) and the Lipidyzer Platform ((Sciex, Framingham, MA) on a 5500 QTrap(r) (Sciex) mass spectrometer). D-serine was measured following previously developed protocols.

Results: Plasma DSR showed a significant correlation with Stroop Word task and associations with SDMT and independence Scale scores, while total serine showed a significant correlation with Stroop Color and Interference tasks. In CSF, D-serine was not significantly correlated with disease progression; significant correlations included asparagine (positive) and arginine (negative). Arginine, citrulline, and glycine in plasma demonstrated negative correlations with cognitive outcomes. CSF creatinine displayed negative correlations across numerous indices of disease severity, while normal in plasma. A number of triacylglyceride and sphingomyelin species were negatively correlated with disease progression.

Discussion: In this pilot study, decreasing DSR in plasma correlates with cognitive decline. Plasma arginine and glycine were negatively correlated with cognitive decline, with glycine positively correlated with TFC progression. Further study is warranted to determine the natural history and
therapeutic potential for modification in HD of DSR, arginine, glycine, and lipid species. **Lay Summary:** In HD, no treatment exists for cognitive disability. Understanding D-serine, an amino acid in the brain thought to be involved in neuronal plasticity and cognitive function, may reveal strategies for the development of new therapies.

59 Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntington’s Disease

Andrew McGarry1, Michael P. McDermott2, Karl Kieburtz2, Jing Peng3, Merit Cudkowicz4, for the Huntington Study Group 2CARE Investigators and Coordinators

1Cooper University Healthcare at Rowan University, Camden NJ, USA; 2University of Rochester, Rochester, NY, USA; 3The Ohio State University, Columbus, OH, USA; 4Harvard Medical School, Boston, MA, USA.

**Introduction:** Huntington’s disease (HD) is a progressive, fatal neurodegenerative disorder involving motor, cognitive, and behavioral abnormalities that exert a cumulative effect on daily function. It is not clear in the literature which demographic and lifestyle factors are most related to functional progression over time. Understanding variables that are associated with functional decline may be of value towards improving management and quality of life. Using data from 2CARE, a large randomized clinical trial that included up to 5 years of follow-up of participants, we sought to identify baseline clinical, demographic and lifestyle factors that are associated with functional decline as measured by the TFC.

**Methods:** The outcome variable in this secondary analysis was rate of change over time (slope) for the TFC score. Potential baseline risk factors for more rapid progression were examined using linear mixed effects models that included TFC score as the outcome variable and the risk factor, time (continuous, expressed as the number of years since randomization), and the interaction between the risk factor and time as independent variables.

**Results:** Variables associated with faster functional decline included worsening motor performance, worsening cognitive test scores, bipolar disorder, female sex, weight and body mass index, CAG repeat length, and an interaction between CAG repeat length and age.

**Conclusion:** Attention to several of the identified risk factors may be useful towards managing functional decline over time. The finding that women experienced a more rapid functional decline than men, an observation that did not have an interaction with weight/body mass index, deserves attention. It is not clear what the biological basis for this asymmetry would be, as sex hormones are not thought to be relevant to disease mechanisms; this finding requires further study to determine if sex is associated with functional preservation in some currently unknown way.

**Lay Summary:** While the importance of preserving function is generally accepted as an aim of clinical care in HD, it is not entirely clear what factors are most related to functional progression over time. Understanding clinical, demographic, or lifestyle features that are associated with functional decline may be of value towards improving management and quality of life.

61 Multi-Step Prescreening Strategies for HD-Trials

Sarah Moroz, Danielle Buchanan, Brittany Brown, Daniel Claassen Vanderbilt University Medical Center, Nashville, TN, USA (all authors)

**Background:** The initiation of disease-modifying therapies for Huntington’s disease has garnered substantial interest in patient communities. We have noted an influx of patient calls for participation in these trials. To address this, we implemented a multi-step recruitment model, similar to those previously reported, with the objectives to ensure high recruitment, low screening failure and dropout rates, as well as to adequately inform patients of trial opportunities and manage their expectations.

**Methods:** This multi-step screening process utilizes internal and observational databases to identify patients who meet inclusion and exclusion criteria for studies. We note families who have expressed specific interest in participating in clinical trials, including those who have reached out to us from outside the VUMC network. These patients, as well as their primary caregivers, are contacted by phone and interviewed to establish eligibility, commitment, and feasibility (i.e. travel logistics). For queries from patients outside our clinic, we require establishing care at our center to begin a clinical relationship with the HD team. Patients are then placed into a pool of potential study participants and contacted based on the lead coordinator’s discrimination.

**Results:** Since initiation of the multi-step screening process, we have had over 100 patient inquiries, scheduled at least 50 new patient visits, and successfully enrolled 39 patients in 3 disease modifying studies. Our site reports a low number of screening failures and study drop-outs. Through this process, we also noticed the need for inter-site communication, generating referrals between 5 other HD sites and thus creating a network through which HD patients and their families can more comfortably seek treatment and access to clinical trials.

**Conclusion:** As a result of this process, we have effectively succeeded in managing recruitment schedules as well as patient expectations.
Clinicians, social workers, and coordinators have all played an integral role in successfully executing the multi-step screening process. **Lay Summary:** With the inception of a number of disease-modifying therapies for Huntington’s disease, our clinic has received a significant increase in calls and emails from individuals with HD, or their family members, who are interested in participating. In order to effectively communicate the requirements of the trials, as well as to manage patient expectations and decrease the likelihood of screening failures and study drop-outs, we have implemented a multi-step prescreening procedure at our clinic. This system has allowed clinicians, coordinators, and social workers to establish better relationships with patients — old and new — and improved screening outcomes for a number of HD trials.

62 **Profiling Microglial Phenotypes in HD Using Flow Cytometry and Cluster Mapping**

Scott D. Olson, Naama Toledo Furman, Karthik Prabhakara, Erin Furr Stimming
University of Texas Health Science Center at Houston, Houston, TX, USA (all authors)

Neuroinflammation has been shown to be a significant component of the development of Huntington’s disease (HD). This inflammation of the CNS leads to chronic activation of microglia, which contributes to neurodegeneration. A number of interventions have been proposed to target microglial activation to reduce neuroinflammation as a treatment for HD. However, the study of microglia has presented several formidable technical challenges, including difficulty in differentiating microglia from invasive peripheral monocytes and macrophages responding to CNS inflammation. Historically, microglial activation has been described using polarized M1 and M2 phenotypes, however more recent work has found this convention to be oversimplified and insufficient to address the dynamic nature of microglial responses to stimuli in vivo. For these reasons, we have applied new multidimensional cluster-based flow cytometry analysis techniques to a multicolor panel featuring microglial surface markers. These techniques are used to map and discover clusters of events across individuals using unbiased comparisons of surface phenotype marker presence and expression levels. When combined with conventional logic-gating based analysis, these new techniques more accurately demonstrate the changes in microglial phenotypes and conventional M1/M2 surface markers in HD. This will be useful in detecting mild or modest effects of therapeutic interventions on microglia.

**Lay Summary:** With many new therapies for HD on the horizon, it is important to identify factors contributing to the decision to test for at-risk individuals. There has been insufficient data published on cost of testing as a factor. Therefore, we sought to determine whether the cost of predictive testing is a factor in the decision to test in the United States.

**Methods:** The Huntington’s Disease Society of America (HDSA) provided de-identified data from individual Centers of Excellence (COEs) on the various components of the predictive genetic testing process at each COE as well as the cost of each component for an uninsured patient. This data was self-reported by each COE as part of an annual progress report. Data from 2017 (28 COEs) and 2018 (19 COEs) progress reports were aggregated and analyzed.

**Results:** In 2017, the average cost of a predictive genetic test was $1128 (range $324–$3640). In 2018, the average cost of the genetic test was $1142 (range $250–$2625). Only 37% of COEs reported the availability of financial assistance in 2017, and only 39% of COEs reported the availability of financial assistance in 2018.

**Conclusions:** Even at COEs, which perform predictive HD genetic testing with greater regularity than a private practitioner, there is great variability in the cost of testing. With costs averaging >$1000, high costs could play a role in the decision to seek pre-symptomatic genetic testing. Future research should closely examine the impact of high costs on the decision-making process of individuals at-risk for HD.

**Lay Summary:** With many new therapies for HD on the horizon, it is important to identify factors contributing to the decision to test for at-risk individuals. Our research seeks to determine if there is a financial barrier preventing many at-risk individuals from undergoing predictive testing.

64 **Brain-Derived Neurotrophic Factor in Cerebrospinal Fluid and Plasma as a Potential Biomarker for Huntington’s Disease**

Zhen-Yi Andy Ou1, Lauren M. Byrne1, Filipe B. Rodrigues1, Rosanna Tortelli1, Eileanor B. Johnson1, Martha S. Foiani1, Marzenna Arridge2, Enrico De Vita2,3, Rachael I. Scullill1, Amanda Heslegrave1, Henrik Zetterberg1,4,5, Edward J. Wild1
1Huntington’s Disease Centre, University College London (UCL) Institute of Neurology, London WC1N 3BG, UK; 2Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK; 3Department of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King’s College London, London SE1 7EH, UK; 4Fluid Biomarker lab, UK Dementia Research Institute at UCL, London WC1E 6BT, UK; 5Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, 405 30 Gothenburg, Sweden; 6Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 413 45 Gothenburg, Sweden

Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, is implicated in the survival of striatal neurons. BDNF function is reduced in Huntington’s disease (HD), possibly because mutant huntingtin impairs its transport from cortex to striatum, which may contribute to dysfunction and degeneration of striatal neurons. BDNF in blood has been suggested as a potential biomarker for HD, but BDNF has not been quantified in cerebrospinal fluid (CSF) in HD. Our aims were to quantify BDNF in CSF and blood plasma to assess its potential as a biomarker for disease progression in HD. We quantified BDNF in CSF and plasma in the HD-CSF cohort, consisting of 20 pre-manifest and 40 manifest HD mutation carriers and 20 age- and gender-matched controls using an ultrasensitive immunoassay (Quanterix® SimoaTM). We also evaluated several conventional BDNF ELISA kits used in previous CSF reports. Statistical analyses included multiple regression, ANOVA, and ROC analysis. Results were Bonferroni-corrected and adjusted for age, gender, BMI, anti-depressant, anti-psychotic, and blood platelet count or CSF erythrocyte count.
BDNF concentration did not differ significantly between controls and HD mutation carriers in CSF or plasma. Plasma and CSF BDNF in controls, premanifest and manifest HD did not differ across groups (ANOVA P = 0.1058 and P = 0.6564 respectively). BDNF in plasma and CSF were not associated with clinical or MRI brain volumetric measures. Plasma and CSF BDNF had poor diagnostic ability in discriminating controls from HD mutation carriers (plasma AUC = 0.494, CSF AUC = 0.602) and premanifest from manifest HD (plasma AUC = 0.409, CSF AUC = 0.454). CSF BDNF concentrations fell below the lower limit of quantification of all tested ELISA kits used in previous reports in neurodegeneration. We conclude that BDNF in both CSF and plasma is not a biomarker of progression in HD, and urge caution in interpreting studies where conventional ELISA was used to quantify CSF BDNF.

**Lay Summary:** Brain-derived neurotrophic factor, a neuronal growth protein produced by the brain, is reduced in HD and its level in blood or cerebrospinal fluid (CSF) has been suggested as a way of measuring or predicting progression. Using an ultra-sensitive measurement platform, we show that BDNF level is not altered in blood or CSF at any stage of HD, and that the methods previously used in other brain diseases were probably not sensitive enough to measure it reliably in CSF.

### 65 National Trends in Inpatient Gastrostomy Placement for Huntington Disease

Meredith Pauly1, Dylan P. Thibault2, Pedro Gonzalez-Alegre3,5, Allison National Trends in Inpatient Gastrostomy Placement for Huntington HD, and that the methods previously used in other brain diseases were predicting progression. Using an ultra-sensitive measurement platform, Lay Summary: Brain-derived neurotrophic factor, a neuronal growth protein produced by the brain, is reduced in HD and its level in blood or cerebrospinal fluid (CSF) has been suggested as a way of measuring or predicting progression. Using an ultra-sensitive measurement platform, we show that BDNF level is not altered in blood or CSF at any stage of HD, and that the methods previously used in other brain diseases were probably not sensitive enough to measure it reliably in CSF.

### 66 Use of the Enroll-HD Observational Study as a Platform for Enriching Data Collection in a 12-month Nested Randomized Controlled Feasibility Study of a Physical Activity Intervention in People with Huntington’s Disease (PACE-HD)

Cheney J Drew1, Olivia Händley2, Jenny Townhill2, Rhys Williams-Thomas1, Monica Busse1, Lori Quinn1,2

1Centre for Trials Research, Cardiff University, Cardiff, UK; 2European Huntington Disease Network, University of Ulm, Germany; 3Teachers College, Columbia University, New York, NY, USA

**Background:** PACE-HD is a multi-site, 12-month trial within a cohort evaluation of a physical activity intervention in people with Huntington’s Disease with a target recruitment of n = 120. The study design incorporates collection of assessment data at baseline and 12 months, supplemented by outcome data collected at participants’ annual Enroll-HD visit.

**Methods:** Trial sites were selected based on information provided in feasibility forms and numbers recruited to Enroll-HD, facilitated by the Enroll-HD clinical trials manager. Following IRB approval, sites were provided with details of potentially eligible participants according to study inclusion/exclusion criteria by the Enroll-HD clinical trials manager. Further screening for eligibility and recruitment was conducted at site. A specific data request was approved by the Enroll-HD scientific planning committee to provide supplementary outcome data at specified timepoints. Lastly, a monitoring strategy utilizing Enroll-HD monitors to confirm veracity of consent and linking of Enroll-HD and PACE-HD identifiers for data linkage was devised in conjunction with the Enroll-HD team.

**Results:** 411 potential participants were identified via Enroll-HD records. Sites reported screening a total of 273 participants for inclusion on the trial, culminating in the recruitment of 116 participants. Enroll-HD monitors were able to visit each site at least once to ensure verification of eligibility, consent and linked participant identifiers, with completion of monitoring triggering the generation of the baseline data set. 88% of baseline assessments were performed within the stipulated 4-week window from the participant’s annual Enroll assessment.

**Conclusions:** The use of a global observational platform study such as Enroll-HD can be used successfully to deliver clinical trial research in terms of site selection, recruitment, site monitoring and data collection. The use of platforms like Enroll-HD for data collection in future studies has the potential to support innovative trial designs and reduce the burden on research participants.

**Lay Summary:** PACE-HD is a multi-site, 12-month trial within-cohort evaluation of a physical activity intervention in people with HD being conducted across 3 countries. Use of the Enroll-HD platform has been essential in coordinating site selection, recruitment, site monitoring and data collection, and has reduced burden on research participants. The use of a global observational platform study such as Enroll-HD can be used successfully to deliver clinical trial research incorporating innovative trial designs such as PACE-HD.
Piloting Data Linkage with the Enroll-HD Dataset: Linking Between Enroll-HD and PACE-HD

Rhys Williams-Thomas¹, Cheney Drew¹, Fransisco Quevedo Fernandez¹, Katie Taiyari¹, Rebecca Playle¹, Mette Gilling²,³, Lori Quinn¹,⁴, Monica Busse¹
¹Centre for Trials Research, Cardiff University, Cardiff, UK; ²The European Huntington’s Disease Network, University of Ulm, Ulm, Germany; ³University of Copenhagen, Copenhagen, Denmark; ⁴Teachers College, Columbia University, New York, USA

Background: PACE-HD is a cohort study with a nested randomized pragmatic controlled trial to evaluate a one-year physical activity and exercise intervention in people with Huntington’s disease (HD). The PACE-HD study sites also participate in Enroll-HD, a worldwide observational study of HD. For efficiency, a large proportion of trial data will be extracted from Enroll-HD and linked to outcome data collected for PACE-HD. PACE-HD is the first study to request large-scale, specific participant level data from the Enroll-HD study for linkage.

Methods: Variables to be included in the dataset were agreed with the Enroll-HD Scientific Review Committee via the Enroll-HD specified data request process. A dummy dataset of agreed variables was produced to allow preparation of the structured query language server (SQL) database for linkage. Upon import, the database reads the uploaded file, populates the data into tables and produces reports on uploaded versus expected data types and ranges. The dummy dataset enabled testing of this functionality before receiving live data. Data for active study participants was requested from Enroll-HD when all PACE-HD study sites had recruited at least five participants. No identifiable data is collected as part of either study dataset, PACE-HD site staff were required to maintain look-up tables matching unique identifiers for Enroll-HD (HDID) and PACE-HD (PID) to enable linkage by the Enroll-HD team.

Results: The pilot dataset was imported and linking functionality of the PACE-HD database fully tested.

Conclusions: We have formalized a data linkage model using a specified dataset from the Enroll-HD study to be used for PACE-HD. This validated linkage procedure will enable us to import future study data without the need for further data checks thus improving trial efficiency. Importantly linkage to a global observational study has the potential to reduce participant burden and has implications for wider use in future HD trials.

Lay Summary: PACE-HD, a within-cohort, one-year physical activity and exercise intervention in people with HD, is the first study to request large-scale specific participant level data from the Enroll-HD study for linkage. We have formalized a data linkage model using a specified dataset from the Enroll-HD study to be used for PACE-HD. This validated linkage procedure will enable us to efficiently import future study data and has implications for wider use in future HD trials.

Making Sense of Wearable Sensors: Associations Between Movement Smoothness Derived from Wearable Sensors and the UHDRS Chorea Subscore

Gregory Youdan Jr.¹, Lisa Muratori², Nora Fritz², Xueyao Li², Tanya Gurevich¹, Noit Inbar², Inbar Hillef², Monica Busse², Jeffrey M. Hausdorff²,⁶,⁷, Lori Quinn¹
¹Teachers College, Columbia University, New York, NY, USA; ²Stony Brook University, Stony Brook, NY, USA; ³Wayne State University, Detroit, MI, USA; ⁴Tel Aviv Sourasky Medical Center, Israel; ⁵Centre for Trials Research, Cardiff University, Cardiff, UK; ⁶Rush University Medical Center, Chicago, USA; ⁷Tel Aviv University, Israel

Background: Chorea, a hallmark sign of Huntington’s disease (HD), is typically assessed using subjective ratings from the Unified Huntington’s Disease Rating Scale (UHDRS). Wearable sensors are poised to provide precise measurement of motor impairments in people with HD; however, objective metrics that reflect chorea have not yet been identified.

Methods: 43 individuals with early to mid-stage HD (mean age: 53.6 years; mean total motor score (TMS): 40.6) sat (30 s) and stood (45 s) with feet apart and feet together, wearing 6 APDM inertial sensors. Pearson’s correlations were performed between jerk (derivative of acceleration that reflects smoothness of movement) of postural sway and UHDRS chorea subscore, total functional capacity (TFC) and TMS.

Results: Larger jerk of seated postural sway moderately correlated with larger TMS ($r^2 = 0.39$), and weakly correlated with lower TFC ($r^2 = -0.21$). Larger jerk of postural sway while standing feet together ($r = 0.38$) and jerk of seated postural sway ($r = 0.54$) were moderately correlated with greater UHDRS chorea subscore. The final model determined that total sway area in standing feet apart and jerk of seated postural sway were the best predictors of UHDRS chorea subscore, explaining 36% of the variance.

Conclusions: Choric movements lead to an unsmooth movement of the center of mass that can be captured during sitting and standing. Jerk of postural sway from wearable sensors may represent a sensitive measure that relates to chorea intensity and frequency. Additional research is needed to assess the reliability and sensitivity to change of this putative measure of chorea that may be useful in clinical trials.

Lay Summary: Chorea is a hallmark sign of HD; however, it is difficult to reliably quantify. Measures from wearable sensors, specifically those related to the smoothness of postural sway, were found to be correlated with subjective measures of chorea from the UHDRS. Wearable sensors may provide quantitative assessment of the intensity and frequency of chorea, although additional research is needed to assess their use as an outcome measure in clinical trials.

Patient and Physician Perspectives on the Care and Assistance Needs in Huntington’s Disease

Karina Raimundo¹, Ruoding Tan¹, Tu My To¹, Jonathan de Courcy², Umang Ondhia², Hugh Rickards², Martha Nance³
¹Genentech Inc., South San Francisco, CA, USA; ²Adelphi Real World, Bollington, Cheshire, UK; ³F. Hoffmann-La Roche Ltd., Basel, Switzerland; ⁴University of Birmingham, Birmingham, UK; ⁵Struthers Parkinson’s Centre, Golden Valley, MN, USA

Huntington’s disease (HD) is a genetic, neurodegenerative and ultimately fatal disease that leads to loss of independence. Eventually, most HD-affected individuals require assistance with daily activities; however, little is known about the type of care they require, or differences in care requirements across countries.

This is a retrospective analysis of data from the Adelphi HD Disease Specific Programme – a cross-sectional survey of neurologists, patients and care partners conducted in France, Germany, Italy, the UK and the US between July and October 2017. Here we describe patient- and neurologist-reported care and assistance.

Data were available for 1050 patients. 555 (52.9%) were reported by the physician to have a care partner. The most common physician-reported types of assistance were help with managing finances (41.1%), emotional support (39.8%), motivation to engage in daily activities (36.5%), planning and organizing everyday activities (34.3%) and preparing meals (33.2%). For patients with a care partner, assistance types were ranked in a similar order at higher rates. The most common needs varied across countries (France: shopping, 42.4%; Germany: daily activities, 62.4%; Italy: meal preparation, 40.9%; UK: finance management, 42.6%; US:...
Impact on Work Status of People Caring for Someone with Huntington’s Disease

Karina Raimundo1, Ruoding Tan1, Tu My To1, Jonathan de Courcy2, Umang Ondhia1, Hugh Rickards4, Martha Nance5,6
1Genentech Inc., South San Francisco, CA, USA; 2Adelphi Real World, Bollington, Cheshire, UK; 3F. Hoffmann-La Roche Ltd., Basel, Switzerland; 4National Centre for Mental Health, Birmingham, UK; 5Struthers Parkinson Centre, Golden Valley, MN, USA

Huntington’s disease (HD) is a genetic, progressive and ultimately fatal neurodegenerative disease that leads to loss of independence. All people with HD eventually require care; however, little is known about the impact caregiving has on a family member’s employment status.

This is a retrospective analysis of data from the Adelphi HD Disease Specific Programme, a one-time survey between July and October 2017 of physicians, patients and care partners in France, Germany, Italy, the UK and the US. Since only a small number of care partners answered the survey, we focus on the physician-reported impact of caregiving on employment status.

Data were collected from 1050 patients. Rates of caregiving were higher in France (69.4%) and Germany (64.9%), while the lowest rates were reported in the US (39.6%). 555 (52.9%) patients had care partners who were; professional only (n = 68, 12.3%) both professional and non-professional (n = 106, 19.1%) or non-professional only (n = 378, 68.1%). Among non-professional care partners, the most common family member to fulfill the role was the partner/spouse (74.5%). 27.4% of care partners worked full-time, 22.7% part-time, 22.5% were retired and 20.1% were unemployed/homemakers. Germany (75.0%) and US (61.0%) reported the highest number of full- or part-time care partners, whereas UK reported the lowest rate (15.2%). Physician-reported impact of patients’ HD on the care partner’s work status was evaluated in 82.8% of cases. 45.7% of care partners reported a change in work status due to HD. Work status changes typically occurred when patients were in Stage II or III. Significant indirect cost exists for caring for patients with HD. Care partners are usually close relatives and caregiving often has a negative impact on the care partner’s employment status, with severity of impact depending on factors including HD stage.

Funding Information: This study was funded by Genentech Inc. and F. Hoffmann-La Roche Ltd.
Research, Cardiff University, Cardiff, Wales, UK; 5Neurology, Taub Institute, GH Sergievsky Center, Columbia University, NY, USA

Introduction: People with Huntington disease (HD) have mobility impairments and increased risk for falls, which limit quality of life. We examined the spatial extent of mobility, characteristics and circumstances of falls in people with Manifest HD.

Methods: 50 people with HD (53.4 ± 11.8 years) and 28 controls (52.3 ± 10.6 years) were tested. Falls were examined with the History of Falls Questionnaire, and physical activity was quantified with the International Physical Activity questionnaire. Postural sway was measured with inertial sensors (APDM). We administered the Life-space questionnaire, a reliable and valid tool that measures the extent, frequency and assistance needed for spatial mobility patterns at home and community in a subset of participants (n = 30). Scores range from 0 (bed bound) to 120 (travel outside town). Clinical assessment included the UHDRS Total Motor Score, Symbol Digit Modality Test, and Functional Assessment. Pearson correlation and regression analyses were used to examine associations.

Results: Age, height and weight were similar across groups. Falls were reported by 58% of HD subjects, among whom 69% reported 2 or more falls. Common causes of falls included loss of balance (48%), slips (24%), trip/stumble (20%) and quick movements (20%). Indoor falls were most common (58%) and environmental hazards contributed to 24% of falls, trip/stumble (20%) and quick movements (20%). Indoor falls were significantly associated with cognitive function (r = 0.42, p = 0.04). The mean Life-space score was 74.2 ± 28.4 (Range 8–120). 60% of HD subjects had scores indicating that their mobility was limited to their home and neighborhood. Life-space score was significantly correlated with postural sway (r = 0.67, p = 0.005) and UHDRS Functional Assessment (r = 0.49, p = 0.01), but not with cognitive function or falls.

Conclusion: Cognitive impairments and environmental hazards contribute to falls, and postural instability contributes to falls and community mobility. Postural stability and environmental modifications may be important targets for intervention.

Lay Summary: Mobility and participation in community activity may prevent falls and contribute to quality of life in people with Huntington disease (HD). It is therefore important to examine patterns of community activity and factors associated with falls in people with HD.

73

Microglia Activation in Basal Ganglia Is a Late Event in Huntington’s Disease Pathophysiology

Natalia P. Rocha1,2,3, Leigh B. Latham4, Odelin Charon2, Gabriela D. Colpo2, Paolo Zanotti-Fregonara2, Leorah Freeman2, Erin Furr Stimming2, Antonio L. Teixeira1

1Mitchell Center for Alzheimer’s Disease and Related Brain Disorders, Department of Neurology, The University of Texas Health Science Center, Houston, TX, USA; 2HDSA Center of Excellence at University of Texas Health Science Center at Houston, Houston, TX, USA; 3Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas, Houston, TX, USA; 4School of Medicine, University of Washington, Seattle, WA, USA; 5Department of Neurology, The University of Texas at Austin, Austin, TX, USA; 6Nantz National Alzheimer Center and Houston Methodist Research Neurological Institute, and Weill Cornell Medicine, Houston, TX, USA

Rationale: Previous studies have shown that inflammatory mechanisms are intrinsically associated with neurodegeneration. However, the role of both central nervous system and peripheral inflammation in HD is still poorly understood.

Objective: To investigate structural and functional changes in microglia in different stages of HD.

Methods: 12 patients with a genetic diagnosis of HD [6 manifest patients (50.8 ± 11.5y;6F), 6 premanifest HD gene carriers (38.2 ± 7.2y;4 M/2F)], and 6 controls (43.3 ± 8.8y;5F/1M) underwent a [11C]-ER176 PET scan and an MRI for anatomical localization. Segmentation of region of interest (ROIs) was performed and group differences in [11C]-ER176 binding (used to evaluate the extent of microglial activation) were assessed by the standardized uptake value ratio (SUVR), that is, the ratio of brain uptake in ROIs to that in the cerebellum. Blood samples were collected and monocytes were used to generate induced microglia-like cells (iMG). In vitro evaluation of the dynamic functions of microglia included a phagocytosis assay.

Results: Patients with HD present higher [11C]-ER176 SUVR in both left and right pallidi and putamens in comparison with controls (p < 0.05; Kruskal-Wallis test followed by Dunn’s test). No differences were observed when we compared premanifest HD with controls or with manifest HD. IMG from controls, premanifest HD and HD patients showed similar phagocytic capacity. However, cytokine production during phagocytosis was increased in iMG from patients with manifest HD in comparison with premanifest HD and controls.

Conclusions: Patients with manifest HD present increased microglia activation in basal ganglia structures that are known to be involved in HD pathophysiology. Premanifest HD gene carriers present SUVRs similar to controls, thus concluding that microglia activation occurs later in HD pathology. It is important to refine the understanding of the more specific immune/inflammatory mechanisms that are involved in HD. This will allow the development of new therapeutic interventions to halt the progression of HD.

Funding Information: Huntington’s Disease Society of America (HDSA).

Lay Summary: Previous studies have shown that inflammatory/immune mechanisms are intrinsically associated with neurodegeneration. Herein, we investigated microglia activation (the brain immune cells) in different stages of HD. We found that patients with manifest HD (but not premanifest HD) present increased microglia activation in brain structures that are known to be involved in HD pathophysiology. It is important to refine the understanding of the more specific immune/inflammatory mechanisms that are involved in HD. This will allow the development of new therapeutic interventions to halt the progression of HD.

74

The Digital-HD Study: Smartphone-based Remote Testing to Assess Cognitive and Motor Symptoms in Huntington’s Disease

Rosanna Tortelli1, Cedric Simillion2, Florian Lipsmeier2, Timothy Kilchenmann3, Filippe Brogueira Rodrigues1, Lauren M Byrne1, Atrieh Bamdadian2, Christian Goossens2, Scott Schobel1, Michael Lindemann2, Edward J Wild1

1UCL Huntington’s Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK; 2Roche Pharmaceutical Research and Early Development, pRED Informatics, F. Hoffmann-La Roche Ltd., Basel, Switzerland; 3F. Hoffmann-La Roche Ltd., Basel, Switzerland

The aim of this study is to evaluate the ability of smartphone-based remote testing to meaningfully quantify signs, symptoms and impairments among participants with premanifest Huntington’s disease (HD) and manifest HD and compare them with healthy controls (HC).

A smartphone application comprising seven active tests (Symbol Digit Modalities Test [SDMT], Stroop Word Reading test [SWRT], Speeded tapping, Chorea, Balance, U-turn, 2-min walk) and continuous passive monitoring is deployed in an observational study (Digital-HD) of participants with premanifest HD, manifest HD and HC. Predefined active test measurements were aggregated over Weeks 5 and 6 post-screening to minimize practice effects. Group differences between HC, premanifest HD and manifest HD were analyzed using the Kruskal–Wallis test and...
Abstract

A subsequent pairwise Mann–Whitney tests. In an exploratory analysis, a broader set of features was analyzed for differences between HC and participants with premanifest HD. Recruitment for Digital-HD is ongoing. Preliminary data were analyzed from 18 participants with premanifest HD, 15 with manifest HD and 19 HC. Predefined digital tests generally had close correspondence with their commonly used in-clinic counterparts and these significantly differed between HC or the premanifest HD group and the manifest HD group (p = 0.01–0.05 for U-Turn speed and 2-min walk step frequency variability, p < 0.01 for all other tests); however, no differences were observed in these tasks between HC and the premanifest HD group. The exploratory analysis identified several features with high face validity that significantly differed between HC and the premanifest group (e.g. tapping regularity in the speeded tapping test and drawing speed and accuracy in the Draw-a-shape test). This preliminary analysis suggests that the digital platform can robustly measure established features of manifest HD, and affords the opportunity for innovative measures that may have great value in assessing premanifest and prodromal phases of HD.

Funding Information: Study funded by F. Hoffmann-La Roche Ltd.

Lay Summary: Digital-HD is a study to compare smartphone-based assessments in Huntington’s disease (HD). Healthy controls and people with premanifest HD were found to perform differently from people with manifest HD in several tests, implying that this technology has the potential to shed light on disease symptoms and progression during the early stages of HD.

Cerebral Blood Flow and Affect Recognition in Early Premanifest and Manifest Huntington’s Disease

M. Agustina Rossetti, Erin Furr Stimling, Natalia Pessoa Rocha McGovern Medical School at UTHealth Houston, Department of Neurology (all authors)

Objective: Emotion recognition deficits have been well studied in Huntington’s disease (HD). The objective of this study was to examine the association between deficits in affect recognition and cerebral blood flow in early premanifest and manifest HD.

Methods: Seven control, seven early premanifest (11.67 ± 7.09 years before the predicted clinical diagnosis), and seven manifest participants completed neuropsychological measures, including an affect naming scale. As part of a larger HDSA funded study, they underwent brain magnetic resonance imaging (MRI) at 3 T with pseudo-continuous arterial spin labeling (pCASL) to quantify cerebral blood flow (CBF), and 3D-MPRAGE for volumetric segmentation. pCASL images were analyzed with the FMRIB Software Library (FSL) and FreeSurfer v5.3.0. Region of interest (ROI) analyses were performed to analyze the correlation between CBF in specific brain regions and affect naming scores (Spearman correlations).

Results: No statistically significant differences among the three groups were observed in age, education, or gender. CAG length did not statistically differ between the manifest (44.67 ± 2.42) and premanifest (42.67 ± 1.86) participants (p = 0.140). Compared to healthy controls and early premanifest individuals, manifest participants had significant difficulties with affect naming with the highest number of errors made on items assessing perception of negative emotions. Among manifest HD, affect naming (total correct responses) correlated with CBF in left pallidum (r = −0.883, p = 0.020), left amygdala (r = 0.971, p = 0.001), and left insula (r = 0.883, p = 0.020). These correlations were not found among controls or the early premanifest HD group.

Conclusion: Early premanifest and healthy controls do not differ in their ability to recognize emotions from facial stimuli. There were no correlations between affect naming and regional CBF in the early premanifest group. Among individuals with manifest HD, there were strong associations among emotion recognition and CBF in the left insula and amygdala, areas well established in the neurobiology of emotional perception. Future studies examining these associations in prodromal HD are warranted to help inform behavioral interventions if and when a disease modifying therapy is approved.

Lay Summary: This pilot study examines affect recognition and cerebral perfusion in early premanifest and manifest HD patients. This research may help elucidate early changes in blood flow in the disease spectrum and help inform when appropriate interventions that target emotion recognition training may be implemented.

76

Sleep Disturbance in Huntington’s Disease – Observational Study

Kasia Gustaw Rothenberg, Lyndsey Sandy, Anwar Ahmed Cleveland Clinic, Cleveland, OH, USA (all authors)

Objective: Both mood disorders as well as sleep disturbances are a prominent feature of Huntington’s disease, and substantially impair patients’ quality of life (Bellosta Diago et al. 2017. Simpson et al. 2016). Similarly, both in Huntington’s disease (HD) as in depression, sleep disturbance becomes one of the dominant pathognomonic features (Morton et al. 2014). Moreover, sleep problems may be the first sign of the onset of a major depressive episode. Some studies involving HD patients suggest that a deficit contributing to disordered sleep is reduced suprachiasmatic nucleus output. The mechanism underlying this deficit is not yet known, but mitochondrial dysfunction and oxidative stress are likely involved (Pallier et al. 2007, Van Wamelen et al. 2013). This raises the possibility that the disordered sleep and circadian function experienced by HD patients may be an integral part of the disease.

Aim: To delineate the nature of sleep disturbances and identify correlates of sleep impairment in the context of depression in HD patients.

Subjects:

Demographics, genetic, mood and sleep parameters were analyzed in:

- 37 Patients (10 M and 27 F) with symptomatic Huntington’s disease
- Mean age 51 (range 32 to 79; median 51)
- Mean numbers of CAG repeats 44 (range 38–62; median 43)
- All diagnosed and treated in HDSA Center of Excellence at Cleveland Clinic (assessment between February 2017 and July 2018).

Methods:

- Clinical questionnaires for sleep and psychiatric assessment for depression were used.
- Sleep-wake disorders were categorized according to DSM 5 criteria.
- Depression was quantitatively assessed by PHQ 9 (maximum score 27).
- Study protocol was approved by The Cleveland Clinic IRB (#18–1040).
- Descriptive statistics and correlates were calculated with Statistica.

Results:

- All examined Patient but four report history of at least one episodes of major depressive disorder (80%).
- Of thought all we actively treated for depression (55% SSRI, 26% SNRI, 18% the other groups of antidepressants, 60% of Patients were on two or more agents).
- At the time of evaluation 88% of patient were in at least partial remission.
- According to PHQ9 (mean score 10.2 range 0–22, median 8) patient presented only with minimal (PHQ1–4) or mild depression (PHQ5–9) at the time of evaluation.
Sleep impairment was prevalent in HD Patients and was reported by almost all examined but two (94.5%).

• Circadian rhythm sleep-wake disorders with delayed sleep phase type dominated in the group (30/37, 81%)
• Followed by insomnia (26/37; 70%) and
• Hypersomnia (7/37; 18%).

More than 60% of Patients suffers from two or more sleep disorders
• Only 13% of Patients however reported the most characteristic for depression early morning awakenings.

• Correlations:
• History of depression correlated with sleep disturbance (r = +0.76) but not with number of CAG repeats (r = +0.17).
• Treatment and remission of depression did not correspond with improvement in the sleep disorders (r = -0.2).
• Sleep impairment seem to persist beyond any form of treatment for depression in (32/37); 86% of Patients.

Conclusions: HD is primarily accompanied by circadian rhythm sleep disturbances, delayed sleep phase, which are associated with depression but does not respond to depression management. This raises the possibility that the disordered sleep and circadian function experienced by HD patients may be an integral part of the disease independent from mood disorder. If these hypotheses are correct, we should focus on treating circadian misalignment and sleep disruptions early in disease progression parallel to addressing depression.

Lay Summary: HD is primarily accompanied by circadian rhythm sleep disturbances, delayed sleep phase, which are associated with depression but does not respond to depression management. This raises the possibility that the disordered sleep and circadian function experienced by HD patients may be an integral part of the disease independent from mood disorder. If these hypotheses are correct, we should focus on treating circadian misalignment and sleep disruptions early in disease progression parallel to addressing depression.

Abnormal Development of Cerebellar-Striatal Circuitry in Huntington’s Disease

Jordan L. Schultz, Alexander V. Tereshchenko, Joel E. Bruss, Vincent A. Magnotta, Eric A. Epping, Peg C. Nopoulos
The University of Iowa, Iowa City, IA, USA(all authors)

Objective: To investigate functional connectivity differences over time of the striatum and the cerebellum between pre-symptomatic patients with the HD gene expansion (GE) and patients with a family history of HD but without the gene-expansion (GNE).

Methods: This study utilized resting-state, functional MRI (rs-fcMRI) data from participants enrolled in the Kids-HD study who were 6 to 18 years old. Participants were divided into the GE (CAG ≤ 36) and GNE (CAG <36) groups. Seed to seed correlations were calculated between four regions that provide input signals to the anterior cerebellum (aCB): 1) Dorsolateral Putamen (dPU); 2) Globus Pallidus Externa (GPE); 3) Subthalamus Nucleus (STN), and 4) Pontine Nuclei (PN) and two regions that represented output from the cerebellum, the Dentate Nucleus (DN) to the: 1) Ventrolateral Thalamus (VL) and 2) dPU. Linear mixed effects regression models evaluated whether the trajectory of development of these connections over time differed between groups.

Results: Four of the six striatal-cerebellum correlations showed significantly different trajectories between groups. All showed a pattern where in the early age ranges (6–12 years), there was hyperconnectivity in the GE compared to the GNE with those trajectories showing linear decline in the latter half of the age range.

Discussion: These results parallel previous findings showing striatal hypertrophy in GE expanded children as early as age 6. These findings support the notion of developmentally higher connectivity between the striatum and cerebellum early in the life of the child with the HD gene expansion, possibly setting the stage for cerebellar compensatory mechanisms.

Lay Summary: This study demonstrates that children who have tested positive for the HD gene expansion have significantly different trajectories over time of functional connectivity between the striatum and cerebellum compared to patients without the gene expansion. These findings are vitally important to enhancing our understanding of how the presence of mutant huntingtin affects neurodevelopment. It also provides further evidence that the cerebellum may play a compensatory role in HD and may be a viable therapeutic target for HD.

Higher CAG Repeats Below Disease Threshold Confers Cognitive Advantage

Jordan L. Schultz, Carsten Saft, Peg C. Nopoulos
1University of Iowa, Iowa City, IA, USA; 2Huntington Center NRW, Ruhr-University Bochum, St Josep-Hospital, Bochum, Germany

Objective: To investigate the relationship between CAG repeat length in patients with and without Huntington’s Disease (HD) and cognitive performance.

Methods: We analyzed the fourth data cut (released December 2018) of the Enroll-HD dataset. Young adults (≤ 25 years) without a history of depression, anxiety, or apathy were included in the analysis. We included participants with and without the gene-expansion (CAG ≥ 36) for HD. The participants with the gene-expansion had to have a Total Functional Capacity Score of 13, a diagnostic confidence level of less than four, and total motor score of ≤20, and be more than 20 years from their predicted motor onset. We performed linear mixed effects regression analyses to investigate the non-linear (quadratic) relationship between CAG repeat length (15 to 46) and various cognitive measures. The models included a random effect per subject and adjustments for age, sex, and educational attainment.

Results: There were significant relationships between CAG and Symbol Digit Modalities Test (p = 0.0005), Stroop Color Naming Test (p = 0.004), and part A of the Trails Making Test (p = 0.035). For all of these findings, performance improved below the disease threshold (CAG <36) and peaked at a CAG repeat length of approximately 40.

Discussion: These results provide further evidence that an increasing number of CAG repeats in the huntingtin protein below disease threshold confer a potential evolutionary advantage in cognitive performance. The advantage begins to decrease at repeat numbers above approximately 40. These findings highlight the potential importance of the wild-type huntingtin protein.

Lay Summary: The normal function of the huntingtin protein is still unclear, but previous studies have demonstrated that increased CAG repeat length below disease threshold (<36) confers cognitive and intellectual advantages. This study aimed to investigate the relationship between CAG repeat length and cognitive function among healthy controls and patients with HD in a large patient population. This information is critically important to the HD community as it may provide evidence for an evolutionary advantage of increased CAG repeat length in healthy controls, which may increase our understanding of the function of the huntingtin protein.
Abstract

79 Preliminary Data from Longitudinal Study of Neuropsychiatric Symptoms in Huntington’s Disease (LATNS-HD)

Sellers J, Isaacs DA, Claassen DO
Vanderbilt University Medical Center, Nashville, TN, USA (all authors)

Objective: 1) To determine the level of agreement between psychiatry and neuropsychology in detection and quantification of neuropsychiatric symptoms in HD and 2) To present preliminary data on the effects of neuropsychiatric symptoms on quality of life in HD.

Background: Neuropsychiatric symptoms are common in HD, though they are often underrecognized and under-treated. Currently, assessment by a psychiatrist is the gold-standard for detection of these symptoms, but many HD providers do not have access to specialized psychiatry resources. Here we present preliminary data from an ongoing, longitudinal study of neuropsychiatric symptoms in HD. Our goal for this analysis was to assess the amount of agreement between psychiatry and neurology clinic assessments in identification and rating of neuropsychiatric symptoms in HD. We also present data on the distribution of symptoms and preliminary effect sizes for correlation of these symptoms with quality of life.

Methods: Fifty HD patients and their caregivers were recruited for Phase A of this longitudinal study. Each patient completed a battery of scales to assess neuropsychiatric symptoms, patient-reported outcomes, quality of life, and other clinical characteristics. A psychiatrist familiar with HD also evaluated each patient, then completed a Likert scale to rate presence and severity of several neuropsychiatric symptoms including depression, anxiety, apathy, irritability/aggressive behavior, obsessive or pervasive behavior, and delusions or hallucinations. We plan to use ROC curves to evaluate the level of agreement between the psychiatrist’s assessment and our battery of scales used in neurology clinic. We will also evaluate the distribution of neuropsychiatric symptoms reported at baseline. Canonical correlations will be used to detect associations between neuropsychiatric symptoms and quality of life outcomes.

Results of the above analyses will be presented and implications for research and clinical practice will be discussed.

Lay Summary: Neuropsychiatric symptoms are common in HD, though they are often underrecognized and under-treated. Currently, assessment by a psychiatrist is the gold-standard for detection of these symptoms, but many HD providers do not have access to specialized psychiatry resources. In this study we assessed the amount of agreement between psychiatry and neurology clinic assessment of neuropsychiatric symptoms in HD to inform best practice for future research and clinical practice.

80 Central Cognitive Processing Speed Is an Early Marker of Huntington’s Disease Onset

Chase Snell1, McKenna E. Williams2, Sameer Aboufadel1, Paul E. Gilbert2,3, Jody Corey-Bloom2
1Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; 2Department of Psychology, San Diego State University, San Diego, CA, USA; 3San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego/La Jolla, CA

Objective: The objective of the current study was to examine central cognitive processing speed, as measured using the Computerized Test of Information Processing (CTIP), as an early marker of Huntington’s disease (HD) onset.

Background: Several studies have suggested that cognitive processing speed may be particularly useful for assessing early cognitive change in individuals with premanifest HD (Pre-HD); however, current measures lack the ability to control for the effects of motor dysfunction that is common in HD. The CTIP is a rapidly administered and useful computerized tool that allows for examination of central cognitive processing speed by using motor-corrected scores to account for motor dysfunction.

Methods: The CTIP, along with a standardized neuropsychological battery, was administered to 100 gene carriers and 55 healthy adults (HA). Gene carriers included 1) Pre-HD, n = 33; 2) transitional HD (T-HD, i.e., individuals close to disease onset or with very mild HD, n = 23; and 3) mild-moderate HD, n = 46.

Results: The HD group performed significantly slower than the HA, Pre-HD, and T-HD groups on both motor-corrected subtests (ps < .05). Additionally, the T-HD group performed significantly slower than the HA group on both motor-corrected subtests (ps < .05). Importantly, effect sizes associated with significant group differences between the T-HD and HA groups on motor-corrected CTIP subtests (d = .73 and .84) were similar to effect sizes associated with group differences on the Symbol Digit Modalities Test (d = .82), a standardized measure of processing speed that does not correct for motor dysfunction, and other traditional cognitive assessments (MoCA d = .75; MMSE d = .84).

Conclusions: Our results suggest that the CTIP may be a useful marker of deficits in central cognitive processing speed in individuals close to HD onset.

Lay Summary: The purpose of this study was to see if central processing speed could be an early marker of HD onset. We found that HD subjects and, more importantly, individuals transitioning to HD, showed slowed central cognitive processing compared to healthy adults. This suggests that central processing speed may be a useful and early marker of progression to HD.

81 Decoding CSF Mutant Huntingtin

Nicholas S. Caron1, Ethan D. Smith2, Christopher Yanick2, Yuanyun Xie2, Stephen E.P. Smith3, Ji Joon Song4, Ihsuk Seong5, Blair R. Leavitt1, Michael R. Hayden1, Amber L. Southwell2
1Center for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada; 2Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, USA; 3Seattle Children’s Research Institute, University of Washington, Seattle, WA, USA; 4Department of Biological Sciences, KAIST, Daejeon, Korea; 5Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

The first huntingtin (HTT) lowering safety trial recently completed, demonstrating dose-dependent reduction of cerebrospinal fluid (CSF) mutant (mt) HTT. However, we do not know where CSF mtHTT comes from or how it enters CSF, which confounds interpretation of treatment-induced changes. We are using immunoprecipitation and flow cytometry (IP-FCM) mtHTT detection to query what this data tells us about therapeutic activity in the brain.

The source of CSF mtHTT is unknown. Some therapeutics, such as ASOs, may be most active in regions in contact with the CSF. If these regions are the major sources of CSF mtHTT protein, then CSF-based predictions of HTT lowering in deeper structures may not be straightforward. Conversely, if regional contributions to CSF mtHTT are similar, then changes in CSF mtHTT level could be used to more accurately infer changes in basal ganglia mtHTT. Thus, we are interrogating the source(s) of CSF mtHTT protein using genetic approaches and ectopic delivery of mtHTT.

Additionally, we do not know how mtHTT enters CSF. Acute brain injury causes a transient increase in CSF mtHTT, suggesting that mtHTT is released from dying neurons. Thus, any neuroprotective therapy would be expected to reduce CSF mtHTT, and HTT lowering treatment-induced changes may represent a combination of target engagement and neuroprotection. However, inhibiting HTT secretion reduces CSF mtHTT protein concentration, suggesting that there may be both passive and active clearance mechanisms involved. If active clearance is the primary
mechanism of mtHTT release, then treatment-induced changes may mostly represent HTT lowering. To investigate the mechanism(s) of mtHTT release to CSF, we are ectopically delivering intra and extracellular mtHTT with or without inhibitors of secretion and glymphatic clearance in the presence or absence of neuronal insult. Delineating the source and mechanism(s) of entry of CSF mtHTT protein will greatly enhance interpretation of this promising HD biomarker.

**Lay Summary:** The first huntingtin lowering clinical trial recently demonstrated dose-dependent reduction of mutant huntingtin in the spinal fluid of treated Huntington disease patients. We are investigating where huntingtin protein in spinal fluid comes from and how it gets there to better understand what this exciting new data means about the brain.

82 A Novel Repeat-Primed PCR Assay to Detect the Full Range of Trinucleotide CAG Repeats Including Pediatric Huntington Disease Associated Alleles

A. De Luca1, F. Consoli1, A. Morella1, A. Onori1, M. D Asdia1, S. Fanelli1, B. D Alessio1, F. Squitieri1,2

1UOS Diagnosi Genetica Molecolare, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo and CSS-Mendel, Rome, Italy; 2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 3Fondazione Lega Italiana Ricerca Huntington (LIRH), Rome, Italy

**Introduction:** Pediatric Huntington disease (PHD) is a rare condition associated with unusually large HTT CAG repeat size, usually of 60 CAG repeats or more. It affects adolescent patients before 18 yrs. of age, and very rarely young children before 10 yrs. of age, with particularly severe presentation and course. In these patients, accurate determination of the CAG repeat number is recommended to confirm the diagnosis. Here we evaluated the reliability of a novel triple repeat primed PCR-based method (AmplideX PCR/CE HTT Kit) for accurate estimation of HTT CAG repeats in PHD.

**Materials and Methods:** Study cohort included a total of 66 DNA samples, comprising: i) a first reference set of 14 cell-line samples (Coriell) with associated genotype data; ii) a second reference set of 5 samples previously genotyped by multiple laboratories, including two cases with alleles larger than 60 CAG repeats; and iii) a set of 47 samples previously genotyped in our laboratory by fluorescent repeat-flanking PCR encompassing the full range of trinucleotide CAG repeats in HTT gene, but enriched for alleles larger than 60 CAG repeats.

**Results:** All samples showed full concordance with the previously verified allele sizes. Identical repeat size or sizing errors within ±1 CAG were obtained for alleles ≤22 CAG repeats, whereas sizing errors within ±3 CAG were obtained for alleles >43 CAG repeats, conforming to established guidelines. The assay was able to accurately size 21 samples with very large alleles comprised between 60 and 100 CAG repeats, and to detect two exceptionally large alleles with more than 200 CAG repeats.

**Conclusions:** This method provides a rapid, sensitive and reliable strategy to accurately genotype the HTT CAG repeat stretch, and extends the detection limit of large expanded alleles to over 200 CAG repeats, thus providing a comprehensive molecular diagnostic evaluation of all Huntington disease samples, including those pediatric forms carrying extremely large, hard to detect, alleles.

83 Exploring Executive Functions in Premanifest and Prodromal Huntington's Disease Subjects

S Migliore1, G D'Aurizio2, S Maffi1, G Curcio2, B D'Alessio3, F Squitieri1,3

1UOI Huntington and Rare Diseases Unit, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo and CSS-Mendel, Rome, Italy; 2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 3Fondazione Lega Italiana Ricerca Huntington (LIRH), Rome, Italy

**Introduction:** Huntington’s Disease (HD) cognitive dysfunction may occur before unequivocal motor signs become apparent. Indeed, composite measures to track presymptomatic life stage include both cognitive and motor assays. We tested executive functions in premanifest and prodromal HD subjects by different assays: 1) task-switching; 2) risky decision-making process by means Game of Dice Task (GDT).

**Methods:** In study 1 we recruited 15 preHD1 subjects with a TMS ≤ 4 (far from onset), 15 preHD2 subjects with a 5 ≤ TMS ≤ 19 and 18 age-sex-education matched Healthy Controls (HC). In study 2 we recruited 30 preHD subjects (TMS < 10) and 21 age-education gender-matched HC.

**Results:** Study 1: All preHD subjects had worse performance than HC in the switch and repetition trials, as indicated by increased switch-cost and reaction times. In particular, preHD2 showed impaired switching abilities with reaction times slower than preHD1 and HC. Study 2: Decision and feedback times were longer in preHD than in HC in both disadvantageous and advantageous choices. Moreover, preHD provided a greater number of “safe” strategies, taken with longer decision-making time than HC, showing a reduced propensity to risk.

**Conclusions:** Our studies highlighted early task-switching impairment and economic decision-making slowness with a reduced propensity to risk since HD was still at a pre-manifest stage. Such abnormalities worsen when preHD subjects start to show subtle motor manifestations, still nonspecific and insufficient to define the clinical diagnosis of HD (DCL < 4). Such dysfunctions might contribute to delineate an early behavioral and cognitive profile in premanifest stage of the disease. Moreover, considering that such abilities have obvious implications for activities of daily living, early cognitive rehabilitation addressing such deficits might be useful in this stage of the disease.

**Lay Summary:** Executive functions dysfunction contribute to delineate an early behavioral and cognitive profile in presymptomatic life stage and may contribute to highlight new potential clinical markers to further update composite measures and new potential targets for therapies.

84 Assessment of Post-dural Puncture Headache Frequency in a Huntington's Disease Clinical Research Population

Ragini Srinivasan, Bhavpreet Dham, Mark Guttman

Centre for Movement Disorders, Toronto, Ontario, Canada (all authors)

**Introduction:** Lumbar puncture (LP) for CSF sampling and intrathecal bolus (ITB) drug administration are being performed more frequently in Huntington’s disease (HD) research. Post-dural puncture headache (PDPH) has been reported in the literature as a complication affecting up to 35% of subjects. As predictors of PDPH in the HD population are not established, we reviewed the rate and risk factors for PDPH in HD patients at our centre.

**Methods:** A retrospective review of LPs performed for research related CSF sampling and ITB research drug administration over the last 30 months was performed. All LPs were first attempted at the L3–4 interspace with either 22G or 24G Whitacre atraumatic needles. LPs performed on the same patient at various time points were considered independent procedures.
Results: A total of 184 procedures were performed in 78 individuals, of which 178 were successful in collecting CSF. The median age of our cohort was 50 years (range 22–73) of whom 41% were male. Symptomatic HD subjects accounted for 116 LPs (65%), whereas presymptomatic HD subjects and control subjects accounted for 34 (19%) and 28 (16%) LPs, respectively. There were 94/178 (52.8%) LPs performed with the 22G needle in 63 patients and 84/178 (47.2%) LPs performed with the 24G needle in 15 patients. PDHP occurred with 10/94 (10.6%) LPs that were performed using 22G needle whereas none of the 84 LPs using 24G were associated with PDHP. This difference across the two needle sizes was statistically significant (p = 0.0017). One patient with PDHP required an epidural blood patch.

Conclusion: This retrospective chart review showed PDHP of 10.6% in the 22G needle group compared to 0% in the 24G group. Based on these observations, we recommend all studies utilize the 24G atraumatic LP needles for HD CSF and ITB studies.

Lay Summary: Lumbar punctures (LPs) are being performed more in Huntington’s Disease research, and a common complication is a severe headache that improves when lying flat, called a postdural puncture headache. We reviewed the LPs done at our site to see if using a smaller spinal needle led to fewer headaches. Postdural puncture headaches happened in 10.6% of LPs with a standard (22G) needle and did not occur at all with the smaller (24G) needle. We suggest that HD studies use the smaller 24G needle for LPs to reduce the risk of headaches.

85 Adipose-derived Mesenchymal Stem Cells Ameliorate Neuroinflammation and Promote Neurogenesis in a Transgenic Mouse Model of Huntington’s Disease

Amit K. Srivastava1, Jose F. Moruno-Manchon2, Karthik S. Prabhakara1, Akshita Kumar1, Naama E. Toledano Furman1, Alex Villarreal1, Gabriela D. Colpo1, Andrey S. Tsvetkov2, Antonio L. Teixeira Jr3, Erin Furr-Stimming4, Scott D. Olson1

1Department of Pediatric Surgery, University of Texas Health Science Center at Houston, Houston, TX, USA; 2Department of Neurobiology and Anatomy, The University of Texas, Houston Medical School, Houston, TX, USA; 3Department of Psychiatry and Behavioral Sciences The University of Texas, Houston Medical School, Houston, TX, USA; 4Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX, USA

Huntington’s disease (HD) is a genetically dominant neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric disturbances associated with neuronal dysfunction and atrophy of the striatum and other brain regions. To date, there are no effective disease modifying treatments approved for HD. Because restorative therapies targeting the underlying cause of neuronal dysfunction do not exist, therapies with anti-inflammatory, neuroprotective and regenerative potential hold great promise. Neuroinflammation is an early pathological feature of HD. Previous studies reported Iba1 and GFAP immunoreactivities in the brains of presymptomatic carriers and an increase with disease progression. Mesenchymal stem cells (MSCs) have demonstrated significant therapeutic effects in various neuroinflammatory diseases. In this study, we examined the therapeutic effect of a commercial preparation of adipose-derived MSCs (HB-AdMSCs) on neuroinflammation and neurogenesis in a transgenic HD mouse model. The cells were obtained from Hope Biosciences (Sugar Land, TX) and intravenously infused twice, first at 7 weeks of age and then at 10 weeks of age of B6CBA-R6/2 transgenic HD or wildtype mice. No immunosuppressive drug was given to any animal. The animals were perfused 14 days after the second cell injection to harvest the brains and perform immunohistochemical assays. We observed that HB-AdMSCs were able to significantly reduce astrocyte reactivity in the cortical region of the HD brains compared to controls. The cells also significantly reduced microglial reactivity and induced neurogenesis in the striatum. We conclude that administration of HB-AdMSCs could ameliorate the inflammatory microenvironment in the brain to support survival of damaged neurons and improve neurogenesis in experimental HD.

Lay Summary: Adipose-derived mesenchymal stem cells therapy could be a good therapeutic strategy for HD.

86 Patterns of Genetic Testing in Huntington’s Disease

Karina Raimundo1, Ruoding Tan1, Tu My To1, Jonathan de Courcy2, Umang Ondhia3, Huu Phuc Nguyen1, Martha Nance3

1Genentech Inc., South San Francisco, CA, USA; 2Adelphi Real World, Bollington, Cheshire, UK; 3Hoffmann-La Roche Ltd., Basel, Switzerland; 4Department of Human Genetics, Ruhr University Bochum, Bochum, Germany; 5Suthers Parkinson’s Centre, Golden Valley, MN, USA

Huntington’s disease (HD) is a genetic disease caused by a CAG trinucleotide repeat expansion in the huntingtin gene. Genetic testing can identify the presence of the CAG repeat expansion before disease manifestation. Here, we describe patterns of genetic testing in five countries. This is a retrospective analysis of data from the Adelphi HD Disease Specific Programme – a cross-sectional survey of neurologists and patients conducted between July–October 2017 in France, Germany, Italy, the UK and the US. We describe physician-reported rates of, and reasons for, predictive and confirmatory genetic testing. Only responses with consistent and non-conflicting reporting of family history of HD were included. This analysis included physician-reported data on 985 manifest patients. Overall, 46% of patients were not aware of family history of HD. Most patients (70%) received, at some point, genetic testing confirming HD. Predictive testing was reported in only 23% of patients who were later clinically diagnosed with HD. Among all reasons reported for undergoing predictive testing, the most common reasons were: desire to know (64%) and awareness of other family members being diagnosed (23%). For the 73% of patients who chose not to undergo predictive testing, the most common reasons were: unaware of family history (48%), rather not know (25%), and no treatment for disease available (12%). Currently not all patients with HD receive confirmatory genetic testing. Rates of testing prior to clinical diagnosis are even lower. Among the reasons not to be tested is the lack of treatments available. In the event therapies are proven to change the course of disease, these patterns may change, potentially leading to an increase in rates of confirmatory testing. Nonetheless, the decision to receive predictive testing is personal and can be influenced by multiple factors.

Funding Information: Study sponsored by Genentech Inc. and F. Hoffmann-La Roche Ltd.

Lay Summary: The authors of this study analyzed data from a survey of physicians and patients with manifest Huntington’s disease (HD) to understand how genetic testing is used in HD and what motivates a person to take the genetic test. Most patients (70%) received a genetic test to confirm their diagnosis of HD, however only 23% of patients received the test before symptoms of HD developed. Wanting to confirm a diagnosis of HD was the most popular reason for taking a genetic test (64% of 160 patients surveyed), while not being aware of a family history of HD was the most common reason for not taking a genetic test (48% of 502 patients surveyed).

87 Sleep Complaints Are Associated with Anxiety Symptoms and Poorer Quality of Life in HD

Will K. Tanigaki1, Maria A. Rossetti1,2, Sadha Tallavajhula2, Natalia P. Rocha1,2, Erin Furr Stimming1,2

s Centre, Golden Valley, MN, USA

s Disease

s disease (HD) to un-
Background: Notwithstanding the high prevalence and the availability of clinical tools, sleep disturbances are still not routinely evaluated in patients with HD. Sleep disturbances can seriously affect the quality of life of the patient, caregiver and family. In addition, sleep dysfunction can result in cognitive impairment and mood disorders. Therefore, the current study was designed to investigate sleep quality and its association with clinical symptoms in HD.

Methods: Fifteen patients with HD (51.15 ± 12.66 years, 10F/5M) completed a series of self-reported questionnaires about sleep quality and pattern [Pittsburgh Sleep Quality Index (PSQI)], daytime sleepiness [Epworth Sleepiness Scale (ESS)], cognitive function (NeuroQOLv2.0 Cognition Function), quality of life [HD Quality of Life Questionnaire (HDQoL)] and depressive and anxious symptoms [Hospital Anxiety and Depression Scale (HADS)]. Spearman correlation analyses were performed to ascertain the association between sleep quality and severity of self-perceived clinical symptoms.

Results: The primary sleep complaints reported by the patients were related to waking up in the middle of the night or early in the morning; and increased sleep latency. Nine out of the 15 patients (60%) reported the use of sleep medications at least once a week. We did not find any significant association between sleep quality and self-perceived cognitive function or depressive symptoms. Worse sleep quality was associated with greater severity of anxiety symptoms, as observed by the significant correlations between HADS-anxiety score and PSQI global score (rho = 0.561, p = 0.046) and PSQI components: subjective sleep quality (rho = 0.577, p = 0.039); sleep latency (rho = 0.675, p = 0.011); sleep duration (rho = 0.586, p = 0.035); sleep disturbances (rho = 0.733, p = 0.004). Importantly, greater severity of sleep latency and sleep disturbances were associated with worse quality of life (rho = 0.673, p = 0.012; and rho = 0.679, p = 0.011, respectively).

Conclusions: In our experience, sleep dysfunction in patients with HD is associated with increased anxiety and worse quality of life. Identifying sleep dysfunction in HD is essential as this could significantly impact the optimal management of individuals with HD.

Lay Summary: Fifteen HD patients completed a series of questionnaires about sleep quality, daytime sleepiness, depressive and anxious symptoms, and quality of life. In our experience, sleep dysfunction in patients with HD is associated with increased anxiety and worse quality of life.

88 How to Navigate the Huntington’s Disease (HD) Big Data Maze?

Muthukumaran Thangaramanijam, Jennifer Hoblyn
Bloomfield Hospital and Trinity College Dublin, Dublin, Ireland (all authors)

Background: It is currently difficult to predict the onset of symptoms, and disease progression as HD data is currently segregated like a maze.

Aims and Objectives: This poster proposes an information model for HD Big Data, for linking all HD research data ranging from Basic Medical Research, Translational Medicine, and Clinical Outcomes.

Methods: An Information Model is a framework that can be used to categorize information resources. We propose The Hourglass Framework for HD Big Data.

Top of the hour glass: At the moment, the treatment a person with HD patient receives trickles down from existing research and clinical data which is still nascent. There appears to be disconnect between HD research and clinical practice in various parameters. It is proposed that a hyperlinked data set be created, covering from genetic data to clinical progression throughout the lifespan of the individual, and to have ethnicity specific population datasets. When the data acquisition is fine-tuned and streamlined as proposed, then this could trickle further on to the person with HD, at the middle.

89 Enroll-HD Platform Services

Enroll-HD is a global research platform with the infrastructure to support clinical trials and studies. Key elements include global study management and governance, an integrated EDC and study database and a user-friendly comprehensive webportal. This infrastructure supports the Enroll-HD study, a prospective, observational, longitudinal registry study of HD, currently with >18,000 participants who have performed standardized clinical assessments and biosample collections from annual visits at over 163 clinical sites in 19 countries, and provides resources for clinical trial sponsors conducting intervention and observational studies in HD.

Resources and services of the platform that are available to the HD research community include easily accessible periodic clinical datasets and associated biosamples, assistance with site feasibility and selection, ICF development and translation, insurance, assessment scale licensing, IRB/ethics submissions, site staff training and certification via the Enroll-HD training portal, database construction, and data monitoring.

Long term working relationships with the clinical sites allows for well-informed site selection and efficient feasibility using Enroll-HD study data and the HD Clinical Trial Site Certification list (sites assessed against a set of standard minimum criteria for clinical trial participation), local knowledge of sites, recorded past performance of sites and access to eligible participants. The Enroll-HD platform’s substantial registry of participants allows for powerful in-silico screening to support participant recruitment and the close working relationships with sites enables ongoing support for issue resolution and trial facilitation.

A team of subject matter experts (SMEs) with extensive experience in study start-up and management are available to assist in the implementation and operationalisation of clinical studies. The provision of platform services, including SME support, is managed by a team of Platform Resource and Service Managers (PRSM). This team also facilitates the interface between clinical study and trial project teams or researchers and the Enroll-HD Platform.

Lay Summary: The Enroll-HD platform infrastructure supports clinical trials and studies by providing resources and services to the HD research community, including clinical datasets and associated biosamples, assistance with site feasibility and selection, ICF development and translation, insurance, assessment scale licensing, training and certification, IRB/ethics submissions, and participant recruitment.

90 Huntington’s Disease Clinical Trial Site Certification

Enroll-HD Platform Team
CHDI Foundation, USA

Abstract
The Huntington’s Disease (HD) Clinical Trial Site Certification Scheme aims to maximize the number of high-quality HD clinical trial sites, improve efficiency and expedite the site selection process for clinical trials. It provides an opportunity for HD clinical sites to register their interest and ability to participate in trials and increases the visibility of these sites to sponsors and clinical study teams. The scheme reduces the administrative burden during trial set-up by maintaining up to date centralized records about sites and providing these details to approved sponsors conducting HD clinical research. More than 100 sites around the globe have received certification, providing an invaluable resource to the HD clinical trial community.

Certification requires that sites meet a specific set of criteria designed to assess clinical trial readiness including clinical trial infrastructure and facilities, information on HD cohort and participant access arrangements, training, education and research experience. The scheme is open to Enroll-HD and non-Enroll-HD sites in Australia, Europe, Latin America, North America, New Zealand, Nordic regions and Russia, and is managed by the Enroll-HD Clinical Trial Committee (CTC). Sites apply for certification by completing a brief application form, completing the GSID-HD (HD Global Site Investigator Database) and submitting a standard set of documents and SOPs for review. For further information contact sitecertification@enroll-hd.org.

**Lay Summary:** The Huntington’s Disease Clinical Trial Site Certification Scheme aims to maximize the number of high-quality HD clinical trial sites, improve efficiency and expedite the site selection process for clinical trials. It provides an opportunity for HD clinical sites to register their interest and ability to participate in trials and increases the visibility of these sites to sponsors conducting HD research.

### Registry Dataset (RDS)

European Huntington’s disease Network, on behalf of Registry investigators and participants

European Huntington’s disease Network

Registry is an observational, prospective, longitudinal, multi-national, multi-centre cohort study of Huntington’s disease (HD) initiated in 2004, which annually collected standardized clinical data and biospecimens on individuals affected by HD, HD family members and controls from 161 expert HD clinical sites across 17 European countries. Over 14,000 participants contributed clinical phenotypical data, with more than 10,000 participants additionally donating biosamples for use in large-scale genetic modifier and biomarker studies. This data is now available via the Registry dataset (RDS) (https://www.euro-hd.net/html/projects/proposals/scipro), which is an invaluable resource for scientists and researchers conducting clinical and genetic modifier studies.

Some values in the RDS have been aggregated to further protect the identity of study participants. Access to disaggregated data and/or data not provided in the RDS can be applied for via a specified dataset request. The procedure for obtaining access to the RDS and renewable biosamples is straightforward and involves a review of the project by the Chairs of the European Huntington’s Disease Network Scientific and Bioethics Advisory Committee (SBAC) and Executive Committee (EC). Requests for a specified dataset or non-renewable biosamples will undergo full review by the SBAC and EC.

The Registry study was closed in 2017 and since 2013, many of the Registry sites and participants have been transitioning from Registry to Enroll-HD, the global observational study of HD (www.enroll-hd.org). The RDS has been prepared in a similar format to the datasets available from Enroll-HD (periodic datasets (PDS)), using the same recoded IDs, which simplifies the analysis for applicants requesting access to both Registry and Enroll-HD datasets. Some Registry data is also included in the Enroll-HD PDS for participants who have transitioned from Registry to the Enroll-HD study, however, there are a wealth of Registry data that are uniquely represented in the RDS.

**Lay Summary:** The Registry dataset (RDS) is a valuable resource for the HD scientific community, comprising annually collected standardized clinical data (>14,000 individuals) and biospecimens (>10,000 individuals) on people affected by HD, HD family members and controls. The RDS is available to researchers via a simple application process: https://www.euro-hd.net/html/projects/proposals/scipro.

### Using Functional Status to Aid Interpretation of cUHDRS Scores in Patients with Huntington’s Disease

**Dylan Trundell**, Giuseppe Palermo, Jeffery D. Long, Blair R. Leavitt, Scott Schobel, Sarah J. Tabrizi

1Roche Products Ltd., Welwyn Garden City, UK; 2F. Hoffmann-La Roche Ltd., Basel, Switzerland; 3University of Iowa, Iowa City, USA; 4University of British Columbia, Vancouver, BC, Canada; 5Huntington’s Disease Research Centre, UCL Institute of Neurology, London, UK

The composite Huntington’s Disease Rating Scale (cUHDRS) has been developed to assess disease progression in early-to-moderate manifest Huntington’s disease (HD). It combines four assessments (Total Functional Capacity [TFC], Total Motor Score, Symbol Digit Modalities Test and Stroop Word Reading) into a single metric that provides more comprehensive sensitive outcome assessment of cognitive, functional and motor impairment in HD. To aid score interpretation, it is important to understand how cUHDRS score relates to typical functional status.

Data from Enroll-HD were evaluated. The cUHDRS score range was calculated for patients meeting the reference population for the Phase III RG6042 study, GENERATION HD1 (manifest HD, TFC ≥13, ≥20 years; N=3490). Patients were divided into groups around each integer score (e.g. for cUHDRS = 11: 10.5 ≤ cUHDRS < 11.5). For each grouping, the mean HD stage, Independence Scale (IS) score, mean Functional Assessment (FA) score and number of FA items that ≥50% of individuals can achieve were calculated.

In this population, cUHDRS score groupings ranged 2–18; however, six individuals were cUHDRS = 2, and so this grouping was excluded from subsequent analyses, leaving a range of 3–18 (N=3484). For those patients in the 14–18 cUHDRS score groupings, ≥50% were able to achieve all 25 FA items and had a mean IS of 95. As cUHDRS scores declined, the number of FA items achievable and the level of independence declined. For patients in the lowest cUHDRS score group, cUHDRS = 3 points, only 12 FA items were achievable by ≥50% and the mean IS = 65. A visual aid was created using these results, to aid interpretation of cUHDRS scores, showing how cUHDRS scores correspond to existing measures of functional ability.

**Funding Information:** This study was funded by F. Hoffmann-La Roche Ltd.

**Lay Summary:** Huntington’s disease (HD) is a complex disease that causes problems with a person’s ability to think, behave and move. Current measurements used in clinical trials do not comprehensively assess the impact of the disease. Scientists have developed an improved measurement of disease progression called the composite Unified Huntington’s Disease Rating Scale. To aid interpretation of this measurement, a visual aid has been developed linking the outcomes of this measurement to other measures of functional ability in HD currently in use.

### Novel Exploratory Outcome Assessments in GENERATION HD1

**Dylan Trundell**, Scott A. Schobel, Raymund Roos, Karen Anderson, Alpa Thobhani, Gregory Hooper, Mai-Lise Nguyen, Sarah J. Tabrizi

1Roche Products Ltd., Welwyn Garden City, UK; 2F. Hoffmann-La Roche Ltd., Basel, Switzerland; 3Leiden University Medical Centre, Leiden, the Netherlands; 4Georgetown University Hospital, Washington, DC, USA

**Funding Information:** This study was funded by F. Hoffmann-La Roche Ltd.
With multidimensional diseases such as Huntington’s disease (HD), there is a need to assess a broad range of symptoms and impacts. Although novel patient-reported outcome measures (e.g., HD-PRO-TRIAD, HD-Health Index, FuRST 2.0) have been developed, there is still need for a clinician-reported outcome (ClinRO) measure of daily function that can assess change in a more granular way than existing ClinROs.

Gaps were identified while evaluating the holistic measurement strategy for the first pivotal Phase III study, GENERATION HD1, against qualitative research, indicating the core symptoms and impacts from the perspectives of patients and their families. It was determined that in addition to a novel ClinRO assessing daily functional ability, brief measures of patient-reported speech difficulty and companion-reported irritability were also required to balance patient burden with the desire for comprehensive measurement. Qualitative research was reviewed and, in collaboration with HD clinical experts, an iterative process was used to develop items and response options to assess clinician-reported daily functional ability.

Additionally, a single-item patient-reported assessment of speech difficulty and three draft companion-reported items to assess observed irritability and angry outbursts were developed. The draft companion-reported measure was shared with the international HD-COPE board of patients and care companions via an interactive online platform. Feedback was used to revise the content.

Three novel scales were developed and are being used for the first time in the GENERATION HD1 study as exploratory measures: the HD-Daily Activities Scale, a 25-item measure of daily activities; the HD-Companion-reported Irritability and Angry Outbursts Scale, a 2–3 item measure of irritability and angry outbursts; and the HD-Speaking Difficulty Item, a single-item measure of speech difficulty.

Future assessment of their measurement properties (e.g., validity and reliability) is required to support their use in longitudinal research.

Funding Information: This study was funded by F. Hoffmann-La Roche Ltd.

Lay Summary: Scientists have developed three new measurement tools to better understand how Huntington’s disease (HD) impacts a person’s speech, their ability to complete day-to-day tasks and how often they experience irritability or angry outbursts. The measures were developed with HD experts and feedback from the global patient/companion advisory board HD-COPE. These measures will be used for the first time in the Roche RG6042 Phase III GENERATION HD1 clinical trial.

94 Huntington’s Disease: Disclosure and Future Decision-Making in Romantic Relationships

Marian Tsang, Moyra Smith, Leslie Thompson, Katherine Hall
University of California Irvine, Irvine, CA, USA (all authors)

Huntington’s Disease (HD) is an inherited neurodegenerative condition in which an affected individual gradually loses control over their behavior, cognition, and movement. Typically, onset of symptoms is in the 30s or 40s, although there are some cases that fall outside of this age range. This means most individuals often achieve early to mid-life milestones, including romantic relationships, marriage, and reproduction, before the onset of symptoms. An individual with HD has a 50% chance of passing down the condition to each child. If an individual decides to disclose to a potential romantic partner their HD history, communicating the symptoms and inheritance aspects of the condition may help the couple make informed decisions regarding their possible future life together. How and when individuals with, or at risk for, HD approach dating, relationships, disclosure, and life decisions with a potential romantic partner is a topic that has not been well documented in the literature. This information can give healthcare providers deeper understanding into this important aspect of life for their patients. This study surveyed individuals both at risk for and diagnosed with HD, as well as their romantic life partners regarding issues surrounding discussion of the diagnosis of HD. The survey included both multiple choice and free response questions on the subject of disclosure and its impact on reproductive decisions including family planning and in vitro fertilization with preimplantation genetic testing (PGT-M). The information collected in this study provides insight into factors considered by those affected and at risk for HD and their romantic partners as they consider their future together.

Lay Summary: This study explored the area of disclosure and family planning decisions from the perspectives of the individual who was either at risk for or diagnosed with Huntington’s disease and the romantic partners of these individuals. The goal of this study is to give healthcare providers important insight into this aspect of life for their patients.

95 Speech in Prodromal and Symptomatic Huntington’s Disease as a Model of Measuring Onset and Progression in Dominantly Inherited Neurodegenerative Diseases

Jess C.S. Chan¹, Julie C. Stour², Adam P. Vogel¹•³
¹Centre for Neuroscience of Speech, University of Melbourne, Victoria, Australia; ²Institute of Cognitive and Clinical Neuroscience, School of Psychological Sciences, Monash University, Victoria, Australia; ³Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany; ⁴Redenlab, Australia

Subtle motor and cognitive changes can manifest prior to diagnosis in many progressive neurological disorders. Most people with Huntington’s disease (HD) develop dysarthria. Yet, how speech evolves, how the brain regulates speech in HD, and the clinical implications of these changes remain unclear. We reviewed existing literature on speech production in premanifest (PreHD) to symptomatic HD. A search of databases yielded 12 eligible studies. Nine of the twelve studies were included in the meta-analysis. Data suggest that speech in PreHD is characterized by impaired speech agility, phonatory function and speech rate. Over the disease course, speech gradually deteriorates across all subsystems of speech. Our findings indicate subtle changes in speech appear prior to a clinical diagnosis of HD. However, distinct patterns of decline and the magnitude of these deficits require further investigation. Our current understanding of speech impairment in HD relies on small cohort studies. Natural history studies documenting changes from premanifest to end stage may facilitate the development of speech as a marker of disease onset and treatment response.

Lay Summary: Subtle but apparently genuine changes in speech occur in HD before clinical diagnosis. Speech changes in prodromal individuals are largely characterized by timing deficits. Limited longitudinal data restricts capacity to predict HD evolution using speech.

96 Motor Speech Phenotype of Huntington’s Disease: A Clinical Biomarker in Premanifest and Early Phases

Jess C.S. Chan¹, Julie C. Stour², Adam P. Vogel¹•³
¹Centre for Neuroscience of Speech, University of Melbourne, Victoria, Australia; ²Institute of Cognitive and Clinical Neuroscience, School of Psychological Sciences, Monash University, Victoria, Australia; ³Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany; ⁴Redenlab, Australia

Background: Speech disturbances have been described in premanifest Huntington’s Disease (HD). Yet a recent systematic review and meta-analysis highlighted disagreement in the literature regarding the nature
and size of these deficits. How speech changes over time is relatively unknown outside of single time point cohort studies.

**Objective:** Drawing on measures known to be sensitive to pathology, we explored the utility of objective analysis of diadochokinesis (DDK) in describing four distinct HD groups and the stability of those measures over time in the premanifest phase.

**Methods:** Sensitivity of speech metrics was determined by comparing production in 55 people carrying the expanded HD gene divided into four groups (14 presymptomatic (PreshyHD); 18 prodomal (ProHD); 14 early (EarlyHD); and 9 middle (MidHD) stages of HD). Participants’ speech data were compared to four groups of age- and sex-matched control subjects (n = 55). Participants repeated syllable sequences, sustained vowel, read a passage and produced a monolog. Stability was investigated in a subset of 13 participants from the two premanifest groups by measuring speech over a 6-months period (7 days, 1 month, 3 months and 6 months post baseline).

All speech data were analyzed objectively using acoustic methods.

**Results:** Speech performance did not differ between control and PreshyHD (farther from disease onset) groups. There were significant differences on measures of syllabic duration and syllable repetition rate between participants with prodomal HD (within 15 years to disease onset) and their matched controls. People in the ProHD group also presented with slower rate of speech in reading tasks with greater pauses and silences compared to controls. Results from stability data revealed differences in speech function between PreshyHD and ProHD groups over the 6-months period, and there were no significant differences across the five time points within each group. As the disease progresses, speech agility and timing appear to gradually deteriorate.

**Conclusion:** Articulatory rate and agility are significantly reduced in individuals closer to the onset of HD. The speech decline observed may be due to task novelty in syllable repetition task, as well as cognitive (e.g. attention) and oromotor changes in the premanifest period. Our data suggest that these features are relatively stable over a six-month period.

**Lay Summary:** Subtle motor speech differences appear to be detectable more than a decade from disease onset using objective analysis of speech. We explored the stability of speech measures over a six-month period in a subset of participants in the premanifest phase of HD. Data show relatively stable production over brief and intermediate inter-recording intervals.

98 **GEORGE® – The First Smartphone Application for Huntington Disease – Pilot Study**

Emma M. Waddell1, Karthik Dinesh2, Kelsey L. Spear1, Christopher G. Taroli1, Molly J. Elson1, Michael J. Curtis1,2, David J. Mitten1,2, Gaarav Sharma3, E. Ray Dorsey1, Jamie L. Adams1,2

1University of Rochester Center for Health + Technology, Rochester, NY, USA; 2University of Rochester Department of Electrical and Computer Engineering, Rochester, NY, USA; 3Chicago Medical School at Rosalind Franklin University, North Chicago, IL, USA; 4Emory University School of Medicine, Atlanta, GA, USA; 5University of Rochester Health Lab, Rochester, NY, USA

**Objective:** Assess the feasibility of using an Android smartphone application, GEORGE®, to quantitatively measure motor features of Huntington disease.

**Background:** Current measures of Huntington disease are insensitive, subjective, and restricted to in-person visits. As technology becomes increasingly inexpensive, ubiquitous, and advanced, smartphones present a unique opportunity to objectively measure disease. Previous studies in Parkinson disease have demonstrated that smartphones effectively measure motor symptoms and correlate well with clinician assessments. We developed the first smartphone application for HD, GEORGE®, at the University of Rochester. This technology may differentiate individuals with and without HD, quantify motor symptoms, and detect response to drug treatment. GEORGE® uses the smartphone’s sensors to assess chorea and balance, the screen to assess tapping speed, and the microphone to assess voice.

**Methods:** This is an observational study of 25 participants: 10 with manifest HD, 5 with prodromal HD, and 10 healthy controls. Participants undergo two in-clinic assessments and complete the application’s tasks three times daily for one month. Primary outcome measures include feasibility and quantitative motor data.

**Results:** To date, 23 subjects have been enrolled, and one withdrew before completing any remote tasks. On average, participants use the application 2.3 times daily, with no significant difference in frequency based on disease status. We have observed a significant difference in speed of finger tapping, gait regularity, and chorea score derived from the application between individuals with and without manifest HD. Individuals with prodromal HD, the youngest cohort, tapped at the fastest rate and had the lowest average chorea score.

**Conclusions:** Our data suggest use of a smartphone application by individuals with HD is feasible. GEORGE® successfully differentiates individuals with and without manifest HD and measures disease features. Refinement of the application’s interface and activities will improve usability and sensitivity of data and, ideally, make it useful for clinical trials.

**Lay Summary:** Developed at the University of Rochester, GEORGE® is the first smartphone application for HD. This novel technology has the potential to distinguish between individuals with and without HD, quantify motor symptoms, and measure response to drug treatment. Enabling faster and more frequent data collection, GEORGE® could expedite the development of novel therapeutics for HD.

99 **Evaluation of Effector Domains Fused to dCas9 for Allele-specific Silencing in Huntington’s Disease Patient-derived Cells**

Jennifer Waldo1,2, Peter Deng1,2,3, Julian Halmai1,2, Jasmine Carter1,2, Casiana Gonzalez1,2,4, Samantha Del Campo1,2,3, David Cameron1,2, Jan Nolta1, David Segal1, Kyle Fink1,2

1Stem Cell Program and Institute for Regenerative Cures, University of California Davis Health Systems, Sacramento, CA, USA; 2Department of Neurology, University of California Davis Health Systems, Sacramento, CA, USA; 3Genome Center, MIND Institute, and Biochemistry and Molecular Medicine, University of California, Davis, CA, USA; 4Department of Biological Sciences, California State University, Humboldt, CA, USA

Huntington’s disease (HD) is caused by a trinucleotide expansion in exon 1 of the Huntington gene, which leads to neuronal dysfunction and eventually cell death. The prospect of allele-specific reduction is important, as it is not known what the consequences of total knockdown of the Huntington protein could be in the long term. We aimed to use single nucleotide polymorphisms (SNPs) found in the patient population to reduce the expression of only the mutant HTT with a modified CRISPR system in HD patient-derived cells. We first characterized disease-associated single nucleotide polymorphisms (SNPs) in patient-derived primary cells that could be used to guide our modified CRISPR system to the mutant allele. We confirmed heterozygous SNPs near regulatory regions of the Huntington promotor in HD patient cells which allowed for the design of allele-specific guide RNAs containing the SNP proximal to the PAM site, which is needed for the Cas9 protein to recognize and bind to DNA. We then cloned a new Cas9 variant, dCas9(3.7), tethered to repressive effector domains into a novel vector via Gibson cloning (dxiCas9). dCas9(3.7) has been shown to have a broader variety of PAM sites and higher binding specificity, which is necessary to target the mutantallele associated SNPs in the HTT promotor. The various dxiCas9 and gRNA plasmids were introduced to an HD patient-derived fibroblast line as an initial proof-of-concept study. After delivery of our gRNAs and different dxiCas proteins, we performed qRT-PCRs to assess knockdown of total HTT transcript levels as a screen for gRNA selection to continue with.
assessed at knockdown at 4 different loci in the HTT gene using various gRNAs and effector domains, and saw downregulation using several of our gRNAs that were designed to be allele specific.

**Lay Summary:** We are currently working towards therapeutics using gene editing technology to turn off the mutant gene that causes HD. Targeting mutant huntingtin at the DNA level could allow for a more substantial effect and prolonged effect.

---

**99 Music Therapy to Address Issues in Huntington’s Disease**

Becky Wellman
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA

Music therapy is a clinical and evidenced-based intervention which can accomplish individual goals within a therapeutic relationship led by a credentialed provider. Music can be an effective tool in addressing the physical, communication, behavioral, and emotional symptoms of Huntington’s disease (HD). Using the innate elements of music such as rhythm, melody, beat, etc., music therapists can aid in regulating gait, increasing diction and annunciation of speech, control fine motor skills, and increase coping skills for and ease emotional concerns associated with HD. Case reports of two patients, information regarding a caregiver/patient support group, and ways to utilize music therapy in other settings will be shared.

Case 1: Specific goal areas of breath endurance, articulation, voice inflection, volume, and oral motor coordination were addressed utilizing singing, vocal exercises, and wind instrument play. Goal areas of safe ambulation, motor coordination, and defined fine motor movement were addressed through instrument play and rhythmic auditory stimulation.

Case 2: Specific goal areas of maintaining respiratory support, fine motor function, and cognitive skills were addressed utilizing instrument play and singing. Goal areas of reduced anxiety were addressed utilizing progressive relaxation and Guided Imagery and Music as well as a therapeutic listening program.

Support Group: The intent of adding music therapy was to allow opportunities for the patients to receive therapeutic support within a positive, success oriented group process while the caregivers were able to meet with a psychologist to discuss their own needs and concerns. Goals included increased communication, emotional support, opportunities for self-expression, cognitive stimulation, and social engagement. These goals were addressed through group singing, song writing, music discussion, cognitive music games, and instrument play.

**Lay Summary:** Music therapy can provide non-pharmacological support for motor, communication, behavioral, and emotional concerns presented with Huntington’s disease. We will show examples of how music therapy has directly impacted patients with HD as well as how other facilities/families can add music therapy to their plan of care.

---

**100 Prevalence of Huntington’s Disease in the US**

George Yohrling 1, Karina Raimundo 2, Valerie Crowell 3, Debra Lovecky 4, Louise Vetter 4, Lauren Seeberger 4
1 Huntington’s Disease Society of America (HDSA), New York, NY, USA; 2 Genentech Inc., South San Francisco, CA, USA; 3 Hoffman-La Roche, Ltd., Basel, Switzerland; 4 Department of Neurology, University of Colorado, Denver, CO, USA

Huntington’s disease (HD) is a genetic, neurodegenerative and ultimately fatal disease. Sources frequently state that 30,000 individuals living in the US have HD, but the methodology used to derive this prevalence estimate is unclear. We aimed to review the existing literature on the prevalence of HD in the US and Canada to estimate the number of people in the US currently affected by this disease.

We reviewed the literature on HD prevalence in Canada and US post the advent of genetic testing (1993–2019) and calculated a range of persons affected in the US by age-adjusting these prevalence estimates to the US population using 2018 US Census data. Two studies were identified (Fisher, et al. 2014 and Bruzelius, et al. 2019). Fisher performed a population-based observational study using multiple ascertainment sources and evaluating clinical and genetic data of people with HD in British Columbia (BC), Canada, which yielded an estimated prevalence of 13.7/100,000 (US age-adjusted: 12.7/100,000). Bruzelius conducted a retrospective database analysis of insurance claims of one insurance company and estimated an age-adjusted HD diagnostic frequency of 6.52/100,000. Applying these age-adjusted prevalence rates to the 2018 US census population, we estimated the true HD prevalence in the US to be 41,467, while the number of persons currently diagnosed is at least 21,331. Adjusting for differences in the BC, and US populations, our assessment indicates that as many as 40,000 US persons may currently have manifest HD. It is probable that many of these patients go undiagnosed. The lower figure (~21,000 patients) may reflect the number of patients currently diagnosed but does not account for the HD prevalence in uninsured individuals. With the advent of disease-modifying treatments, HD disease awareness and diagnosis rates may increase, enabling improved detection of patients.

**Funding Information:** Study sponsored by Genentech Inc. and F. Hoffmann-La Roche Ltd.

---

**101 Ancillary Service Utilization and Impact in Huntington’s Disease**

Jacob Yontzoo, Chen Yeh, Danny Bega
Northwestern University Feinberg School of Medicine, Chicago, IL, USA (all authors).

**Background:** Prior Huntington’s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life but frequency of use and clinical characteristics are unclear.

**Objective:** Describe ancillary service utilization in a cohort of individuals with HD and determine which participant characteristics are associated with ancillary service utilization.

**Methods:** Retrospective cross-sectional analysis of Enroll-HD database. Participants were grouped by therapy: physical and/or occupational (PT/OT), psychotherapy and/or counseling (PC), speech and/or swallowing (ST). We performed bivariate comparisons analysis of demographic and disease characteristics between those with/without each therapy and to analyze one-year mean change in assessment scores.

**Results:** Of 4751 participants, 1537 (32.35%) utilized therapies (11.82% PT/OT, 5.33% PC, 3.01% ST, 1.98% all three, 10.21% two therapies). PT/OT participants had worse motor and functional scores: median UHDRS motor score (41.17 vs. 38.05, p < 0.002), median total functional capacity score (TFC) (8.00 vs. 9.00, p < .001). PC participants had worse mood but better cognitive and functional scores: median depression score (7.00 vs. 2.00, p < .001), median MMSE (28.00 vs. 26.00, p < .001), median TFC (10.00 vs. 8.00, p < .001). ST participants had more dysarthria, and worse cognitive and functional scores: dysarthria (32.2% vs 20.1% p < .001), mean correct Symbol Digit Modality Test (16.79 vs. 23.27, p < .001), median TFC (6.00 vs. 9.00, p < .001). Over one year, PC participants’ depression scores improved compared to untreated (−1.24 vs. −0.11, p = 0.040). ST participants’ depression scores worsened
Propensity Score Models (PSM) can be used to correct the imbalance of use remains unclear. We aimed to describe use of these services in the large worldwide Enroll-HD cohort and examine how participant characteristics were associated with different service use. Only 32% of study participants had received these services. Our study will better inform referral practices to make these vital resources available to more people with HD.

102 Using Propensity Scores to Balance Covariates in Exercise Trials in People with Huntington’s Disease (HD)

Gregory Youdan Jr,1 Xueyaol Li,2 Beth Ann Griffin,2 Rebecca Playle,2 Monica Busse,3 Lori Quinn.1
1Teachers College, Columbia University, New York, NY, USA; 2Rand Corporation, Santa Monica, CA, USA; 3Centre for Trials Research, Cardiff University, Cardiff, UK

Background: Achieving sufficiently powered trials of exercise and other lifestyle interventions in Huntington’s Disease (HD) are difficult not least due to the small, geographically dispersed population. Observational studies together with propensity score models (PSM) can be used to estimate causal effects of treatment without requiring randomization by accounting for the key confounding covariates that predict both receiving treatment and the outcome of interest.

Methods: Data from five feasibility exercise RCTs, not powered to detect difference (i.e., Move to Exercise, COMMET, TRAIN, EXERT, and ENGAGE) were pooled together using an individual patient data (IPD) meta-analysis. To account for missingness, 30 multiple imputations were pooled using Rubin’s rules. PSM was used to match individuals in exercise groups and control groups. Covariate balance was assessed using a criterion of ≤0.1 mean difference and variance ratios to signify good balance. The PSM was created using a logistic regression and an optimal criterion of <0.1 mean difference and variance ratios to signify good balance. Results: There was a 1.44 (95% CIs [~0.65, 3.53]) simple mean difference in modified motor score (mMS) in favor of the control group. After balancing covariates using PSM, this difference changed to be in favor of the exercise group with an average treatment effect of treated (ATT) of −0.88 (95% CIs [−0.86, −0.91]).

Conclusions: Although each study was independently randomized (different minimization variables), when combined (using the IPD) the groups were unbalanced on baseline covariates. Correcting the imbalance by using PSM reversed the signal to provide weak indication that exercise might improve motor function. PSM may provide a better way to estimate causal effects of exercise when large scale randomized controlled trials (RCTs) are not feasible, and researchers must rely on using large observational cohort studies such as Enroll-HD.

Lay Summary: Propensity Score Models (PSM) can be used to make causal inference in observational studies where randomization may not be feasible. Data from five feasibility exercise RCTs were pooled together and analyzed with PSM showing a weak indication that exercise may improve motor function in people with HD, after covariates were balanced between exercise exposure and control group. PSM should be considered as a viable approach by HD researchers, especially in lieu of large observational cohort studies such as Enroll-HD.

103 A Systematic Review of the Clinical Evidence for Complementary and Alternative Medicine in Huntington’s Disease

Margaret Yu, Danny Bega
Northwestern University Feinberg School of Medicine, Chicago, IL, USA (all authors)

Background: There is a lack of published guidelines related to the use of Complementary and Alternative Medicine (CAM) for Huntington’s disease (HD). We conducted a systematic review of the literature to summarize the available evidence for various mind-body practices and nutraceuticals.

Methods: PubMed and Cochrane Library electronic databases were searched independently from inception to February 2019 by two independent raters. Studies were classified for the level of evidence (class I, II, III, or IV) according to the American Academy of Neurology (AAN) classification scale.

Results: Randomized controlled trials in HD were reviewed for mind-body interventions (dance therapy, music therapy, and exercise), alternative systems (traditional Chinese medicine), and nutraceuticals/diet (aminooxyacetic acid, coenzyme q10, creatine, cannabinoids, alpha-tocopherol, eicosapentaenoic acid, idebenone, levocarnitine, triheptanoin). Few studies met AAN class I or II level of evidence for benefits, and are highlighted.

Discussion: There is a relative paucity of clinical trials examining CAM modalities in HD when compared to other neurodegenerative disorders. Presently there is no evidence supporting disease modification or symptom improvement with any specific dietary or nutraceutical supplement for HD. Supervised exercise and contemporary dance are safe for people with HD but more robust studies are warranted to guide specific recommendations for these and other mind-body interventions.

Lay Summary: Huntington’s Disease (HD) does not have curative medications, only symptomatic treatment. Complementary alternative medicine has been found to be helpful in other neurodegenerative disorders like Parkinson’s disease and Alzheimer’s disease, but has not been investigated for HD. This review bridges this current gap in knowledge.

104 Validity of Irritability in Huntington’s Disease: A Scoping Review

Jane Simpson1, Maria Dale2, Rachael Thed3, Sarah C Gunn4, Niccolò Zanotti,5 Fiona Eccles1
1Division of Health Research, Lancaster University, Lancaster, LA 1 4YT, UK; 2Adult Mental Health Psychology, Leicestershire Partnership NHS Trust, Leicester, LE4 8PQ, UK; 3Department of Neuroscience, Psychology and Behaviour, University of Leicester, Leicester, LE1 7RH, UK.

Purpose: To scope the literature concerning irritability in Huntington’s disease to determine whether or not irritability is a valid and meaningful construct within this population.

Method: A scoping literature review was conducted based on findings from a search of five databases (Academic Search Ultimate, PsycINFO, CINAHL, Scopus and Web of Science) in November 2018. From an initial return of 453 papers, 40 were found suitable for review.

Results: Review of the 40 studies highlighted several aspects of irritability in people with HD which influence its validity as an independent construct in context of the disease. While various measures are used to assess irritability, a gold standard has yet to be identified and consequently irritability is assessed inconsistently across the literature. In addition, the results suggest that irritability may not reflect pathological disease processes in HD, but rather comprises a multidimensional construct which appears to be...
The current concept of irritability in people with HD continues to lack a general consensus in the clinical literature, in terms of both operationalisation and assessment. Consequently, further research is warranted in order to determine the extent to which irritability is a valid construct within the context of HD, including its associated behavioral, cognitive and affective dimensions.

**Conclusions:** The current concept of irritability in people with HD continues to lack a general consensus in the clinical literature; in terms of both operationalisation and assessment. Consequently, further research is warranted in order to determine the extent to which irritability is a valid construct within the context of HD, including its associated behavioral, cognitive and affective dimensions.

**Lay Summary:** Based on the review of the literature which is currently available, no satisfactory definition of irritability within the context of HD appears to exist. Indeed, considering the correlates of irritability, including depression, apathy and anxiety, these may currently provide more meaningful information about a person’s experience. Additionally, current treatment options appear designed to treat these associated psychological difficulties rather than specifically targeting irritability. However, the present investigation does not exclude or cast doubt on the reality of what is described as irritability for many individuals affected by HD and their clinicians, but suggests that if effective help is to be provided, it needs to be much clearer on all aspects of this often extremely distressing experience.

**Abstract**

Systemic Administration of Exosomal siRNA Inhibited Huntington Expression in Transgenic Mice of Huntington’s Disease

Tengteng Wu1, Mengchao Yu2, Li Zhang2, Xi Chen2, Zhong Pei1
1Department of Neurology, the First Affiliated Hospital, Sun Yat-Sen University; 2State Key Laboratory of Pharmaceutical Biotechnology, NJU Advanced Institute of Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Sciences, Nanjing University

Cell-derived exosomes have been demonstrated to be efficient carriers of small RNAs into brain tissue. However, the therapeutic effect of exosome-mediated siRNA has not been tested in Huntington’s disease. In the present study we aimed to explore the therapeutic potential of exosome-mediated siRNA delivery in HD mice models.

We employed modified exosomes expressing the neuron-specific rabies viral glycoprotein (RVG) peptide to deliver siRNA into brain tissue. To determine the ability of modified exosomes selectively entering brain tissue, eGFP-siRNA loaded exosome was administrated to eGFP transgenic mice. Five siRNA targeting human huntingtin exon 1 (HuHtt) transcript were designed and then screened in SH-SYSY cells. To evaluate the in vivo efficiency, HuHtt-siRNA RVG-exosomes were intravenously injected to BACHD mice at 10 mg/kg every two days for 2 weeks. The most effective HuHtt-siRNA RVG-exosomes were then intravenously injected to N171-82Q and YAC128 transgenic mice at 10 mg/kg twice per week for 2 to 6 weeks. Performance of rotarod test and balance beam test was determined post treatment.

We found that RVG modified exosomes efficiently and specifically delivered siRNA into the mouse brain. In addition, siRNA-loaded RVG exosomes reduced HuHtt mRNA (55% ±13%) and protein (51% ±14%) in N171-82Q mice as well as improved rotarod performance. Similarly, exosomal siRNA significantly inhibited huntingtin expression and improved motor function in YAC128 mice. The present study demonstrates that systemic exosomal siRNA efficiently lowers HTT and improves disease-phenotypes. Thus, systemic exosomal siRNA has a great potential for affordable, non-invasive solution for HTT lowering therapy.

**Lay Summary:** Systemic exosomal siRNA efficiently lowers HTT and improves disease-phenotypes. Thus, systemic exosomal siRNA has a great potential for affordable, non-invasive solution for HTT lowering therapy.

Coping Humor and Cognitive Reframing by Huntington’s Disease Caregivers

Robin Zingales-Browne, Joy Elwell, Regina Barreca, Christopher Napolitano
University of Connecticut School of Nursing (all authors)

There is nothing humorous about Huntington’s Disease (HD). It is a slow, progressive neurodegenerative disease that affects cognition, mood and coordination. HD is an autosomal dominant disease meaning offspring have a 50% chance of inheriting it from one affected parent (Pickett, Altamaier, and Paulsen, 2007). There is no cure and it is eventually fatal. Treatment focuses on management of symptoms and palliative care. Yet even with this daunting disease, patients and families are initiating laughter in the clinic, exam rooms and in support groups. The humor is not in telling jokes, making fun or being cynical, sarcastic or degrading. The humor serves as a form of coping, a brief distraction from the disease and in a sense, hope for the future. A pilot study using humor in cognitive reframing was conducted to enhance caregivers’ coping and self-efficacy. Caregivers attended two classes and completed a homework assignment. A thematic analysis revealed 5 shared concepts: control, emotion, humor, reframing and laughter. The results validate the need for future research and programs using coping humor and reframing with other healthcare populations.

**Lay Summary:** This is a creative program to improve self-efficacy and coping for Huntington’s Disease caregivers. Cognitive reframing using humor can turn negative perceptions into more optimistic views. Caregivers who believe they can change their perceptions (self-efficacy) will have improved well-being and confidence to face the challenges of HD.

Characterization of Depressive Symptoms in Individuals with Reduced Penetrance Huntington’s Disease Allele Expansions using Enroll-HD

Christina Dailey, Tara Newcomb, Emily Spoth, Meghan Zorn
University of Utah, Salt Lake City, UT, United States (all authors)

Huntington’s Disease is a rare neurodegenerative condition characterized by a triad of motor, cognitive, and psychiatric symptoms caused by a trinucleotide repeat expansion in the HTT gene. Individuals with 40 or more CAG repeats experience classic symptoms of the disease. Reduced penetration alleles in Huntington’s Disease occur when there are 36–39 CAG repeats in the HTT gene and pose a challenge to clinicians due to their variable nature. Recent studies have suggested that reduced penetrance alleles are more frequent in the general population than previously anticipated.

Some individuals with reduced penetrance alleles will have motor signs of the disease and others will not. However, the psychological symptoms affecting individuals with reduced penetrance alleles have not been investigated thoroughly. Depression is one of the most common psychiatric manifestations in Huntington’s Disease and can occur before the onset of motor symptoms; however, the risk for depressive symptoms has not been examined in patients with reduced penetrance alleles. More comprehensive information surrounding the psychological symptoms affecting individuals with reduced penetrance alleles could aid health professionals to provide the best anticipatory guidance and aid in advocating for medical services.

It is hypothesized that there will be distinct psychological phenotypic differences between those with reduced penetrance Huntington’s allele expansions, full penetrance Huntington’s allele expansions, and normal

---

Edited by: Professor Richard T. DeHaven, PhD. Springer
Abstract

allele lengths that could be used to guide medical care. The Enroll-HD Periodic Dataset 4, comprised of multiple psychological assessments from over 15,000 participants, will be used in conjunction with statistical software to analyze psychological manifestations of Huntington’s Disease in reduced penetrance allele carriers compared to full penetrance allele carriers and those with normal allele lengths.

**Lay Summary:** Individuals with Huntington’s Disease reduced penetrance alleles (36–39 CAG repeats) represent a unique patient population. It is unknown whether these individuals are at risk for the same psychological symptoms as those with full penetrance Huntington’s Disease alleles. This study will use the Enroll-HD dataset to examine the psychological differences in the reduced penetrance allele patient population to provide better anticipatory guidance to healthcare providers.
THANK YOU

HSG extends special thanks to the HSG Publications Committee, which reviews and selects all research abstracts.

HSG Publications Committee:

ERIN FURR STIMMING (CHAIR)
University of Texas Health Science Center at Houston

LISA DE BLIECK
University of Rochester

CLEMENT LOY
Westmead Hospital

PAUL MCCANN
University of Alberta

ERIC MOLHO
Albany Medical College

FRANCIS WALKER
Wake Forest Health

MEGHAN ZORN
University of Utah

Publication Support:

KATE HAROLD
Kate Harold Freelance Writing, LLC

KEVIN GREGORY
Huntington Study Group

THANK YOU!

HSG would like to thank you for your commitment to HSG’s mission of seeking treatments that make a difference.
The Huntington Study Group (HSG) is the world’s first Huntington disease (HD) cooperative therapeutic research organization. The HSG is a world leader in facilitating high-quality clinical research trials and studies that bring us closer to finding more effective treatments and reducing the burden of HD for those affected by the disease.

OUR VISION IS TO BE AN INVALUABLE RESEARCH PARTNER TO HSG FAMILIES, MEMBERS, SPONSORS, AND PARTNERS.

OUR MISSION IS TO SEEK TREATMENTS THAT MAKE A DIFFERENCE.

OUR NETWORK IS MADE UP OF HSG FAMILIES, MEMBERS, SPONSORS, AND PARTNERS.

The Huntington Study Group (HSG) has conducted more than 30 clinical trials and studies since its founding in 1993. HSG developed the Unified Huntington’s Disease Rating Scale (UHDRS), an invaluable research tool that provides a uniform assessment of the clinical features and course of HD. More recently, HSG conducted trials that led to the first two, and to-date, only, FDA-approved drugs (tetrabenazine and deutetrabenazine) for the treatment of chorea in HD.

FOR MORE INFORMATION, VISIT OUR WEBSITE: WWW.HUNTINGTONSTUDYGROUP.ORG